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Abstract 
 
Multiple sclerosis (MS) is an inflammatory disease, mediated by immune cells attacking 
the myelin sheaths that surround nerve axons. The autoimmune nature of this disease 
combined with heterogeneity in disease presentation and pathology makes MS a difficult 
disease to treat. Although some treatment options are currently available, there is strong 
demand for more effective treatment alternatives. Therefore, this thesis utilises an animal 
model of MS, experimental autoimmune encephalomyelitis (EAE), to identify new 
treatment strategies for MS. These studies encompass three separate lines of inquiry with 
the primarily focus on investigating the use and mechanisms of action by which 
microtubule-stabilising drugs (MSDs) modify EAE expression. Two other distinct and 
novel immunotherapies were also explored: the anti-psychotic drug, risperidone, and the 
Toll like receptor-9 and nucleotide oligomerization domain-containing protein 2 (TLR-
9/NOD2) agonist, MIS416. 
 
MSDs are a class of anti-proliferative compounds, which can delay EAE disease onset and 
reduce disease burden. Administration of the MSD, paclitaxel, directly after EAE 
immunisation resulted in complete inhibition of antigen-specific encephalogenic responses 
within the spleen and attenuated responses within the lymph nodes. In contrast, 
administration of paclitaxel at a later time point did not alter antigen-specific responses, 
but inhibited immune cell infiltration into the central nervous system (CNS). Using in vivo 
proliferation and migration assays it was demonstrated that paclitaxel inhibited both 
immune cell proliferation and migration; indicating these two factors are likely to 
contribute to the disease modifying effects of MSDs. Futhermore, the combined 
administration of two MSDs, peloruside A and ixabepilone, resulted in synergistic disease 
suppression in vivo while the combination of paclitaxel and a currently used MS 
therapeutic, glatiramer acetate, also exhibited synergistic EAE suppression.  
 
Risperidone is an atypical antipsychotic used to treat schizophrenia, however there is 
evidence that risperidone can also modulate the immune system. The current study 
 iii 
demonstrated that risperidone reduced EAE disease severity and induced an increase in 
splenic CD4
+
 T cells and antigen-specific IFN-γ production. Additionally, as macrophages 
have a crucial role in EAE disease development, the effect of risperidone on macrophage 
activation was explored. In cultured macrophages risperidone induced a reduction in IL-12 
production and CD40 expression while increasing IL-10 production. These findings 
suggest that regulation of macrophage activation may contribute to the reduction in EAE. 
 
MIS416 is a novel microparticle that stimulates TLR9 and NOD2 receptors. A phase 2A 
trial is currently underway to evaluate the effects of MIS416 in progressive MS patients, 
yet the mechanisms by which MIS416 alters the immune system are not completely 
understood. The current study found that MIS416 effectively but transiently reduces EAE 
and that IFN-γ is necessary for this disease reduction. These experiments demonstrate that 
EAE is an appropriate model to further explore the precise mechanisms of action of 
MIS416. 
 
In summary, the work conducted in this thesis has identified the potential of three separate 
approaches to modify inflammatory disease processes in an animal model of MS. This 
research provides an initial foundation from which further research can be conducted, with 
the ultimate goal of developing new treatments for MS.  
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1.1 The immune system 
The principle function of the immune system in all organisms is to differentiate self and 
non-self and thus, protect the host from potentially harmful pathogens. The mammalian 
immune system is a complex collection of cells and cellular processes that are commonly 
divided into two complementary arms: the innate and the adaptive. The innate immune 
system provides a rapid response and acts as a first line of defence, but it does not form 
immunological memory or mount antigen-specific responses. In contrast, adaptive immune 
responses are slower to develop but can provide a more comprehensive and targeted 
response. Crucial characteristics of a successful adaptive immune response are the 
recognition of previously encountered pathogens (i.e. memory) and the ability to respond 
to specific antigens.  
 
In the process of identifying non-self, it is critical to avoid initiating an immune response 
to self. Therefore, the mammalian immune system has developed a multifaceted system of 
regulatory mechanisms to maintain immune tolerance to self. Failures in these processes 
can lead to autoimmune diseases, whereby the immune system attacks the body’s own 
cells. Multiple sclerosis (MS) is considered to be one of many autoimmune diseases in 
which the discrimination between self and non-self has become confused. MS, like other 
autoimmune diseases is extremely difficult to treat, and there is an increasing demand for 
more effective treatment options. The current study uses experimental models to explore 
potential ways to interfere with the autoimmune responses associated with MS, in the hope 
more successful treatments can be developed.     
   
This general introduction provides a background on the immune system and MS. 
Pathogenesis of the disease and current treatments are discussed and experimental methods 
for which novel treatments can be developed are introduced. More specific information on 
disease processes and the compounds used to target these are introduced in the subsequent 
results chapters.   
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1.2 Innate immune response  
Components of the innate immune system include physical barriers, such as skin and 
mucosal membranes, soluble proteins (eg. complement) as well as specific immune cells 
(Janeway et al., 2002). The cells of the innate immune system include mast cells, 
neutrophils, natural killer (NK) cells, basophils, eosinophils and phagocytic cells (Turvey 
et al., 2010). To distinguish non-self, the innate immune system utilises a  number of cell-
expressed and soluble factors that can recognise pathogen-associated molecular patterns 
(PAMPs) (Medzhitov et al., 1997). These molecules are conserved structures (such as 
specific carbohydrate or DNA motifs) that are expressed by bacteria, viruses, yeast or 
protozoa but not by human cells. Recognition of PAMPs by cells of the innate immune 
system occurs though pattern recognition receptors (PRRs). PRRs cover a wide range of 
receptor types including lectin binding receptors, complement receptors, scavenger 
receptors, NOD-like receptors and toll-like receptors (Meylan et al., 2006; Siamon, 2002). 
Activation of PRRs results in downstream signalling though nuclear factor–κB (NF-κB), 
mitogen activated protein kinases (MAPKs) and type I interferons (i.e IFN-α and IFN-β), 
which together lead to inflammatory and antimicrobial or antiviral responses (Akira et al., 
2006).   
 
An important class of PRR are the Toll-like receptors (TLRs). Signalling though TLRs 
triggers innate immune responses as well as providing the necessary signals for an adaptive 
immune response. Within humans 10 TLRs (TLR 1-10) have been identified; while 12 
functional TLRs have been found in mice (Kawai et al., 2010). Each TLR has unique 
functions in PAMP recognition and across the 10 known TLRs in humans, multiple 
PAMPS from bacteria, fungi, viruses and protozoa can be recognised (Akira et al., 2006). 
TLR induced signalling results in the rapid activation of transcription factors that promote 
the expression of pro-inflammatory cytokines, chemokines and co-stimulatory molecules 
(Janeway et al., 2002).  
 
There are multiple innate immune cell types that can respond to PAMPs and other 
pathogenic signals. Responses from these cells can result in the direct destruction of 
pathogens as well the recruitment of additional immune cells. Neutrophil granulocytes are 
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one of the innate immune system’s main effector cells involved in the destruction of 
invading pathogens and the containment of infections. Neutrophils can engulf and kill 
micro-organisms though phagocytosis and release of highly reactive antimicrobial 
molecules (Nathan, 2006; Segal, 2005). Neutrophils can also play an important role in 
recruitment of macrophages and dendritic cells to the site of tissue injury of infection 
(Nathan, 2006). Basophils, another type of granulocyte, are particularly important cellular 
responders to parasites. They respond rapidly through the release of cytokine and 
leukotrienes and are thought to be involved with the initiation of Th2 type adaptive 
immune responses (Karasuyama et al., 2011; Min, 2008). Eosinophils, like basophils, also 
have a role in immune response to parasites and can release cytotoxic granules, 
inflammatory cytokines and leukotrienes (Munitz et al., 2004; Shamri et al., 2011). They 
also can assist in tissue remodelling (Hogan et al., 2008).   
  
Mast cells respond quickly to PAMP stimuli or antibody cross linking and upon activation 
they can release granuals containing chemokine, cytokine and lipid based mediators 
(Marshall, 2004). A key function of mast cells is enhancing the speed and magnitude of 
immune response by recruiting other innate and adaptive immune cells, as well as causing 
local vasodilatation through the release of histamine and serotonin (Abraham et al., 2010). 
 
NK cells represent a type of cytotoxic lymphocyte that can recognise and kill virus infected 
cells or tumour cells through the release of perforin and granzymes (Moretta et al., 2008). 
NK cells also contribute to defense from certain parasites and bacteria and are an important 
source of inflammatory cytokines such as IFN-γ and TNF-α (Bryceson et al., 2006) They 
also can have a immune regulatory role through interactions with APC and T cells (Vivier 
et al., 2008) 
 
Monocytes and macrophages, which are found in blood and other tissues respectively, 
have numerous roles in the innate immune response. As well as directly killing pathogens 
they recruit additional immune cells and secrete inflammatory cytokines such as IL-1, IL-6, 
TNF-α and IL-12 (Parihar et al., 2010). Like macrophages, dendritic cells (DCs) respond 
to PAMPs by expressing inflammatory cytokines, can phagocytose pathogens and recruit 
Chapter 1: General Introduction                                                                                         5 
 
other cells of the innate immune system (Steinman et al., 2006). DCs and macrophages 
also provide an important link between the innate and adaptive immune systems by 
presenting pathogen-derived antigens along with activation signals to cells of the adaptive 
immune system (Janeway et al., 2002; Steinman et al., 2006).    
 
1.3 Adaptive immune response  
Adaptive immune responses are much slower to develop than those of the innate immune 
system; however once developed, these responses can more specifically target invading 
pathogens. Additionally, due to the formation of immunological memory, a subsequent re-
encounter of a particular pathogen can result in a rapid and strong immune response. The 
adaptive immune system includes B and T lymphocyte responses and can be divided into 
humoral and cell-mediated immune responses, respectively.   
 
1.3.1 B cells 
B cells constitute the humoral arm of the adaptive immune response. The primary role of B 
cells is the production of antibodies, however they also secret cytokines and can act as 
APCs (Lund et al., 2010). B cell-produced antibodies function in three complementary 
ways: binding and neutralising pathogens or toxins, opsonising and mediating pathogen 
destruction via phagocytic cells, and activating complement (Casadevall et al., 2004). 
Following B cell receptor recognition of a specific antigen, and under the influence of T 
cell signaling, naïve B cells undergo a process of differentiation and proliferation (Batista 
et al., 2009). Following activation, B cells can also undergo a process of antibody class 
switching and somatic hypermutation, leading to improved antigen-specificity and changes 
in the isotypes that are produced (Li et al., 2004; Manis et al., 2002). Most mature B cells 
develop into plasma B cells, which produce large quantities of antibody; while a small 
number will form memory B cells, which are long lived and respond quickly to subsequent 
antigen challenge (McHeyzer-Williams et al., 2005).  
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1.3.2 Antigen presenting cells  
In contrast to B cells, which can recognise antigen directly via antibody, T cells only 
recognise antigen via their TCR when it is presented by an APC on surface-expressed 
major histocompatibility complex (MHC) molecules. There are two major mechanisms of 
antigen presentation, which occur via MHC molecules or human leukocyte antigens (HLA) 
in humans. Endogenous antigen derived from both host cells and intracellular viruses or 
bacteria are presented via MHC I molecules, whereas exogenous antigens from external 
pathogens are expressed on MHC II molecules (Jensen, 2007). The process of antigen 
presentation via the endogenious pathway involves the digestion of proteins into peptide 
fragments within the proteasomes of cells (Vyas et al., 2008). These peptide fragments are 
then attached to MHC I molecules which are expressed on the cell surface. Presentation of 
exogenous proteins on MHC II occurs following digestion of endocytosed proteins by 
proteases within the endosomes (Vyas et al., 2008). However, in some circumstances cross 
presentation can occur whereby extracellular antigens from the endosome are loaded onto 
MHC I molecules (Vyas et al., 2008). Antigen presentation on MHC I occurs in nearly all 
cell types, while antigen presentation via MHC II is mostly limited to professional APCs 
(Jensen, 2007). Professional APCs include dendritic cells, macrophages, B cells and 
thymic epithelial cells (Jensen, 2007). However MHC II antigen presentation can also 
occur via other cell types such as vascular endothelial and intestinal epithelial cells under 
specialised circumstances (Choi et al., 2004; Hershberg et al., 2000). 
 
Interactions between antigen expressing MHC molecules and T cell receptors (TCR) are 
crucial in the induction of cellular based adaptive immune responses. Along with antigen 
and MHC, APC provide other signals necessary for subsequent activation and 
development of T cell responses, and the success of the subsequent immune response is 
dependent not only on the specific recognition of the antigen, but also the presence of a 
number of adaptor proteins and co-stimulatory signals. The complex nature of these 
interactions allows for fine tuning of the immune response as well providing a regulatory 
mechanism with which to inhibit the development of non-specific or self reactive T cell 
responses.       
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1.3.3 T cells  
T cells are thymus-derived cells that are crucial for effective cellular based adaptive 
immune response. There are two distinct types of T cell lineages, that can be distinguished 
by their expression of αβ or γδ TCR (Ciofani et al., 2010). γδ T cells represent a small 
subset of T cells with both innate and adaptive immune characteristics (Bonneville et al., 
2010; Ciofani et al., 2010). αβ T cells make up the vast majority of T cells and can be 
broadly divided into two distinct cell types, CD8
+
 cytotoxic T cells which recognise 
antigens expressed by MHCI and CD4
+
 T helper cells which recognise antigen expressed 
by MHCII. Although CD4
+
 T cells and CD8
+
 cells are conventionally defined as helper 
and cytotoxic T cells, respectively, it should be noted that these definitions relate to the 
major but not exclusive role of these cells.  
 
1.3.4 CD8 Cytotoxic T cells 
The main function of CD8
+
 cytotoxic T cells (CTLs) is to identify and directly kill infected 
or abnormal cells (Choy, 2010). Recognition of a foreign antigen expressed on the surface 
of any cell within the body makes it a target for CTL-mediated destruction. This 
destruction occurs primarily though the release of granules containing perforin and 
granzymes or though Fas-Fas ligand (CD95/CD95L) interactions. Although the 
mechanism is not quite clear, perforin facilitates entry of granzymes into the target cell. 
Granzyme is a serine protease that initiates cell death though a number of pathways 
including caspase activation (Voskoboinik et al., 2006). Similarly, the ligation of CTL-
expressed Fas ligand to Fas on a target cell leads to caspase-mediated apoptosis (Krammer, 
2000). The release of cytokines, such as IFN-γ and TNF-α, from CTL can also assist in the 
destruction of target cells, as well as inducing recruitment of other effector cells (Harty et 
al., 2000). With their capacity to directly kill cells, CTL have an important role in 
controlling viral infections. 
 
1.3.5 CD4 T helper cells  
In contrast to CD8
+
 CTLs, the main function of CD4
+
 T helper cells is to activate or direct 
other immune cells to generate an appropriate immune response. CD4
+
 T cells are essential 
for B cell class switching, inducing most but not all CD8
+
 T cell responses and enhancing 
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or controlling macrophage responses. Formerly, naïve CD4
+
 T lymphocytes were thought 
to differentiate into distinct subsets T helper 1 (Th1) or T helper 2 (Th2) (Mosmann et al., 
1986); however in recent years the Th1/Th2 dichotomy has been reassessed and expanded 
to include other subsets including Th17 and regulatory T cells (Korn et al., 2009). All of 
these CD4
+
 Th subsets are defined by their cytokine profiles, expression of specific 
transcription factors, and their functional impact on other immune cells.  
 
Th1 cells develop following concurrent interaction with APC and IL-12 signalling and can 
be identified by expression of the transcription factor, T-bet (Jenner et al., 2009). Th1 cells 
are the classical inflammatory T helper linage, producing cytokines that include IFN-γ, 
TNF-α, and IL-2 (Abbas et al., 1996; Mosmann et al., 1986). These cells are important for 
clearance of intracellular pathogens and signalling by Th1 cells induces a primarily cell 
mediated immune response. In contrast Th2 cells play a major role in directing immune 
defenses against extracellular pathogens and inducing humoral immune responses. Th2 
cells produce cytokines such as IL-4, IL-5 and IL-13 and can be identified by the 
transcription factor GATA3 (Zhu et al., 2006). Th17 cells differentiate under the influence 
of IL-6 and TGF-β and require IL-23 to stabilise their phenotype. They can be identified 
by the expression of the transcription factor RORγt and they support neutrophil-mediated 
inflammation (Ivanov et al., 2006). Th17 cells primarily express IL-17, IL-21 and IL-22 
and appear to have a role in defending against extracellular bacteria and fungi (Louten et 
al., 2009). 
 
More recently further division of the T helper linage has been proposed, with IL-9 
producing Th9 cells and IL-22 producing Th22 being suggested as distinct subsets 
(Dardalhon et al., 2008; Eyerich et al., 2009; Veldhoen et al., 2008). Additionally, the 
concept that T cells commit to a distinct T cell linage may need revising, as more 
understanding is gained on the plasticity of specific T cell subsets (O'Shea et al., 2010).  
As novel cellular markers are identified and the ability to differentiate between subtle 
cellular differences is enhanced, it is likely further classification will develop. However, 
within the context of MS, the present focus of research has primarily been on the 
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Th1/Th17 inflammatory pathways and the regulation of these by regulatory T cells (Tregs) 
and Th2 cells.   
 
1.3.6 Regulatory T cells  
Unlike the other cell types mentioned Tregs are thought primarily to regulate the activity of 
the immune response and participate in the maintenance of immune tolerance (Sakaguchi 
et al., 2008). They can be identified by their high expression of the IL-2 receptor (CD25) 
and the transcription factor Foxp3 (Sakaguchi, 2001). A number of different types of Tregs 
have been described; however the main distinction is of those ‘naturally’ arising from the 
thymus and those that are ‘induced’ from naïve T cells within the periphery (Campbell et 
al., 2011; Sakaguchi et al., 2006). Although the majority of Tregs are technically 
autoreactive in the sense that they express TCR that recognise self-antigen (Picca et al., 
2006) these cells act to suppress other T cell subsets though activation of Foxp3 dependent  
regulatory processes, the induction of regulatory cytokines such as IL-10, regulation of 
cytokine levels (e.g. IL-2), or through direct cell to cell interactions (Campbell et al., 2011; 
Li et al., 2008; Tang et al., 2008; Vignali et al., 2008).  
 
1.4 T cell activation  
The specificity of the adaptive immune response is provided by a system in which each 
naïve T cell carries TCRs specific for a particular antigen. The membrane bound α and β 
chains of the TCR each contain variable regions which are formed by the recombination of 
gene segments (VDJ) during T cell development in the thymus (Smith-Garvin et al., 2009). 
This process provides a huge array of potential antigen receptors. The variable regions 
interact with antigen expressed on MHC molecules and are critical in the antigen 
recognition process. In addition to the TCRs, T cells express either CD8 or CD4 co-
receptors, which recognise conserved regions of MHC I or MHC II respectively. While the 
TCR/MHC interaction supports antigen-specific recognition, the TCR requires the CD3 
complex to generate the signaling cascades that lead to gene transcription and T cell 
activation (Smith-Garvin et al., 2009). For successful naïve T cell activation, signaling via 
co-stimulatory molecules has to occur in concurrence with TCR activation.  
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The most well characterised co-stimulatory molecules are CD80 (B7.1) and CD86 (B7.2) 
which are expressed on APCs and interact with T cells though CD28 or cytotoxic T 
lymphocyte associated protein 4 (CTLA-4; CD152) (Merwe et al., 2003) The functional 
difference between CD80 and CD86 still remains unclear; however, ligation of either of 
these molecules with CD28 promotes T cell activation (Sansom et al., 2003). In contrast, 
CD80 or CD86 interactions with CTLA-4 negatively regulates T cell activation. and 
although CTLA-4 has higher affinity for CD80 and CD86 than CD28, unlike CD28, it is 
not constitutively expressed (Alegre et al., 2001). CTLA-4 acts to limit the immune 
response or inhibit T cell activation and is highly expressed by Tregs (Sakaguchi et al., 
2009). Expression of CTLA-4 can also be up-regulated on effector T cells following TCR 
engagement (Jain et al., 2010). In addition to CD80/86, other co-stimulatory molecules 
include (but are not limited to) CD40, inducible co-stimulator (ICOS) and PD-1. 
Interaction of CD40 with CD40L (CD154) on T cells results in an up-regulation of MHC-
II and production of inflammatory cytokines (Suttles et al., 2009). CD40 is also an 
important co-stimulatory molecule for the activation of antigen-specific T cell responses 
(Grewal et al., 1998). ICOS is involved in inducing effector T cell responses and initiating 
the up-regulations of chemokine receptor expression, which is necessary for the 
development of effective humeral immune responses (Nurieva et al., 2009; Sharpe, 2009). 
In contrast, PD-1 interaction acts to induce tolerance and regulate T cell activation 
(Nurieva et al., 2009).   
 
1.5 Immune tolerance  
After successful V(D)J recombination during T cell development, a single cell will only 
express one unique receptor. This recombination process allows a relatively small number 
of genes to generate a vast number of unique antigen receptors. However, as this process 
can result in receptors that are non-functional (i.e. cannot recognise self MHC) or 
recognise self-antigens, a number of selective steps are used to identify and remove non-
functional or self-reactive cells. These processes are referred to as immune tolerance.  
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Central immune tolerance is the main mechanism by which self-reactive T cells are 
eliminated. This process occurs in the thymus, where immature T cells go through both a 
positive and negative selection process. During positive selection only T cells that can 
successfully interact with MHC molecules are allowed to survive, ensuring that only 
functional T cells are positively selected (Starr et al., 2003). On the other hand, negative 
selection provides a screening mechanism to identify and remove T cells that are self-
reactive. This process involves the expression of many but not all self-antigens within the 
thymus by thymic APC. Any T cell that reacts strongly to one of these self-antigens is not 
allowed to progress and is deleted (Palmer, 2003). If however, a T cell possesses weak to 
modest affinity for a self-antigen it is driven to express FoxP3 and develop into a ‘natural’ 
thymic-derived Treg. 
 
Despite effective central tolerance, some self-reactive T cells may slip through the 
selection process and be released into the periphery and ultimately induce autoimmunity. A 
variety of secondary safety mechanisms, collectively referred to as peripheral tolerance, 
are used to stop these T cells from causing autoimmune disease.  Peripheral tolerance can 
occur via active suppression, through regulatory cell populations such as Tregs or other 
direct cell to cell interactions, while passive suppression can occur though for example,  a 
process of cell anergy (Mueller, 2010; Walker et al., 2002). 
 
For successful naïve T cell activation, the TCR must recognise antigen expressed on MHC 
molecules as well as receive a second co-stimulatory signal often through CD28 (Fathman 
et al., 2007). Failure to simultaneously receive both signals results in T cell anergy, where 
by the T cell becomes permanently unresponsive (Fathman et al., 2007). As co-stimulatory 
molecules are up-regulated on APC after ligation of PRR by microbial products, it is 
unlikely that co-stimulatory molecules will be expressed under normal conditions when 
primarily self-antigens are presented by APC. Thus, it is believed that in this case, 
autoreactive naïve T cells recognising antigen in the absence of co-stimulation will become 
anergic.  
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Active forms of peripheral tolerance are mediated by cells directly intervening in the 
activity of another immune cell. This can take the form of cell surface expressed molecules 
such as PD-1 or CTLA-4, which when ligated can transmit inhibitory signals to T cells 
expressing these receptors (Alegre et al., 2001). There are also specific cell types that 
appear to act as regulators of the immune system, these include Tregs and myeloid-derived 
suppressor cells (MDSCs) and certain macrophage subsets. (Gabrilovich et al., 2009; 
Sakaguchi et al., 2008; Zorro Manrique et al., 2011).  Tregs can suppress autoreactive cell 
responses through multiple mechanisms including co-stimulatory blockade, impairing T 
cell/APC interactions and though secretion of cytokines such as IL-10 and IL-35 or pro-
apoptotic factors such as granzyme (Chaturvedi et al., 2011; Collison et al., 2007; Tang et 
al., 2008). MDSCs can alter cell activation through depletion of essential amino acids, 
production of reactive oxygen or nitrogen species and through cell to cell interactions 
(Condamine et al., 2011; Gabrilovich et al., 2009). Additionally certain macrophage 
phenotypes act in a regulatory manner by secretion of cytokines such as IL-10, down-
regulation of co-stimulatory molecules and inflammatory cytokines (Anderson et al., 
2002b; Tierney et al., 2009; Zorro Manrique et al., 2011).   
 
There are certain tissues of the body, such as the eyes, testes and CNS that are less 
immunologically reactive than the rest of the body. These areas are maintained in what has 
traditionally been referred to as ‘immune privileged’ states though a number of active and 
passive toleragenic process (Streilein et al., 2000). In addition to the tolerance mechanisms 
mentioned already, cells within these tissues can have decreased MHC expression and 
secrete increased levels of regulatory cytokines and inhibitors of migration (Hong et al., 
1999; Rosenzweig et al., 2011; Streilein et al., 2000). This combined with physical barriers 
and reduced lymphatic drainage reduces the immune surveillance and reactivity of immune 
cells within these tissues.  
 
If the maintenance of immune tolerance fails, immune cells reactive to self-peptides can 
elicit an inflammatory immune response. This can lead to the development of autoimmune 
diseases, such as MS. 
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1.6 Multiple sclerosis  
MS is a chronic inflammatory disease, mediated by immune cells targeting the myelin 
sheaths that surround nerve axons. The damage caused is characterised by plaque 
formation and CNS dysfunction. The symptoms of MS are mainly related to altered nerve 
conduction which results in muscular neuropathy/spasticity, altered pain and tactile 
sensation, loss of bowel or bladder control and potential cognitive dysfunction (Lutton et 
al., 2004). There is much heterogeneity in disease presentation and pathology, particular 
disease symptoms can be chronic or transient and range from mild to severe (Lucchinetti et 
al., 2000). The diversity in disease symptoms, clinical progression and the immune 
responses that underlie these, adds to the complexity of both diagnosing and treating MS.  
 
There are two main forms of multiple sclerosis, relapsing-remitting (RRMS) and primary 
progressive (PPMS) (Lubin et al., 1996). Relapsing-remitting is the most prevalent with 
85-90% of all cases initially falling within this category (Sospedra et al., 2005a). Many 
relapsing-remitting cases develop into a secondary-progressive form within five to ten 
years of disease onset (Steinman, 2001). The usual age of onset ranges between 20-40 
years of age, however MS can be diagnosed within the first decade of life (Banwell et al., 
2007). Although MS is not usually considered a lethal disease, mortality can result in some 
rare circumstances, when brainstem lesions occur (Barnett et al., 2004). Additionally, it 
has been estimated that MS sufferers have an overall 5-10 year reduction in life expectancy 
compared to the general population (Ragonese et al., 2008). Women are more susceptible 
to MS than men, with a prevalence ratio of around 2.5:1 in RRMS, however this gender 
bias is not evident in PPMS (Keegan et al., 2002; Willer et al., 2003). 
 
1.6.1 Disease aetiology  
Despite an extensive amount of research no definitive causative factors for MS have been 
identified, although epidemiological studies have identified a variety of potential risk 
factors including diet, smoking, infectious agents, geographical location and genetics 
(George C, 2008; Handel et al., 2011; Nielsen et al., 2007). Several large studies have 
explored genetic risk factors for MS. Genes that have consistently been recognised to 
confer risk are those associated with MHC II alleles, these include HLA-DR and HLA-DQ 
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(Consortium, 2011; Dyment et al., 2005; Dyment et al., 1997). The concordance rate of 
MS in monozygotic twins is around 25% in high prevalence countries (Mumford et al., 
1994; Willer et al., 2003). Overall concordance in dizygotic twins is around 3-5% and non-
twin siblings is around 0.1-0.4% (Mumford et al., 1994; Sadovnick et al., 1996). However, 
if males are analysed separately the concordance between dizygotic and monozygotic 
twins is similar, which highlights the important role sexual dimorphism has in MS (Willer 
et al., 2003). The relatively low concordance rates and minimal gene associations suggest 
non-genetic factors are more significant determinants in the aetiology of MS. 
 
It has been postulated that viral agents such as human herpes virus 6, JC virus and Epstein 
Barr virus (EBV) could have a role in causing MS, however strong causative associations 
between these viruses and the development of MS have yet to be shown (Donald H, 2005; 
Noseworthy, 1999). Most of the research investigating the potential link between MS and 
viruses has focused on EBV and its clinically defined condition, infectious mononucleosis. 
Studies on large cohorts of MS patents have shown an approximate 2-fold increase in the 
risk of MS development in people that had previously had infectious mononucleosis 
(Lucas et al., 2011; Nielsen et al., 2007). However EBV is estimated to infect over 90% of 
the world’s population, with around 40% of adolescent or adults experiencing infectious 
mononucleosis (Ascherio et al., 2011; Macsween et al., 2003). The fact that EBV infection 
is so wide spread suggests that any role this infection has in MS etiology is only a small 
contributing factor.  
 
A correlation between latitude and MS has been reported with increased prevalence at 
higher latitudes. A meta-analysis of over 300 peer-reviewed studies has recently 
demonstrated a significant correlation between latitude and MS prevalence, although  this 
correlation is not absolute since some areas, such as Italy and a few Scandinavian countries, 
do not follow the overall trend (Simpson et al., 2011). This correlation between latitude 
and MS has been postulated to be associated with reduced sunlight hours at higher 
latitudes and the subsequent reduction in vitamin D production (Pierrot-Deseilligny et al., 
2010).  
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The vitamin D hypothesis has gained momentum as a credible explanation for the 
latitudinal variance. Low plasma levels of Vitamin D correlate both to higher latitude and 
to increased risk of MS (Handel et al., 2010). While most vitamin D is synthesised during 
exposure to sunlight (ie. UVB radiation), certain foods can also provide a source of 
vitamin D (Ascherio et al., 2010). In some populations that consume large quantities of 
vitamin D rich food, the prevalence of MS is lower than would be predicted by latitudinal 
variance (Ascherio et al., 2010). Additionally, within a large 30 year prospective study, 
supplementation with vitamin D was associated with reduced MS incidence risk (Munger 
et al., 2004).    
 
Another potential explanation for some of the geographical variation could be associations 
with infectious organisms that are more prevalent in warmer climates (Fleming et al., 
2006). The low incidence of MS in tropical regions relative to colder climates has been 
suggested to be associated with parasitic load of the populations living in the respective 
regions (Correale et al., 2011). Epidemiological studies have demonstrated that areas with 
high autoimmune disease prevalence exhibit an inverse relationship to areas of high 
parasitic load (Bach, 2002; Zaccone et al., 2006). This inverse relationship also occurs 
with MS, as countries with a high prevalence of helminth infections have low MS 
incidence rates (Fleming et al., 2006; Philippe, 2009). Additionally longitudinal studies in 
the West Indies have found incidence of MS increased over time while parasitic infections 
have concurrently decreased (Cabre et al., 2005). Moreover, patients with RRMS who are 
subsequently infected with helminths have a reduced relapse rate and disease progression 
suggesting that parasites may have a protective effect on the autoimmune process (Correale 
et al., 2007; Correale et al., 2008). On the strength of this evidence and of studies in 
animal models, a phase I clinical trial was run and demonstrated the potential of helminths 
to treat RRMS and a phase II trial is currently underway (Fleming et al., 2011).  
 
Like the heterogeneity in disease symptoms and pathology, it is likely that the factors 
which cause MS may vary and be specific to the individual. The epidemiological research 
discussed above indicates that no clear single causal factor has been established. This 
suggests that multiple culminating factors are required to induce MS and that pinpointing a 
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particular cause for this disease may not be possible. Therefore development of treatments 
for MS needs to rely on understanding the immunology and pathology of disease 
progression and ways to alter these processes.  
 
1.6.2 Multiple sclerosis immunology  
MS is thought to be primarily driven by autoreactive CD4
+
 T cells targeting myelin 
proteins, such as myelin basic protein (MBP), proteolipid protein (PLP) and myelin 
oligodendrocyte glycoprotein (MOG) (Steinman, 1996). However, the mere presence of 
myelin reactive T cells is not sufficient to induce disease, as these autoreactive cells can be 
found within the blood of both MS patients and within the general population (Ota et al., 
1990; Pender et al., 1996). Nevertheless autoreactive cells from MS patients do become 
activated more readily than cells from healthy individuals and these cells occur in higher 
numbers, suggesting clonal expansion of these self-reactive cells occurs within MS 
patients but not the general population (Bar-Or et al., 1999). While MS is considered to be 
a CD4
+
 T cell mediated disease, many other cell types have a role including local glial 
cells, CD8
+
 T cells, macrophages, mast cells and B cells (Friese et al., 2009; Genain et al., 
1999; Henderson et al., 2009; Sospedra et al., 2005b). 
 
What initiates the underlying immune response is not known, however it is generally 
believed that the induction of the autoimmune cascade that ultimately leads to MS occurs 
in the periphery (McQualter et al., 2007). It has been suggested that these initial events 
could be caused by molecular mimicry, whereby myelin reactive T cells become activated 
after encounters with bacterial or viral antigens that have a similar molecular sequence or 
structures to that of myelin based antigens (Libbey et al., 2007). Although molecular 
mimicry could potentially provide an explanation for the heterogeneity of disease onset 
and pathology, as well as the regional differences in incidence, there is very little evidence 
to support this theory.   
 
It has also been found that Tregs, which usually suppress the activation of autoreactive T 
cells, are often functionally deficient in MS patients (Haas et al., 2005; Viglietta et al., 
2004). While Tregs are found in MS patients they often occur in lower numbers and have 
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impaired regulatory activity (Costantino et al., 2008; Viglietta et al., 2004). It is possible 
that impaired Treg function allows for expansion of autoreactive T cell responses and the 
induction of an autoimmune response. 
 
From the periphery, the myelin reactive T cells must traffic into the CNS to induce disease 
pathology. Because the CNS is an immune privileged area, any immune cell trafficking 
that occurs is tightly regulated by the specialised endothelial cells that make up the blood 
brain barrier (BBB)(Carson et al., 2006). For autoreactive T cells to enter into the CNS, it 
is believed that some perturbation of this regulatory barrier must occur (Larochelle et al., 
2011). In MS patients, breakdown and permeability of the BBB is apparent, allowing for 
immune cell infiltrations into the CNS (Minagar et al., 2003; Stone et al., 1995). This 
infiltration can occur though the secretion of inflammatory cytokines, chemokines and 
reactive oxygen species, which results in increased permeability and immune cell 
migration (Wilson et al., 2010). These processes are also aided by the destruction of 
extracellular matrix components by macrophage- and T cell-derived matrix 
metalloprotenases (Minagar et al., 2003). Immune cell transit from the periphery into the 
CNS is clearly a crucial factor in the disease process since inhibiting this migration is an 
effective way of treating MS (Hutchinson, 2007). Once autoreactive T cell have gained 
access to the CNS and recognised myelin antigens (present within the CNS white matter), 
these cells can recruit further cells and cause development of an inflammatory lesion. 
Although most of the lesions occur in white matter, grey matter (i.e. neuronal tissue) 
lesions can often also be detected, indicating that tissue damage occurring during MS is not 
solely limited to myelinated areas (Stadelmann et al., 2008). Reactive oxygen and nitrogen 
species, complement, antibodies, microglia, CD4
+
, CD8
+
, neutrophils, B cells and 
macrophages are all thought to have a role in tissue destruction (Disanto et al., 2011; 
Frohman et al., 2006; Gay et al., 1997; Genain et al., 1999). However, while CD4
+
 cells 
are crucial for initiation of disease, macrophages and CD8
+
 T cells are the most prevalent 
within lesions, suggesting these cell may have a significant role in causing the damage 
(Disanto et al., 2011; McQualter et al., 2007). After the initial inflammatory influx, over 
time the inflammation will usually recede and depending on the severity of damage, the 
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myelin may regenerate or scars may be formed and irreversible axonal damage could have 
occurred (Frohman et al., 2006).   
 
Due to the obvious limitations in studying immune responses and disease pathology in MS 
patients, most of the knowledge of underlying immunology of MS within the CNS has 
been gained from post-mortem studies or is inferred from animal models of MS (discussed 
below). 
 
1.6.3 Current treatment options  
There are currently eight food and drug administration (FDA) approved disease modifing 
therapies, which are mainly used in the treatment of relapsing–remitting MS. None of the 
current drugs are effective for primary-progressive disease (Leary et al., 2005). While all 
MS therapies have distinct mechanisms of actions, most have a limited efficacy rate of 
between 30-60% for reducing relapse rates or disability progression (Confavreux et al., 
2006; DeAngelis et al., 2008; Sorensen, 2007). The exception is Natalizumab which can 
provide 40-70% reductions in disease progression, but is also associated with progressive 
multifocal leukoencephalopathy (PML), a potentially fatal brain disease (Hutchinson, 
2007).         
 
The first drug introduced to the market was Betaferon/Betaseron®, an interferon-β 1b 
cytokine in 1993. Two further interferon-based cytokine treatments, Avonex® and Rebif ®, 
which are both recombinant interferon-β 1a, followed in 1996 and 2002, respectively. 
These drugs potentially work by altering the immune response through a number of 
mechanisms, including preventing up-regulation of MHC II expression on antigen 
presenting cells (APC), causing down-regulation of co-stimulatory molecules and 
inhibiting cell migration across the BBB (Dhib-Jalbut et al., 2010; Nakatsuji et al., 2007). 
interferon-β is administered 1-3 times a week by subcutaneous or intramuscular injection 
and despite inducing flu-like symptoms it is generally well tolerated (Limmroth et al., 
2011). However, the efficacy of interferon-β can substantially diminish as the body begins 
to develop antibodies against the recombinant protein (Giovannoni et al., 2002).     
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In 1996, glatiramer acetate (GA) was approved under the name Copaxone® and is 
currently the most prescribed treatment in the United States (Boster et al., 2011a). It 
consists of short random length polypeptide sequences constructed of tyrosine, glutamic 
acid, alanine and lysine residues in similar ratios to that found in myelin basic protein 
(Schrempf et al., 2007). GA is administered every day by subcutaneous injection and is 
considered by some to have the mildest adverse reactions, which include injection site 
inflammation, chest tightness and anxiety (Boster et al., 2011b; Ruggieri et al., 2007). Like 
interferon-β treatments, patients can develop antibodies to GA, however, anti-GA 
antibodies do not appear to have much of an impact on treatment efficacy (Karussis et al., 
2010; Teitelbaum et al., 2003). GAs mechanism of action is not fully understood, however 
it is known to be presented by MHC II on APCs and cause alterations in T cell effector 
responses (Ruggieri et al., 2007). In animal studies as well as human studies, GA has also 
been shown to have a variety of other effects including Th2 response biasing induction of 
Tregs, and altering monocyte and microglial activation (Aharoni et al., 2010; Aharoni et 
al., 1997; Toker et al., 2011; Weber et al., 2007). How GA mediates these wide ranging 
effects is, however, unclear. 
 
Mitoxantrone, a type II topoisomerase inhibitor that is used in cancer chemotherapy, was 
released as Novantrone® in 2000 and is the only treatment available for secondary 
progressive MS (SPMS). It is an effective treatment for both RRMS and SPMS resulting in 
30-60% reductions in relapse rates and disability progression, respectively (Esposito et al., 
2010; Hartung et al., 2002). Mitoxantrone is administered by intravenous infusion every 
few months and causes acute side effects which include nausea, vomiting and hair loss; as 
well as long term side effects, which include cardiotoxicity and increased risk of leukemia 
(Marriott et al., 2010). Due to the severity of the long term side effects, its use is limited to 
patients that have very active disease or have not responded to other treatment options 
(Marriott et al., 2010). Moreover, it has a restricted cumulative lifetime limit of 8-12 doses 
meaning it can only be used as a transitory treatment option (Neuhaus et al., 2006). 
 
Natalizumab, marketed as Tysabri®, is a humanised monoclonal antibody against α4β1-
integrin (VLA-4), which is an important adhesion molecule expressed on T cells. Binding 
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of α4β1-intergrin to the endothelial-expressed VCAM-1 is a necessary step for T cell 
migration into the CNS, and the inhibition of this process by Natalizumab has proved an 
effective method of decreasing MS relapses (Hutchinson, 2007). Natalizumab is 
administered by monthly intravenous infusions and side effects include infusion reactions, 
nausea, fatigue and limb swelling (Pucci et al., 2011). Additionally, three months 
following Natalizumab release in 2004, it was quickly withdrawn when it became apparent 
that it contributes to the development of the usually lethal viral disease, progressive 
multifocal leukoencephalopathy (PML), in some patients (Chaudhuri, 2005; Tan et al., 
2010). Despite this finding, Natalizamab was re-released in 2006 due to its high efficacy 
rates but under strict monitoring guidelines and with the patients’ knowledge that there is a 
1:1000 risk of developing PML (Tan et al., 2010; Yousry et al., 2006).  
 
Fingolimod (FTY720) is an oral treatment that was approved by FDA in 2010 (Singer et 
al., 2011).  It is marketed under the name Gilenya® and is indicated for RRMS. 
Fingolimod is a fungual derivative that modulates sphingosine 1-phosphate and causes 
inhibition of the egress of lymphocytes from lymph nodes (Kataoka et al., 2005). This in 
turn prevents subsequent lymphocyte migration into the CNS; however it may also have 
more direct effects within the CNS (Brinkmann, 2009; Kataoka et al., 2005; Lee et al., 
2010). Fingolimod is the first orally administered treatment for MS, side effects include 
headache, back pain and increased risk of contracting influenza (Kappos et al., 2006; 
Singer et al., 2011). The disease modifying effects of fingolimod diminish rapidly once the 
drug has been cleared from the body and thefore daily doses must be taken (Kovarik et al., 
2007). Results from Phase III trials indicate that fingolimod is well tolerated and may have 
improved efficacy over interferon-β in reducing relapse rates and disability progression 
(Cohen et al., 2010; Kappos et al., 2010). 
  
MS is a chronic disease that can afflict patients for many decades. None of the current 
treatments cure the disease, and patients will spend their lives using these drugs. 
Additionally the cost effectiveness of the current disease modifying therapies is very low 
(Noyes et al., 2011). The combination of these two factors makes MS a very costly disease 
to treat and places a large burden on patients and health care providers. It becomes 
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apparent when considering the limited scope and efficacy of current treatments that more 
effective options are needed. However, the variable nature of immunological and clinical 
disease manifestations, as well as the limited understanding of disease aetiology, makes 
disease specific drug targeting difficult. To overcome the heterogeneity in disease 
expression, future therapies will ideally provide a broad spectrum of effects, which may 
include the removal or tolerance of autoreactive T cells, the inhibition or reversal of CNS 
pathology and the restoration of normal immune activity. 
 
1.7 Animal models of multiple sclerosis  
A number of different animal models have been used to explore potential factors 
associated with MS. These include viral and antigen-induced encephalomyelitis, drug 
induced demyelination and genetically modified models. Of these models, experimental 
autoimmune encephalomyelitis (EAE) is the most commonly used and well defined, and 
has been used to develop many of the current MS treatments (Steinman et al., 2005). To 
induce EAE, laboratory animals are immunised with myelin peptides or proteins, which 
leads to an autoimmune response that mimics aspects of MS pathology. There are two 
main forms of EAE induction; active, which involves direct immunisation with 
encephalitogenic compounds and passive, which involves the adoptive transfer of primed 
encephalitogenic CD4
+
 T cells into naïve animals (Gold et al., 2000). Using these basic 
techniques, many variations have been developed to induce distinct aspects of disease 
presentation which emulate that of MS (Gold et al., 2006).  
 
Mice, a species regularly used in EAE experiments, often exhibit strain specific 
susceptibly and pathology to a particular antigen. SJL/J mice are susceptible to MOG, PLP 
and MBP and exhibit a relapsing-remitting type EAE (Amor et al., 1994; Pettinelli et al., 
1982; Tuohy et al., 1988). In C57BL/6 mice MOG is often used to induce EAE, which 
results in severe, chronic disease expression (Bernard et al., 1997). Balb/c mice have 
traditionally been considered more resistant to EAE (Duong et al., 1994a; Tuohy et al., 
1988). While disease can be induced in Balb/c by PLP, in contrast to C57BL/6, the disease 
has a lower induction rate (50-60%), milder disease symptoms, and the disease completely 
resolves (Greer et al., 1996; Lyons et al., 2002). The divergence in disease presentation 
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between different experimental protocols or mice stains can be used beneficially to explore 
different aspects of pathology, relevant to MS. 
 
There is ongoing debate on the applicability of the different animal models of MS and 
whether they are useful for drug development (Baker et al., 2011; Sriram et al., 2005). 
Many novel treatments which have shown some success within animal models have failed 
to translate into human therapies. However most of the current MS treatments were 
developed within EAE models, indicating that there is some value to this method of drug 
development (Steinman et al., 2005). Additionally, as no adequate alternative methods of 
MS drug development have been proposed, animal models currently provide the most 
likely pathway to identifying new treatments for MS.  
 
Most of the experiments conducted in the current study have used C57BL/6 mice 
immunised with a synthetic MOG peptide comprising of amino acids 35-55, which is 
injected in complete Freund's adjuvant (CFA). Using this model, 80-100% of mice develop 
a ‘chronic progressive’ disease 1-2 weeks after immunisation. Within four weeks after 
immunisation, partial remission of disease symptoms can be observed, but full recovery is 
rare. This model is the most commonly used EAE model and due to high incidence rates 
and robust disease expression, it provides a good platform with which to explore potential 
MS treatments. 
  
1.7.1 Immunology of EAE  
EAE is primarily a CD4
+
 T cell mediated disease and exhibits many of the characteristic 
immunological events that occur in MS. It is, however, important to keep in mind that 
unlike MS, for EAE to occur, the immune system has to be artificially induced to break 
self-tolerance and develop an autoimmune state. As mentioned above induction of EAE 
can be by immunisation with a combination of myelin based peptide/proteins and a strong 
immune adjuvant, or though the transfer of T cells that are already reactive to myelin 
antigens. In either of these systems autoreactive T cells have to be generated to induce 
disease.  
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Induction of autoreactive T cells occurs following exposure to APCs that present myelin 
based peptides and co-stimulatory molecules to naïve CD4
+
 T cells. T cells that recognise 
these peptides undergo a process of maturation and clonal expansion that results in the 
development of a large pool of myelin-reactive T helper cells. The particular subset of T 
helper cells (eg Th1/Th2/Th17) that develops depends on the cytokine environment present 
during the development process. It was originally believed that EAE and MS were Th1 
mediated diseases. However, the identification and characterisation of Th17 cells has led to 
revision of this paradigm, and it is now apparent that Th17 cells have a crucial role in EAE 
(Steinman, 2007).  
 
A number of factors implicate Th17 immune responses in mediating disease pathology. 
EAE is exacerbated in either IFN-γ deficient or IFN-γ receptor deficient mice (Ferber et al., 
1996b; Sabatino et al., 2008). In contrast IL-17 deficient mice or mice treated with anti-IL-
17 antibodies have attenuated disease expression (Hofstetter et al., 2005; Komiyama et al., 
2006b). Additionally mice lacking functional IL-23 (which sustains Th17 cells) but not IL-
12 (which induces Th1 cells) are resistant to EAE (Cua et al., 2003). It also appears that in 
some situations Th1 expressed IFN-γ can reduce Th17 encephalogenic cell numbers, while 
conversely an absence of IFN-γ results in increased Th17 cells (Berghmans et al., 2011). 
These studies suggest that Th17 cell may have an important role in EAE disease pathology. 
Despite these findings, EAE is not completely ablated in the absence of IL-17 indicating 
that EAE is not solely mediated by Th17 cells (Komiyama et al., 2006a). Indeed this idea 
is supported by adoptive transfer experiments whereby purified populations of myelin 
reactive Th17 cells only induce mild EAE, while adoptively transferred Th1 cells result in 
severe disease (O'Connor et al., 2008). Collectively these results suggest a role both for 
Th1 and Th17 type responses in EAE.  
 
For autoreactive T cells to induce disease, they must migrate from the peripheral lymphoid 
organs into the CNS. Studies have shown that leukocytes enter CNS in healthy individuals 
although in relatively low numbers and with the majority of cells being CD4
+
 memory T 
cells (Ransohoff et al., 2003). It is thought that these cells gain access by migration across 
the endothelium and epithelium associated with the choroid plexis to enter into the cerebral 
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spinal fluid within the subarachnoid space (Carrithers et al., 2002; Ransohoff et al., 2003). 
In EAE immunised mice, the subarachnoid space is the first site within the CNS where 
autoreactive T cells are detected, suggesting this maybe the initial site of T cell re-
activation within the CNS (Kivisäkk et al., 2009). It is thought that following reactivation, 
cytokine and chemokine signalling results in the recruitment of other immune cells to the 
CNS as well as causing up-regulation of adhesion molecules on vascular endothelial cells 
(Engelhardt, 2010; Goverman, 2009; Steinman, 2005).  
 
Expression of adhesion molecules on vascular endothelial cells is crucial to the extravasion 
process necessary for large numbers of activated T cells to cross the BBB.  During EAE, 
intracellular adhesion molecule-1 (ICAM-1) and vascular adhesion molecule-1 (VCAM-1) 
are up-regulated by vascular endothelial cells (Steffen et al., 1994). These bind to α4β1 
integrin (VLA-4) and lymphocyte function-associated antigen 1 (LFA-1) which are 
expressed on encephalogenic T cells (Engelhardt, 2010; Engelhardt et al., 1998b). 
Interactions between these adhesion molecules are a crucial step in the process of T cell 
extravasations from the blood into the CNS and inhibition of  α4β1 or  VCAM1 inhibits 
EAE development (Engelhardt et al., 1998a; Piraino et al., 2002). 
 
As more T cells infiltrate into the CNS and recognise myelin antigens, the inflammatory 
response is amplified. Cytokines (e.g. IFN-γ, IL-17, TNF-α) and chemokines (e.g. CCL3, 
CCL20) are secreted from the infiltrating T cells to further enhance inflammation and 
recruit additional inflammatory cells including more Th cells, NK cells, macrophages, and 
CD8
+
 T cells (Behi et al., 2005; Engelhardt, 2010; Karpus et al., 1998; McFarland et al., 
2007; McQualter et al., 2007). These cells can mediate direct damage to the 
oligodendrocytes and induce demyelination. CD8
+
 T cells can participate in this 
destruction with the release of cytotoxic molecules or by receptor mediated apoptosis, 
through for example granzyme B and Fas-FasL interactions, respectively (Johnson et al., 
2010). Macrophages and microglia also have an important role in pathology and can cause 
direct tissue damage through production of MMPs, NO and reactive oxygen species (Herz 
et al., 2009; McQualter et al., 2007).  
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However the inflammatory responses do not proceed unchecked, as most mice exhibit 
some form of remission. The regulation of the inflammatory process appears to be 
associated with Tregs, which accumulate in the CNS during the recovery phase of disease 
and depletion of these cells worsens disease and inhibits recovery (McGeachy et al., 2005; 
McNeill et al., 2007). Regulation of effector T cells by Tregs during EAE appears to be 
mediated by production of  IL-10 and TGF-β as well as direct cell-to-cell mediated 
interactions (Fletcher et al., 2010; Vignali et al., 2008; Zhang et al., 2004).  However, 
these cells are not the only cells important in regulation of the inflammatory response and 
in some cases their regulatory function may be inhibited. For example, Tregs can be 
present during the height of inflammation but during this time, inflammatory cytokines 
such as TNF-α and IL-6 may be inhibiting Treg function or even subverting Tregs towards 
an inflammatory phenotype (Hawiger et al., 2009; Korn et al., 2007; O'Connor et al., 
2010). This finding suggests that other cell types may have to initiate regulatory processes 
before Tregs can be effective. Additionally, classical pro-inflammatory cytokines such as 
IFN-γ may also have a paradoxical role in regulating the magnitude and duration of 
inflammatory responses (Sabatino et al., 2008; Zhang, 2007). Thus both the cytokine 
melee as well as the cellular composition of the lesions, is likely to influence the regulatory 
processes necessary for remission.     
 
In summary, EAE is clearly a complex disease that involves a large cascade of events. 
Overall, the disease process can be divided into three crucial steps: 1) activation and clonal 
expansion of myelin reactive T cells, 2) migration of myelin reactive T cells from the 
periphery into the CNS, 3) amplification of inflammatory responses in the CNS and 
development of inflammatory lesions. These three steps provide targets against which drug 
interventions can be directed. 
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1.8 Overall aims and objectives 
From the outset, the overall goal of this thesis was to identify potential therapies for MS, 
using the EAE model. As such, this thesis developed into three separate lines of inquiry. 
The primarily focus has been expanding previous work conducted in our laboratory 
investigating the use and mechanisms of actions of microtubule-stabilising drugs for the 
treatment of EAE. As opportunities arose, two other distinct and novel therapies; the use of 
an antipsychotic, risperidone and using a TLR-9/NOD2 agonist to treat EAE, were also 
explored. The specific details of each compound, the justifications for exploring each 
treatment option and specific hypotheses are introduced at the start of each chapter. 
 
 
The overall aims of this thesis are: 
 
1. To explore the use of microtubule-stabilising drugs to treat EAE. 
 
2. To identify potential mechanisms of action by which microtubule-stabilising drugs 
alter disease expression. 
 
3. To determine if the treatment efficacy of microtubule-stabilising drugs are 
enhanced when used together or in combination with another disease modifying 
agent.   
 
4. To evaluate whether the anti-psychotic drug, risperidone, can modify EAE disease 
expression and inflammatory macrophage activation. 
 
5. To investigate if a novel TLR9/NOD2 agonist, MIS416, can alter EAE disease 
responses.  
  
 
 
 
Chapter 2:  
Materials and Methods 
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2.1 Mice 
All animals were housed in the animal facilities at Victoria University of Wellington, New 
Zealand. Experimental protocols were approved by the Victoria University of Wellington 
Animal Ethics Committee (AEC) under the licenses 2002R6 and 2004R17. The animals 
were maintained in a temperature-regulated environment with a 12-hour light/dark cycle. 
Mice were kept in filter-top cages and any handling of the animals was conducted in a 
laminar flow workspace. 
 
C57BL/6J (H-2b) mice were bred at the Malaghan Institute of Medical Research 
(Wellington, NZ), or the Biological Research Unit (Wellington School of Medicine, 
Wellington, NZ). Breeding stock was originally purchased from the Jackson Laboratory 
(Bar Harbour, ME, USA). 
 
SJL/J mice were bred at Victoria University of Wellington. Breeding stock was originally 
purchased from Animal Resource Centre (Canning Vale, WA, Australia).  
 
Balb/c mice were bred at Victoria University of Wellington. Breeding stock was originally 
obtained from Frank Brombacher (University of Cape Town, Cape Town, South Africa). 
 
2D2 mice, which express a transgenic TCR for the MOG35-55 peptide (Bettelli et al., 2003), 
were bred at the Malaghan Institute of Medical Research (Wellington, NZ) or at Victoria 
University of Wellington. Breeding stock was originally obtained from Prof. Vijay K. 
Kuchroo (Harvard Medical School, Boston, MA, USA). 
  
B6.SJL-ptprca mice, which express CD45.1 on a C57BL/6 background, were bred at the 
Malaghan Institute of Medical Research (Wellington, NZ). Breeding stock was originally 
purchased from Animal Resource Centre (Canning Vale, WA, Australia). 
 
C57BL/6-ifngtm1Ts IFN-γ deficient mice (Dalton et al., 1993), were bred at the Malaghan 
Institute of Medical Research (Wellington, NZ). Breeding stock was originally obtained 
from the Walter and Eliza Hall Institute of Medical Research (Melbourne, VIC, Australia). 
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2.2 Peptides 
MOG
35-55
 peptide (MEVGWYRSPFSRVVHLYRNGK) was synthesised by GenScript 
(Piscataway, NJ, USA)  
 
PLP
139-151
 peptide (HSLGKWLGHPDKF) was synthesised by GenScript (USA)   
 
PLP
180-199 
peptide (WTTCQSIAFPSKTSASIGSL) was synthesised by GenScript (USA)
 
 
2.3 EAE induction 
2.3.1 C57BL/6J mice  
Eight to twelve week old mice were immunised with an emulsion consisting of 50 μg 
MOG
35-55
 peptide (Genscript, Piscataway, NJ, USA) and 500 μg heat-inactivated 
Mycobacterium tuberculosis (Difco Laboratories, Detroit, USA) in incomplete Freund’s 
adjuvant (Sigma, St. Louis, MO, USA).  The components were emulsified prior to 
injecting by repeatedly passing through an 18g needle until a thick homogenised emulsion 
was achieved. Mice were injected s.c. with 100 μl in each hind flank. In addition, each 
mouse was injected i.p. with 200 ng pertussis toxin (Sapphire Bioscience, Redfern, NSW, 
Australia) in 200 μl pertussis toxin buffer on days 0 and 2 p.i. as previously described 
(Crume et al., 2009).  
 
2.3.2 SJL/J mice  
Eight to sixteen week old mice were immunised with an emulsion consisting of 50 µg 
PLP
139-151
 peptide (Genscript, USA) and 500 μg heat-inactivated Mycobacterium 
tuberculosis (Difco Laboratories, USA) in incomplete Freund’s adjuvant (Sigma, USA). 
The components were emulsified prior to injecting by repeatedly passing through an 18g 
needle until a thick homogenised emulsion was achieved. Mice were injected s.c. with 100 
μl in each hind flank. Mice received i.p. injections of 100 ng pertussis toxin (Sapphire 
Bioscience, AU) in 200 μl pertussis toxin buffer on days 0 and 2 p.i. Optimisation 
experiments were initially conducted to ascertain the concentrations of PLP
139-151 
and 
pertussis toxin that would induce optimal relapsing-remitting EAE within the SJL/J mice 
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housed at the animal facilities at Victoria University of Wellington (data not shown). The 
concentrations of used PLP
139-151 
and pertussis toxin used in the current experiments are 
consistent with concentrations used in previously published research (Kleinschek et al., 
2007).  
2.3.3 Balb/c 
Eight to sixteen week old mice were immunised with an emulsion consisting of 100 μg 
PLP
180-199
 peptide (Genscript, USA) and 500 μg heat-inactivated Mycobacterium 
tuberculosis (Difco Laboratories, USA) in incomplete Freund’s adjuvant (Sigma, USA) 
(Keating et al., 2009).  The components were emulsified prior to injecting by repeatedly 
passing through an 18g needle until a thick homogenised emulsion was achieved. Mice 
were injected s.c. with 100 μl in each hind flank. Each mouse received additional i.p. 
injections of 100 ng pertussis toxin (Sapphire Bioscience, AU) in 200 μl pertussis toxin 
buffer on days 0 and 2.  
 
2.3.4 EAE disease severity rating scale  
The mice were weighed daily using a Mettler PB6000 balance (Mettler Tolodo; Columbus, 
OH, USA) and monitored for any signs of disease throughout the duration of the 
experiment. Mice were scored for EAE using a commonly used 0-5 disease severity rating 
scale: 0.5 = loss of tonicity in distal region of tail, 1 = loss of tail tonicity; 2 = full tail 
paralysis; 3 = one hind limb paralysis or severe weakness in both hind limbs; 4 = full hind 
limb paralysis; and 5 = moribund (Keating et al., 2009; Tierney et al., 2009). Mice that 
reached an EAE score of 5 were euthanised. 
2.4 Compounds for in vivo use  
Paclitaxel (Sandoz (Ebewe), Hilzkirchen, Germany) 
Docetaxel (Taxotere®; Sanofi Aventis, Bridgewater, NJ USA) 
Ixebepilone (Ixempra®; Bristol-Myers Squibb, New York city, NY, USA) 
Peloruside A, generously provided by Dr. Peter Northcote (Victoria University of 
Wellington, Wellington, NZ) 
Glatiramer acetate (GA, Copaxone®) Teva Pharmaceutical Industries Ltd. (Petach Tikva, 
Israel) 
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Risperidone was generously provided by Douglas Pharmaceuticals Limited, (Auckland, 
NZ)  
MIS416 was generously provided by Innate Immunotheraputics (Auckland, NZ) 
 
 
 
2.5 Compounds for in vitro use (if different from above) 
Paclitaxel (LC laboratories, Woburn, MA, USA) 
Docetaxel (LC laboratories, USA) 
Laulimalide, generously provided by Dr. Peter Northcote (Wellington, NZ) 
 
2.6 In vivo techniques 
2.6.1 Drug administration  
MSDs or their respective vehicles were diluted in dPBS (Invitrogen, Carlsbad, CA, USA) 
at indicated concentration to a final volume of 300µl and injected i.p. using a 27g needle. 
 
Risperidone was dissolved in 0.1M acetic acid to a stock concentration of 6 mg/mL then 
diluted to the required final concentration using mouse drinking water. To achieve correct 
daily dosages, average daily water consumption was measured before initiation of 
experiments and the correct dosage of risperidone was calculated accordingly.  
 
Glatiramer acetate was diluted in dPBS (Invitrogen, USA) to a final volume of 100µl and 
injected s.c. into the scruff of the neck using a 29g needle.  
 
MIS416 or saline vehicle was injected undiluted at indicated amounts (between 100 and 
250 µl total volume) into the lateral tail vein using a 29 or 31g needle.  
 
Anti-interferon-γ antibody (clone: AN18 (Prat et al., 1984)) was diluted in dPBS 
(Invitrogen, USA) to the indicated concentration in a final volume of 300 µl and injected 
i.p. using a 27g needle. 
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2.6.2 In vivo proliferation assay  
Cells from spleen and lymph nodes of 2D2 mice were isolated and processed into single 
cell suspensions. Following staining with 2 nM carboxyfluorescein succinimidyl ester 
(CFSE; Sigma, USA), the reaction was quenched with FCS then cells were washed 3 times 
in dPBS (Invitrogen, USA) (see section 2.8.1). Following resuspension in dPBS 
(Invitrogen, USA), 2 x 10
7
 2D2 cells in a volume of 200 µl, were injected i.p. into B6.SJL-
ptprca mice. One day later mice were immunised for EAE (see section 2.3.1). Mice were 
left untreated or were treated with 20 mg/kg paclitaxel i.p. on days 0-4. Five days 
following immunisation, mice were culled and lymph nodes, spleen, blood and spinal cord 
were harvested and processed for flow cytometry analysis, as described (see sections 2.7 
and 2.12).      
 
2.6.3 In vivo migration assay  
Cells from the spleen and lymph nodes of 2D2 mice were isolated and processed into 
single cell suspensions. Following staining with 2 nM CFSE (sigma, USA), the reaction 
was quenched with FCS then washed 3 times in dPBS (Invitrogen, USA). Following 
resuspension in dPBS (Invitrogen, USA), 2 x 10
7
 2D2 cells were injected i.p. into 
C57BL/6 mice. On the following day mice were either treated with 20 mg/kg paclitaxel i.p. 
or an equal volume of dPBS (vehicle) for 5 consecutive days. After the final injection 1 µg 
of the chemokine CCL5 (RANTES; Peprotech Rocky Hill, NJ, USA) was injected in 100 
µl dPBS (Invitrogen, USA) into the left hind flanks of the mice, while an equal volume of 
dPBS (vehicle) was injected into the right hind flank. Eighteen hours following hind flank 
injections, cells from the dLNs were isolated, counted and processed for flow cytometry 
analysis, as described (see sections 2.7 and 2.12). To control for potential variations in 
injection technique that could potentally affect cell numbers in the dLNs, additional 
paclitaxel (PTX) treated or untreated mice were injected with dPBS (Invitrogen, USA) in 
both the right and left hind flanks (i.e no CCL5 was administered to these mice). No 
differences in cell numbers between right and left LNs were observed in these mice (data 
not shown) 
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2.6.4 In vivo microtubule-stabilising drug combination treatments 
Peloruside stocks were dissolved in high-grade 100% ethanol. Clinical grade ixabepilone 
(Ixempra®; Bristol-Myers Squibb, USA) stocks were dissolved in the provided solvent 
(polyoxyethylated castor oil 52.8% w/v and dehydrated ethanol 39.8% w/v; Bristol-Myers 
Squibb, USA). Working concentrations were achieved by dilution of stocks in dPBS 
(Invitrogen, USA) to the indicated drug concentrations in a final injection volume of 300 
µl per mouse. C57BL/6 mice were immunised for EAE (see section 2.3.1). Mice were 
injected i.p. on days 6, 8, 10 and 12 p.i. with indicated amounts and combinations of MSD 
drugs. Untreated animals were administered the equivalent concentration of ethanol and 
chemaphor vehicles that were present at the highest drug concentrations. 
2.6.5 Isolation of blood for serum cytokine analysis  
Mice were restrained, within a mouse restrainer and the distal tip of their tails nicked with 
sharp sterile scissors. Droplets of blood were collected in sterile microcentrifuge tubes then 
incubated at RT until the blood had coagulated. Following centrifugation (12,000g for 10 
minutes) serum was removed and used immediately or stored at -80°C until required. 
 
2.7 Ex vivo techniques  
2.7.1 Dissection and organ removal  
Mice were sacrificed by CO2 asphyxiation and washed with absolute ethanol. The 
peritoneal cavity was opened and spleen and lymph nodes were removed using sterile 
tweezers. Bone and other organs were removed by blunt dissociation from connective 
tissue. Blood was harvested by cardiac puncture following cutting of the diaphragm and 
exposure of the heart. Progenitor cells for bone marrow derived macrophages were isolated 
from mice femurs via insertion of a 23g needle into a cut end and flushing the marrow out 
with sterile dPBS (Invitrogen, USA). To perfuse, dPBS (Invitrogen, USA) was slowly 
injected into the left ventricle and blood was drained via the hepatic portal vein. Spinal 
cords were removed, following decapitation, by inserting a 19g needle into the lumbar 
region of the vertebral column and exerting positive pressure onto the spinal cord via a 
syringe containing dPBS (Invitrogen, USA).   
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2.7.2 Preparation of a single cell suspension from lymphoid organs  
Spleens and lymph nodes were isolated and placed into wash buffer (see appendix 4). 
Single cell suspensions were made by dissociating tissue through 70 µm cell strainers (BD 
Biosciences, Franklin Lakes, NJ, USA) and washing into 50ml centrifuge tubes. To 
remove red blood cells, splenocyte cell suspensions were incubated for 2 minutes in 2mls 
of red cell lysis buffer (Sigma, USA) before being washed in 8mls wash buffer, 
centrifuged at 700g for 3 minutes and resuspended in fresh wash buffer. Live cell numbers 
were counted by trypan blue exclusion (see section 2.7.5).  
 
2.7.3 Preparation of a single cell suspension from Blood 
Mouse blood was harvested by cardiac puncture using a heparin (Sigma, USA) coated 27g 
needle on a 1ml syringe (BD Biosciences, USA). Blood samples were centrifuged at 1400g 
for 5 minutes and the supernatant was removed. Red cells were removed by incubation in 
2mls red cell lysis buffer (Sigma, USA) before being washed in 5mls wash buffer, 
centrifuged at 700g for 3 minutes and resuspended. The above steps were repeated to 
ensure full lysis of red blood cells. Cells were resupended in FACS buffer before being 
stained for flow cytometry.     
 
2.7.4 Preparation of a single cell suspension from the spinal cord 
Single cell suspensions were prepared from spinal cords using a commonly used process 
(Sedgwick et al., 1991; Weir et al., 2006). Spinal cords were placed in a Petri dish and cut 
into small pieces using a scalpel blade. The tissue was then suspended in 5ml PBS 
containing 2.4mg/mL type II collagenase (Invitrogen, USA) and incubated at 37°C for 30 
minutes. To remove any clumps the tissue solution was repeatedly passed through a p1000 
pipette tip and incubated for a further 10 minutes at 37°C. Following passage through a 70 
µm cell strainer (BD Biosciences, USA), tissue samples were centrifuged at 700g for 3 
minutes before the supernatant was discarded. Following resuspension in 10ml 37% 
Percoll (Sigma, USA) in Percoll dilutent (see appendix 4), cells were centrifuged at 700g 
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for 30 minutes before the supernatant was removed. The cells were washed in FACs buffer 
before being stained for flow cytometry.  
 
2.7.5 Trypan Blue exclusion 
To count live cell numbers, cells were mixed with 0.4 % Trypan blue (Sigma, USA) in a 
1:1 or 10:1 dilution (in media) and counted on an improved Neubauer haemocytometer 
(Hawksley, Lancing, UK) using a compound microscope (CX41: Olympus, PA, USA).  
 
2.7.6 Histology  
Mice were perfused and spinal cords were isolated as described (see section 2.7.4), then 
fixed in Zinc fixative. Spinal cords were paraffin embedded, sectioned longitudinally, 
mounted on slide and stained with haematoxylin and eosin by staff at the Department of 
Pathology (University of Otago Wellington School of Medicine, NZ). Mounted sections 
were analysed using an Olympus IX51 inverted microscope (Olympus, PA, USA).  
 
2.8 In vitro techniques 
2.8.1 CFSE staining    
Single cell suspensions (up to 1x10
8
) were resuspended in 1ml dPBS (Invitrogen, USA) 
and mixed with 1ml of dPBS containing 1 or 2 µM CFSE (Invitrogen, USA) and incubated 
in low light for 8 minutes at RT. To quench the reaction 2mls of FCS was added followed 
by 6 mls of wash buffer. Following centrifugation (700g for 3 minutes) the sample was 
washed twice using 10 ml of wash buffer. Cells were then resuspended in media or dPBS 
(Invitrogen, USA) depending on the specific application.  
 
2.8.2 Preparation of bone marrow derived macrophages  
Progenitor cells, flushed from mice femurs, were cultured (5% CO2 at 37°C) overnight in 
complete T cell medium (CTCM; see appendix 4) in 90mm petri dishes (Techno Plas, St 
Marys, Australia), before non-adherent cells were isolated and cultured in the presence of 
granulocyte-macrophage colony-stimulating factor and IL-3 (both 5 ng/ml; Peprotech, 
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USA). After 7 days adherent cells (macrophages) were detached by repetitive flushing with 
cold dPBS (Invitrogen, USA). For experiments, the bone marrow derived macrophages 
were plated at 1 x 10
5
 cells/well in 96-well flat-bottomed plates (BD Biosciences, USA). 
Following overnight stimulation with 20 U/ml IFN-γ (Sigma, USA), cells were incubated 
with or without lipopolysaccharide (LPS 200 ng/ml; Sigma, USA) and indicated drugs.  
 
2.8.3 In vitro cell proliferation assays   
Cells were resuspended in CTCM and cultured in duplicate or triplicate in U-bottomed 96-
well plates (BD Biosciences, USA) at a concentration of 1x10
6
 or 5x10
5
 cells per well for 
splenocytes and lymph node cells respectively. Cells were incubated (5% CO2 at 37°C) for 
48 or 72 h in the presence or absence of concanavalin A (Con A; Sigma) or MOG
35-55
 
respectively at indicated concentrations. If cytokines were to be measured, 100µl of 
supernatant was removed following indicated culture periods. 
 
For measurement of proliferation by thymidine incorporation, cells were pulsed with 0.5 or 
1 µCi [
3
H] thymidine (GE Healthcare Little Chalfont, BU, UK) and cultured for an 
additional 8-16 hours before being frozen for later processing. Defrosted cells were 
harvested on glass fibre filters (PerkinElmer, Wellesley, MA, USA) using a cell harvester 
(Tomtec Inc., Hamden, CT. USA) and [
3
H] thymidine incorporation was measured as 
counts per minute (CPM) using a β-counter (Microbeta trilux, PerkinElmer, USA). Cell 
proliferation is expressed as “proliferation index” (CPM of MOG or Con A wells/cpm of 
medium-alone wells).  
 
For measurement of proliferation by CFSE dilution tissue was processed into a single cell 
suspension and stained with 1 mM CFSE (Sigma, USA) as described above. For unstained 
controls the same procedure was carried out minus the addition of CFSE. Live cell 
numbers were counted by Trypan blue exclusion (see sections 2.7.5) and cultured in 96 
well U-bottom plates (BD bioscience, USA). Following 48 or 72 hours in culture, 
supernatant was removed and cells were washed in FACs buffer before being stained for 
flow cytometry.     
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2.8.4 MTT assay  
Following incubation (5% CO2 at 37°C) of cells (see section 2.8.2) in flat bottom 96 well 
plates (BD Bioscience, USA) for a defined period of time (eg. 8 or 24 hours), 100 µl/well 
of supernatant was removed for cytokine analysis and 20 µl/well 3-(4,5-dimethylthiazol-2-
yl)-2.5-diphenyrtetrazolium bromide) in dPBS (MTT solution, Sigma, USA) was added. 
After incubation for a further 2 hours, 100 µl/well MTT solubliser was added and 
incubated at 37°C overnight. MTT reduction was measured by absorbance (570 nm wave 
length) in a multiwell plate reader (Versamax, Molecular Devices, Sunnyvale, CA). Drug 
response was calculated as percent-control (% control) (absorbance-blank/ average control-
blank) x 100. 
 
2.8.5 In vitro synergy (using a CFSE dilution assay)  
Peloruside, Laulimalide, Docetaxel and Ixabepilone were reconstituted to 1mM in absolute 
ethanol and stored at -80°C. Working stocks (800nM or 1600nM) were diluted in media.  
Spleen cells were isolated and stained with CFSE as described (see section 2.7.2 and 2.8.1). 
Cells were cultured (5x10
5
 cells/well) in 96-well round-bottom plates (BD Biosciences, 
USA). Following stimulation for 48 hours in the presence or absence of Con A (3 µg/ml; 
Sigma, USA) and drug, the cells were harvested and stained for flow cytometry. 
Combination treatments and individual drug dose-response curves were conducted 
concurrently and in duplicate. Proliferation, represented as a reduction in CFSE 
fluorescence in cell progeny, was analysed using CellQuest Pro software (BD Biosciences, 
USA). A minimum of 10,000 events was collected for each sample, and results were 
calculated as the percentage of total splenocyte or CD4
+
 cell populations that had 
proliferated. 
 
Drug interaction between MSD combinations were assessed using a combination index (CI) 
equation of Chou and Talalay and Berenbaum as follows: CI = (D1/ Dx1)+ (D2/ Dx2) 
(Berenbaum, 1985; Chou et al., 1984). A CI value equal to one indicates additive effects of 
two drugs, a value greater than one indicates a antagonistic relationship and a value less 
than one indicates a synergistic relationship. The doses D1 and D2 are the two drugs in 
combination and the Dx1and Dx2 are the amounts of each drug alone that would produce the 
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same response obtained with the drug in combination.  To calculate the concentration of 
drug needed for a given response on its own the following logit-log equation was used: 
Dose (x) + IC50x (max-response/resonse-min)
1/hillslope
 (Berenbaum, 1985). IC50, maximum, 
minimum and hillslope data was obtained using individual drug dose response curves 
analysed in Sigmaplot software. CI values were compared to the value of 1 using a one-
sample student’s t-test.  
 
2.9 Cytokine multiplex assays (CBA; Cytokine bead assay/Cytometric Bead Array) 
CBA kits, either Mouse Th1/Th2 10plex FlowCytomix Multiplex (Bender 
MedSystems/ebioscience, San Diego, CA, USA) or Mouse Th1/Th2/Th17 Cytokine Kit 
(BD Bioscience, USA) were used. Protocols were conducted as per manufacture’s 
instructions. Data was collected using either a FACScan or FACS Canto II flow cytometer 
(BD Biosciences, USA). Cytokine detection for the MIS416 experiments was conducted 
by Rebecca Girvan at Innate Immnotherapeutics (Auckland, NZ), using the same CBA kits 
as described above. The detection limit for individual cytokines ranged from 2-20pg/ml as 
indicated in the manufactures instruction booklets.  
 
2.10 ELISA 
Enzyme linked immunosorbent assays (ELISA) were conducted as per manufacture’s 
instructions (BD Bioscience, USA). 96 well ELISA Plates (BD Bioscience, USA) were 
coated overnight with a primary ‘capture’ antibody in sodium phosphate buffer at 4 °C (see 
appendix 4). The following day capture liquid was removed and plates were blocked using 
5 or 10% FCS in PBS for 2 hours. After washing plates in ELISA wash buffer (0.05% 
Tween 20 (Sigma, USA) in PBS), 50µl of standards and samples were added (if it was 
determined that samples needed dilution, samples were diluted in block solution). 
Following 2 hours of incubation, liquid from the samples/standards was removed and the 
plates were washed 4 times. Biotinylated secondary ‘detection’ antibody was added and 
incubated for 1 hour and then liquid was removed and the plate washed 6 times. 
Streptavidin conjugated horseradish peroxidase was then added to the plates and incubated 
for 1 hour. Following removal of any liquid, plates were washed 8 times. Tetramethyl 
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benzidine (TMB) reagents A and B (BD Bioscience, USA) were mixed in equal volumes 
and 100µl was added to each well. After sufficient colour development the reaction was 
stopped by the addition of 100µl of stop solution (0.18 M sulphuric acid). Absorbance 
values were measured at 450nM using a VersaMax (Molecular Devices, USA). A standard 
curve was constructed from the absorbance values of the standards and cytokine 
concentrations were calculated. The detection limits were 15-30 pg/ml for IL-12 and IFNγ 
or 50-100 pg/ml for IL-10. 
 
2.11 Griess assay/reaction  
As nitric oxide (NO) is unstable and breaks down rapidly to nitrite and nitrate, measuring 
these breakdown products provides a relative measure of NO production (Sun et al., 2003). 
The Griess assay measures nitrite and is commonly used as an indicator of NO production 
in culture supernatant (Stuehr et al., 1985; Sun et al., 2003). Griess reagents A and B 
(Sigma, USA) were combined in equal volume and 50µl of this mixture was added to 50µl 
of culture supernatant in flat bottom 96 well plates (BD Bioscience). Serially diluted nitrite 
standards in duplicate were also included. Absorbance was measured at 570 nM using a 
VersaMax (Molecular Devices, USA) and a standard curve of nitrite standards was 
produced from which unknown sample values were determined. The detection limit was 2-
4 µM. 
 
2.12 General antibody staining and preparation of cells for flow 
cytometry     
Samples were washed in FACS buffer and Fc receptors blocked with 2.4G2 antibody (BD 
Biosciences, USA). Cells were stained with primary antibodies in a total volume of 50µl 
FACS buffer. All antibodies were pre-titrated, to optimise separation between cell 
populations and to minimise background fluorescence. Samples were incubated for 30 
minutes at 4 °C or 15 minutes at RT.  Excess buffer was added and samples were 
centrifuged at 600g for 3 minutes and then resuspended. When biotin conjugated 
antibodies were used, cells were incubated for 10-20 minutes with strepavidin conjugated 
fluorophores, then washed with excess FACS buffer, centrifuged and resuspended. 
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Samples were collected on a BD FACSScan or FACS Canto II using CellQuest pro or 
Diva software respectively (all BD Bioscience, USA). Data was analysed using Cellquest 
pro (BD Bioscience) or FLOJO 7 software (Tree Star, Ashland, OR, USA). See appendix 5 
for a list of antibodies and strepavidin conjugated fluorophores used. 
2.13 Graphs and Statistics 
Graphs were produced using GraphPad Prism 5 (GraphPad Software Inc., La Jolla, CA, 
USA) or SigmaPlot 11 (Systat Software Inc, San Jose, CA, USA). Data analysis and 
statistical tests were conducted using GraphPad Prism 5, SigmaPlot 11 (Systat Software 
Inc, USA) or Microsoft Excel 2003 (Microsoft Corporation, Redmond, WA, USA). To test 
if values came from a Gaussian distribution a Shapiro-Wilk normality test was used. 
Correlation was assessed by the Pearson’s test. The Student’s t-test was used to determine 
statistical significance when comparing two treatment groups. In experiments for which 
more than two groups were compared a one-way ANOVA with a Newman-Keuls multiple 
comparisons test was used. If multiple treatment groups were being compared only to a 
control group, a one-way ANOVA with a Dunnett’s test was used. For non-parametric 
tests comparing two groups a Mann-Whitney test was used. For non-parametric tests 
comparing more than two groups a Kruskal-Wallis test with Dunn’s post-hoc analysis was 
used. Differences that gave p values < 0.05 were considered statistically significant.         
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3.1 Introduction  
Autoimmune diseases such as MS are mediated by the activation and proliferation of self-
reactive T cells. Therefore one strategy to treat autoimmune disease is to use anti-
proliferative drugs to inhibit expansion of these cell populations. Mitoxantrone, an anti-
mitotic drug, is already used for this purpose in the treatment of MS, and it is currently the 
only therapy licensed for progressive forms of the disease. However, due to irreversible 
cardiotoxicity, the use of mitoxantrone is very limited (Neuhaus et al., 2006). Microtubule-
stabilising drugs (MSDs) are another class of anti-mitotic compounds that have similar 
anti-proliferative effects but do not cause such severe and irreversible toxicity. Given the 
proven efficacy of inhibiting proliferation to treat MS, MSDs may provide a safe and 
effective treatment alternative. While there is a large body of research on the use of MSDs 
for the treatment of cancers, only a few studies have investigated these compounds within 
the context of autoimmune disease. This chapter explores the potential of MSDs to inhibit 
disease in an animal model of MS.    
 
Microtubules are an important cytoskeletal component and have a diverse range of 
functions. As well as maintaining cellular structure, they are involved in intracellular 
transport, cell migration, polarisation and cell division (Hirokawa, 1998; Jordan et al., 
2004; Nogales, 2001). Dynamic instability, the shortening and lengthening of the 
microtubule structures, is an important process in the normal functioning of microtubules 
(Erickson et al., 1992). Drugs that cause either stabilisation or destabilisation disrupt the 
dynamicity of the microtubule networks and ultimately cause perturbation of microtubule 
associated cellular process (Jordan et al., 2007). Microtubule destabilisers interfere with 
microtubule function by limiting the ability of the microtubule subunits (α and β tubulin) to 
polymerise into functional microtubules. Clinically microtubule destabilising drugs, such 
as vinorelbine and colchicine have been used for the treatment of cancers and 
inflammatory conditions, respectively (Aapro et al., 2011; Terkeltaub et al., 2010). In 
contrast to the destabilisers, MSDs stabilise microtubules and promote the polymerisation 
of tubulin subunits. Stabilisation of microtubules results in reduced microtubule 
dynamicity and can also cause microtubules to bundle together (Chan et al., 2011; Kamath 
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et al., 2003). MSDs are used clinically in drug eluting stents to prevent restenosis, and for 
the treatment of various cancers (Altmann, 2001; Colmenarez et al., 2010).  
 
As microtubules play a crucial role in mitosis the main cellular effect of MSDs is believed 
to be their anti-mitotic activity (Abal et al., 2003). In mitosis microtubules are important 
for the movement, alignment and subsequent separation of the chromosomes. Microtubules 
associated with this process are 10-100 fold more dynamic than cytoplasmic microtubules, 
which make them particularly sensitive to MSDs (Rusan et al., 2001; Zhai et al., 1996). 
Stabilisation of microtubules during mitosis results in cell cycle arrest and apoptosis 
(Jordan et al., 2007). The effectiveness of these compounds in inhibiting proliferation has 
made MSDs one of the most widely used class of cancer chemotherapeutics (Altmann, 
2001; Jordan et al., 2004). While the mechanism of action of MSDs in cancer 
chemotherapy is inhibiting tumour cell proliferation, other advantageous effects such as 
inhibition of angiogenesis and cell motility also contribute (Belotti et al., 1996; Jordan et 
al., 2007).   
 
Most MSDs are either isolated from natural products or are semi-synthetic derivatives. 
While there have been many MSDs identified, only a few have been developed for clinical 
use. The most commonly used MSD is the taxane, paclitaxel (PTX) which was originally 
isolated from the bark of the Pacific yew tree (Schiff et al., 1979). Due to limited solubility 
PTX is administered in Cremophor EL, a vehicle that consists of polyethoxylated castor oil 
and ethanol. However, Cremophor, itself is biologically active and causes both alterations 
in pharmacokinetics of co-administered drugs, as well as a hypersensitivity reaction in 
some people (Gelderblom et al., 2001; Gelderblom et al., 2002). An alternative taxane, 
also widely used, is docetaxel (DTX). DTX is a semi-synthetic analogue of PTX that does 
not need to be administered in Cremophor and has proved to be more effective in some 
forms of cancers (Crown et al., 2004). Ixabepilone (IXB), a semi-synthetic analogue of the 
compound epothilone B, is the third MSD to be licensed as a cancer chemotherapeutic 
(Cobham et al., 2009). IXB  has been shown to be less susceptible to active cellular drug 
efflux and is effective in treating some taxane-resistant cancers (Fojo et al., 2007; Rivera et 
al., 2011).  
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The anti-proliferative activity of MSD, makes these drugs attractive compounds to explore 
in the context of autoimmune disease. Previous studies have found that PTX can inhibit 
collagen induced arthritis (a model of rheumatoid arthritis), and when administered after 
induction can suppress established disease (Brahn et al., 1994; Oliver et al., 1994).  PTX 
has also been shown to be beneficial in treatment of immune mediated psoriasis (Ehrlich et 
al., 2004). Additionally, within EAE and spontaneous demyelination models of MS, PTX 
has been found to modify disease progression and severity in rats (Cao et al., 2000). 
 
Research in our laboratory, using a mouse model of EAE, has found that both PTX or a 
novel MSD peloruside, show therapeutic potential in modifying disease expression in mice 
(Crume, 2007; Crume et al., 2009). When PTX or peloruside was administered on days 0-4 
following EAE immunisation, onset of symptoms was delayed and incidence was reduced. 
This dosing regime however caused mortality between 7-12 days after immunisation in 
30% of PTX treated mice. The toxicity only occurred in mice immunised for EAE and 
coincided with the time of disease onset in mice not treated with MSDs (7-14 days post 
immunisation) (Crume, 2007). Additionally this toxicity only occurred in PTX but not 
peloruside treated mice, suggesting that PTX may have a specific toxicity within the EAE 
model.  
 
3.2 Aims and Objectives 
This chapter further investigates the potential of MSDs for the treatment of EAE and 
explores the effectiveness of different treatment regimes. The current study also identifies 
if the toxicity seen in immunised drug-treated mice is specific to PTX or occurs following 
treatment with MSDs. As past research using MSDs in an autoimmune context has focused 
on PTX, the potential of other clinically available MSDs to treat EAE is determined in the 
present study. Finally, this study examines if the anti-proliferative actions of these drugs 
result in any alterations in chronic antigen-specific immune cell responses.  
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3.2.1 Specific Aims:  
1. To explore the potential of MSDs to modify EAE at different time points in 
disease process  
2. To identify if toxicity observed in drug-treated mice is specific to paclitaxel  
3. To assess if chronic antigen-specific immune responses are altered following 
MSD treatment  
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3.3 Results 
3.3.1 Paclitaxel and docetaxel have similar disease modifying effects and toxicity 
Previous research conduced in our laboratory found that PTX administered on days 0-4 
post immunisation (p.i.) delayed EAE onset. However, drug treatment caused mortality 7-
12 days after immunisation in 30% of mice (Crume, 2007). This toxicity only occurred in 
immunised mice and coincided with the disease onset in immunised vehicle treated mice 
(d7-14 p.i.). A potential explanation for this mortality is the capacity of PTX to activate 
TLR-4 receptors and stimulate proinflammatory cytokine release (Byrd-Leifer et al., 2001). 
TLR-4 activation combined with the highly reactive inflammatory environment during 
EAE disease induction could result in an anaphylactic-like response.  
 
To test if TLR activation by PTX was the cause of toxicity DTX was compared to PTX. 
Although DTX is a analogue of PTX it does not induce TLR-4 activation in mice 
(Fitzpatrick et al., 2003). Therefore, if toxicity was observed in the PTX but not DTX 
treated animals, this finding would support the possibility that the toxicity was associated 
with TLR-4 activation. As previous work had found that PTX is only effective at the 
maximum tolerated dose  (MTD; 20mg/kg) (Crume et al., 2009), DTX was used at a dose 
near to the MTD (10 mg/kg). Mice that were immunised but untreated began to exhibit 
disease symptoms 16 days following immunisation with 80% disease incidence being 
reached 30 days p.i. (Figure 3.1a and b). Both PTX and DTX treated mice had delayed 
disease onset until day 30, which is consistent with previous research using PTX (Crume, 
2007). Despite the delayed onset of disease in drug treated animals, once disease 
symptoms had established no reduction in incidence or difference in chronic disease 
courses was observed in ether PTX or DTX treated mice compared to untreated (Figure 
3.1a and b). Although no symptoms of EAE were evident, toxicity was observed on days 
6 to 9 post immunisation with 20% of PTX and DTX-treated mice dying during this period. 
Some of the mice that exhibited toxicity also displayed symptoms of dyspnea, a hunched 
posture and reduced activity when compared to other mice within the drug treated groups. 
Similar symptoms however can also sometimes be observed in untreated mice just prior to 
symptom onset. 
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Collectively these results support the previous findings that while PTX does delay disease 
onset it also causes toxicity in 20-30% of the drug treated mice (Cao et al., 2000; Crume, 
2007). As fatalities also occurred in DTX treated animals, it is unlikely TLR-4 activation is 
associated with the observed drug toxicity. Furthermore, the finding that toxicity occued in 
both PTX- and DTX-treated animals indicates that the observed effect is not related to the 
PTX vehicle cremophor, as DTX is administered in polysorbate 80, instead of cremophor. 
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Figure 3.1 Paclitaxel or docetaxel treatment (d0-4 p.i.) delays EAE disease onset  
C57BL/6 mice were immunised for EAE and treated with paclitaxel (PTX; 20 mg/kg) or 
docetaxel (DTX; 10mg/kg) daily on days 0-4 p.i. or left untreated. (a) Disease score of sick mice 
(b) Disease incidence; calculated as percent of mice with clinical disease (≥0.5 on disease score). 
Data represents one of two identical experiments. (n = 3-5mice per group). Any mice that died 
were excluded from the analysis. 
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3.3.2 Paclitaxel and docetaxel treatment does not inhibit the development of antigen-
specific responses in peripheral T cells  
Since the main effect of MSDs is considered to be anti-mitotic, it is possible that the 
alteration in disease expression in PTX and DTX treated mice was due to inhibition of 
immunisation-induced T cell proliferation. If administration of MSDs was inhibiting clonal 
expansion of antigen-specific T cells, it is likely that antigen-specific responses in the 
peripheral lymphoid organs of MSD treated mice would be reduced. As MS is a chronic 
disease any new treatment would ideally lead to long-term alterations in encephalitogenic 
immune responses. In the context of EAE, chronic changes of antigen-specific T cell 
responses could provide an indication of long-term alterations in encephalitogenic immune 
responses. Thus initial investigations into the effects of MSDs on the immune system 
focused on antigen-specific T cell responses present in the chronic stages of disease (i.e. ≥ 
30 days p.i.).  
 
To determine if PTX or DTX treatment chronically affected peripheral T cell proliferative 
responses, splenocytes were isolated 30 or 57 days after immunisation and cultured 
individually in the presence of a polyclonal T cell stimulus, concanavalin A (Con A) or 
myelin oligodendrocyte glycoprotein peptide 35-55 (MOG). No significant difference in 
splenocyte proliferation occurred in response to Con A stimulation (Figure 3.2a). In 
contrast antigen-specific T cell responses to MOG
 
were higher in splenocytes from either 
PTX or DTX treated mice when compared to untreated mice (Figure 3.2b). This result 
may indicate that during the cronic stages of disease more antigen-specific T cells are still 
present within the spleen of PTX or DTX mice compared to untreated mice. The observed 
changes in proliferation were not due to alterations in total percentages of T cells within 
the spleens between any of the treatment groups (Figure 3.3a-c). Proliferation in response 
to MOG
 
indicates the presence of an EAE specific T cell response; while, proliferation in 
response to Con A indicates total T cell responses. Therefore, these results indicate that 
PTX and DTX does not inhibit the development of long term antigen-specific T cell 
responses following immunisation nor do they alter the total T cell population’s 
proliferative capacity.     
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IFN-γ is a classic indicator of a Th1 type inflammatory response and can contribute both  
to pathogenesis and protection in EAE (Sabatino et al., 2008; Williams et al., 2011; Yura 
et al., 2001; Zhang, 2007). To investigate if the drugs also resulted in altered IFN-γ 
production, supernatants from the splenocyte cultures were analysed. Cells from PTX 
treated mice produced significantly more IFN-γ at the highest concentration of Con A 
compared to DTX and untreated groups (Figure 3.4a). Cells from PTX treated mice also 
produced increased IFN-γ in response to MOG but this increase was only apparent at the 
low concentration of 3 µg/ml MOG (Figure 3.4b). This increase in IFN-γ, however, does 
not correlate to either disease protection or exacerbation, as there was no substantial 
diffrence between disease scores of drug treated and untreated mice (Figure 3.1 and data 
not shown). Taken together these results suggest that PTX and DTX treatment does not 
prevent the induction of antigen-specific responses in this model. 
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Figure 3.2 Paclitaxel or docetaxel treatment (d0-4 p.i.) does not inhibit ex vivo antigen-specific 
proliferation  
C57BL/6 mice were immunised for EAE and treated with paclitaxel (PTX; 20 mg/kg) or docetaxel 
(DTX; 10mg/kg) daily on days 0-4 p.i. or left untreated. Spleen cells were cultured in medium alone 
or in the presence of (a) Con A or (b) MOG, 30 or 57 days p.i.  Proliferation was assessed by 
3
[H]thymidine (1µCi) incorporation and is expressed as Proliferation index; CPM of stimulated 
wells/CPM of media alone. Shown are means and SEM of individual mice from the two experiments 
(n = 8-9 mice/group). * P < 0.05 significant differences between PTX and DTX compared to 
untreated, within each of the stimulation concentrations by one-way ANOVA with Newman-Keuls 
Multiple Comparison test. 
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Figure 3.4 Paclitaxel or docetaxel treatment (d0-4 p.i.) does not inhibit ex vivo IFN-γ production  
C57BL/6 mice were immunised for EAE and treated with paclitaxel (PTX; 20 mg/kg) or docetaxel (DTX; 
10mg/kg) daily on days 0-4 p.i. or left untreated (N/T). Spleen cells were cultured in medium alone or in 
the presence of (a) Con A or (b) MOG for 48 and 72 hours respectively. At 30 or 57 days p.i.. IFN-γ 
production was assessed by ELISA in culture supernatants. Shown are means and SEM of individual mice 
from the two experiments (n = 8-9 mice/group). * P < 0.05 significant difference between PTX compared 
to DTX and untreated by one-way ANOVA with Newman-Keuls Multiple Comparison test. 
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Figure 3.3 Paclitaxel or docetaxel treatment (d0-4 p.i.) does not alter the percentage of T cells in the 
spleen 
C57BL/6 mice were immunised for EAE and treated with paclitaxel (PTX; 20 mg/kg) or docetaxel (DTX; 
10mg/kg) daily on days 0-4 p.i. or left untreated. Splenocytes were isolated 30 or 57 days p.i. and 
analysed by flow cytometry for percentages of total (a) CD4
+
, (b) CD8
+
 and (C) CD4
+
CD25
+
 cells. Shown 
are means and SEM of individual mice from the two experiments (n = 8-9 mice/group). There were no 
significant differences between treatment groups by one-way ANOVA with Newman-Keuls Multiple 
Comparison test. 
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3.3.3 Treating after the initial inflammatory response delays disease onset 
Administration of PTX or DTX immediately following immunisation may inhibit the 
induction of an encephalgenic immune response rather than modifying the inflammatory 
milieu. In order for a treatment to be of therapeutic benefit within the context of MS, it 
would have to be effective after an already established encephalgenic immune response. 
Previous research has shown that in EAE the induction and proliferation of encephalgenic 
cells occurs within the first week following immunisation (Hofstetter et al., 2010; Targoni 
et al., 2001). To explore if treating after this period with PTX or DTX modifies disease, 
mice were treated on d6-10 p.i. Similar to the d0-4 p.i. treatment, MTDs of PTX or DTX 
significantly delayed disease onset and reduced disease incidence at d30 p.i. (Figure 3.5a 
and b) Interestingly, a similar rate of toxicity was observed between d7-11 p.i. as seen in 
the d0-4 p.i. treatment. Again this period of toxicity appeared in a similar time frame to 
when immunised untreated mice began to exhibit EAE symptoms. This suggests that 
toxicity coincides with CNS immune infiltration. 
 
Thirty days following immunisation, spleens and dLN were analysed for potential changes 
in antigen-specific responses or cellularity. No difference in CD4
+
, CD8
+
, CD4
+
 CD25
+
 T 
cells or total cell numbers, within either the spleens or dLN was observed between 
treatment groups (Note: only 2-4 mice per drug treatment group) (Figure 3.6a-d). To 
investigate if antigen-specific responses were altered by drug treatment, splenocytes and 
LN cells, from individual animals were cultured in the presence of Con A or MOG. Only 
LN cells from DTX treated mice exhibited an increased proliferative response following 
Con A stimulation relative to the untreated group; while, no difference was not observed in 
splenocytes (Figure 3.7a). Cells from PTX and DTX treated mice exhibited no difference 
in proliferative response to MOG when compared to untreated immunised mice in either 
splenocyte or LN cultures (Figure 3.7b). Additionally no difference in levels of IFN-γ was 
detected between splenocytes or LN cells from any of the treatment groups when 
stimulated with either Con A or MOG (Note: only 2-4 mice per drug treatment group) 
(Figure 3.8a and b). 
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These results indicate that despite altering disease progression PTX and DTX, 
administered on d6-10 p.i., do not cause permanent alterations in antigen-specific T cell 
proliferative responses. Additionally, no difference in IFN-γ production or total T cell 
numbers was observed suggesting that the development of T cell responses occurs 
similarly in drug-treated and untreated, immunised mice. This finding suggests that any 
effect these drugs have on the immune system are transient and only occur either during or 
directly after drug treatment. Alternatively, PTX or DTX treatment may not be causing any 
direct effect on the encephalgenic immune response, and the alteration in disease 
progression in drug-treated animals occurs due to non-immune associated factors.   
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Figure 3.5 Paclitaxel or docetaxel treatment (d6-10 p.i.) delays EAE disease onset 
C57BL/6 mice were immunised for EAE and treated with PTX (20 mg/kg) or DTX (10 mg/kg) 
daily 6-10 p.i. or left untreated. (a) Disease score of sick mice (b) Incidence = cumulative disease 
incidence; calculated as percent of mice with clinical disease.. Data represents two experiments (n 
= 4 PTX, 4 DTX, 10 untreated). Any mice that died were excluded from the analysis. 
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Figure 3.7 Paclitaxel or docetaxel treatment (d6-10 p.i.) does not inhibit ex vivo antigen-
specific proliferation 
Spleen (a) or dLN (b) cells were cultured in medium alone or in the presence of MOG (27µg/ml) or 
Con (3µg/ml), 30 days p.i.. Proliferation was assessed by 
3
[H]thymidine (1µCi) incorporation and 
is expressed as Proliferation index; CPM of stimulated wells/CPM of media alone. Shown are 
means and SEM of individual mice from two experiments (n = 6 PTX, 4 DTX, 10 untreated). * P < 
0.05 significant difference between groups within each of the stimulation conditions by one-way 
ANOVA with Newman-Keuls Multiple Comparison test. 
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Figure 3.6 Paclitaxel or docetaxel treatment (d6-10 p.i.) does not chronically alter spleen 
or lymph node cellularity 
C57BL/6 mice were immunised for EAE and treated with PTX (20 mg/kg) or DTX (10 mg/kg) 
daily 6-10 p.i. or left untreated. Splenocytes and lymphocytes were isolated 30 days p.i. 
counted and analysed by flow cytometry to calculate total (a) CD4
+
, (b) CD8
+
, (c) CD4
+
CD25
+
 
and (d) total cell numbers. Shown are means and SEM of individual mice from one experiment 
(n = 2 PTX, 4 DTX, 5 untreated). There were no significant differences between treatment 
groups within spleen or dLN analysed by one-way ANOVA with Newman-Keuls Multiple 
Comparison test 
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3.3.4 A dual dosing regime delays disease but does not reduce long-term disease 
burden  
To explore if repeating the drug treatment could provide a prolonged therapeutic benefit, 
immunised mice were injected with PTX or DTX on days 6-10 p.i. and then again on days 
21-25 p.i. Interestingly no deaths were seen after PTX or DTX treatment at d6-10. One 
mouse from the DTX treatment group died on d29 p.i. after exhibiting abnormal disease 
symptoms that included loss of balance and hind limb tone, but normal tail movement, 
which is unexpected when hindlimb weakness is occuring. The mouse exhibited no 
symptoms that were consistent with those seen in the presence of drug toxicity, making it 
ambiguous as to wheather the drug treatment was the cause of this death. However, due to 
the timing of the death it is likely that drug treatment was a contributing factor.  
 
While a substantial delay in full disease severity occurred in all drug treated groups, little 
extra benefit in overall disease burden was achieved with the administration of a second 
PTX or DTX treatment on d21-25 p.i. (Figure 3.9a). Despite this, an increased delay in 
disease onset occurred in both d21-25 p.i. treatment groups (Figure 3.9b). This was 
particularly pronounced following DTX treatment with only 40% incidence until around 
day 40. As a treatment group receiving a single dosing regime of DTX was not included in 
this experiment, the possibility that this delay could have occurred following a single 
dosing regime cannot be excluded. These results indicate that using a dual dosing regime 
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Figure 3.8 Paclitaxel or docetaxel treatment (d6-10 p.i.) does not inhibit ex vivo IFN-γ 
production 
Spleen (a) or dLN (b) cells were cultured in medium alone or in the presence of Con A (3 µg/ml) or 
MOG (27 µg/ml) for 48 and 72 hours respectively. At 30 days p.i. IFN-γ production was assessed 
by ELISA in culture supernatants. Shown are means and SEM of individual mice from one 
experiment (n = 2 PTX, 4 DTX, 5 untreated). There were no significant differences between groups 
within each of the stimulation conditions by one-way ANOVA. 
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of treatment at d6-12 and d21-25 confers little benefit to altering long-term disease severity 
or disease burden but may further delay disease onset.     
 
3.3.5 Ixbepilone alters disease expression without causing toxicity 
Ixabepilone (IXB) is a MSD that is structurally unrelated to the taxanes. To test if IXB, 
like PTX could alter disease expression in EAE a comparison of the two MSD was 
conducted. Previous studies in mouse cancer models found IXB to be well tolerated when 
administered at 10 mg/kg every other day (QOD) over a 7 day period. Using this treatment 
strategy, mice were immunised and treated on day 6-12 p.i. QOD with IXB. Because 
previous experiments had shown a daily PTX treatment at 6-10 p.i. effective, this strategy 
was compared to PTX administered on d6-12 p.i. QOD. Mice receiving PTX d6-12 p.i. 
QOD or daily doses on d6-10 p.i. exhibited a similar disease onset and disease severity 
(Figure 3.10a and b). While one mouse died (d13 p.i.) following PTX d6-10 p.i. treatment 
and all mice within this group exhibited significant weight loss (Figure 3.10c), no toxicity 
or weight loss was observed in the IXB or PTX QOD d6-12 p.i. treated animals. This 
observation may indicate that the toxic effects of the drug are associated with exposure to 
prolonged high drug concentrations. The QOD treatment would result in lower peak drug 
concentrations as more drug would be excreted or metabolised between doses. 
Additionally QOD treatment on d6-12 p.i. involves administration of a total of 4 doses 
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Figure 3.9 A dual dosing regimen of paclitaxel or docetaxel does not improve in vivo efficacy   
C57BL/6 mice were immunised for EAE and treated with paclitaxel (20mg/kg) or docetaxel (10mg/kg) 
daily on days 6-10 p.i. or left untreated. An additional 5 day course of paclitaxel (PTX 2) or docetaxel 
(DTX 2) was administered following disease onset (d21). a) Disease score of all mice (b) Disease 
incidence; calculated as percent of mice that develop clinical disease. Data represents one experiment (n = 
4-5 mice per group). Any mice that died were excluded from the analysis. 
Chapter 3: Using microtubule-stabilising drugs to treat EAE                                            56 
compared to 5 doses in the daily treatment. The extra dose in the daily treatment may 
exacerbate the toxic effects but is unlikely to be the sole cause of toxicity, as weight loss in 
the PTX daily treatment group is already apparent as early as d8-9 p.i. This loss of weight 
is prior to the administration of the final dose on d10 p.i. indicating that toxicity may begin 
to occur part way through the daily treatment regime.   
 
Only 1 out of 5 mice treated with IXB exhibited disease symptoms and these resolved 
within ten days of onset (Figure 3.10a). This contrasts with PTX treated mice of which 
60% exhibited disease by d30 p.i. with no sign of disease resolution. However, in 
subsequent experiments, IXB treatment did not cause such drastic alterations in disease. 
The IXB (d6-12 p.i. QOD) treated mice had a similar delay of disease onset compared to 
the PTX (d6-12 p.i. QOD) treated mice and disease severity and long-term disease burden 
were similar (Figure 3.11a and b). The delay in disease onset within drug treated mice 
was also not as pronounced as was seen in previous experiments (eg. Figures 3.1 and 3.5). 
When experiments using PTX and IXB d6-12 p.i. QOD are collectively compared, a 
similar delay in disease onset and reduction in disease burden can be observed for both 
drugs (Table 3.2). However IXB treatment also led to a significant reduction in peak 
disease score (untreated = 3.9 +/- 0.1 vs. IXB = 3.3 +/- 0.3) and the maximal disease score 
reached for any mouse was 4 compared to 4.5 and 5 for PTX and untreated mice 
respectively. These results suggest that IXB may provide a small therapeutic advantage 
over PTX. 
 
Spleen and dLN were analysed for changes in cellularity 30 days following immunisation. 
No difference in CD4
+
, CD8
+
 T cell numbers or total cell numbers in the spleen or dLN 
was observed between any of the treatment groups (Figure 3.12a-d). Additionally, no 
significant difference in proliferative response of splenocytes and LN cells was observed 
between groups, when cultured in the presence of Con A or MOG (Figure 3.13a and b). 
These results indicate that IXB like PTX does not appear to alter long-term peripheral T 
cell responses. 
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Figure 3.10 Ixabepilone treatment (d6-12 p.i.) delays EAE onset and severity  
C57BL/6 mice were immunised for EAE and treated with paclitaxel (20mg/kg) on days 6-10 or days 6-12 
QOD or with Ixabepilone (10mg/kg) on days 6-12 QOD. a) Disease score of all mice (b) Disease incidence; 
calculated as percent of mice that develop clinical disease. (c) % weight change; calculated as % change of 
individual mice from d0. Data represents one experiment (n = 4-5 mice per group). Any mice that died were 
excluded from the analysis. 
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Figure 3.11 Ixabepilone treatment (d6-12 p.i.) exhibits similar efficacy to paclitaxel in delaying EAE 
onset 
C57BL/6 mice were immunised for EAE and treated with paclitaxel (20mg/kg) or with Ixabepilone 
(10mg/kg) on days 6-12 QOD. a) Disease score of all mice (b) Disease incidence; calculated as percent of 
mice that develop clinical disease. Data represents three experiments (n= 10 PTX, 14 IXB and 15 untreated). 
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Drug Treatment  Untreated Paclitaxel Docetaxel 
Incidence  80%  (25) 65% (19) 42% (19) 
Mortality before disease onset  0% 25% (5) 20% (4) 
Day of onset 13.8 ±  1.4 22.3 ± 2.7 23.0 ± 4.7 
Peak disease score 3.6 ± 0.2 3.3 ± 0.1 3.3 ± 0.1 
Disease burden (% untreated) 100 51.7 ± 11.0 50.7 ± 18.2 
Maximum score 5 4 4 
Drug Treatment  Untreated Paclitaxel Ixabepilone 
Incidence  100%  (35) 90% (20) 80% (19) 
Mortality before disease onset  0% 0% 0% 
Day of onset 13.86 ±  0.6 22.78 ± 1.0 ** 21.93 ± 1.0 ** 
Peak disease score 3.9 ± 0.1 3.8 ± 0.1 3.3 ± 0.3 * 
Disease burden (% untreated) 100 50.52 ± 6.9 * 55.38 ± 13.0 * 
Maximum score 5 4.5 4 
Days at peak disease 5.8 ± 0.2 2.6 ± 0.2 3.1 ± 0.7 
Table 3.1: Paclitaxel and docetaxel alter EAE disease parameters 
Drug treatments = paclitaxel (20 mg/kg) or docetaxel (10mg/kg) on d0-4 or 6-10 p.i.. 
Total mice used is indicated in parentheses. Day of onset peak disease score are 
calculated mean ± SEM of sick mice only. Disease burden was calculated as mean ± 
SEM percent area under the curve of drug treated relative to untreated mice for 
individual experiments. No significant difference between drug treated compared to 
untreated mice was observed. 
Table 3.2: Paclitaxel and Ixabepilone alter EAE disease parameters 
Drug treatments = paclitaxel (20 mg/kg) or ixabepilone (10mg/kg) d6-12 p.i. QOD. 
Total mice used is indicated in parentheses. Day of onset and peak disease score are 
calculated as mean ± SEM of sick mice only. Disease burden was calculated as mean 
± SEM percent area under the curve of drug treated relative to untreated mice for 
individual experiments. * P < 0.05, ** P < 0.01 ANOVA with Dunnett’s post-test 
(drug treated compared to untreated).  
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Figure 3.12 Ixabepilone treatment (d6-12 p.i.) does not chronically alter spleen or lymph node 
cellularity 
C57BL/6 mice were immunised for EAE and treated with paclitaxel (20mg/kg) or with Ixabepilone 
(10mg/kg) on days 6-12 QOD. Splenocytes and lymphocytes were isolated 30 or 40 days p.i. counted 
and analysed by flow cytometry to calculate total CD4
+
 (a), CD8
+
 (b), CD4
+
CD25
+
 (c) and total cell 
numbers (d). Shown are means and SEM of individual mice from two experiments (n = 10 
mice/group). There were no significant differences between treatment groups within spleen or dLN 
analysed by one-way ANOVA with Newman-Keuls Multiple Comparison test. 
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Figure 3.13 Ixabepilone (d6-12 p.i.) does not inhibit ex vivo antigen-specific proliferation 
C57BL/6 mice were immunised for EAE and treated with paclitaxel (20mg/kg) or with Ixabepilone 
(10mg/kg) on days 6-12 QOD. Spleen or lymph node cells were cultured in medium alone or in the 
presence of Con A (3 µg/ml) or MOG (27 µg/ml), 30 or 40 days p.i.. Proliferation was assessed by 
3
[H]thymidine (1µCi) incorporation and is expressed as a proliferation index; expressed as CPM of 
stimulated wells/CPM of media alone. Shown are means and SEM of individual mice from three 
experiments (n = 10 PTX, 10 IXB and 15 untreated). No significant differences were observed between 
groups within each of the stimulation concentrations by one-way ANOVA with Newman-Keuls 
Multiple Comparison test. 
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3.3.6 Treating with ixabepilone after disease onset 
To explore if administering IXB after disease onset would alter disease progression, 4 
doses of IXB (10 mg/kg QOD) were administered to immunised mice following disease 
onset (d11 p.i.). During drug treatment disease symptoms progressed to a similar severity 
as to untreated mice and no reduction in peak disease scores occurred (Figure 3.14a). 
However, by d30 p.i. the IXB treated mice began to exhibit reduced disease severity and 
increased weight gain compared to those in the untreated group (Figure 3.14a and b). 
These results suggest that IXB may be effective at limiting the severity of disease when 
given after onset. However, as this IXB treatment regime was only used in one experiment, 
further experiments are needed to confirm this. 
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Figure 3.14 Ixabepilone reduces disease severity when administered after EAE onset 
Mice were immunised for EAE and treated after with Ixabepilone (10 mg/kg QOD) after disease onset (d 
11: shown by arrows). (a) Disease score of all mice (b) % weight change; calculated as % change of 
individual mice from d0. Shown are means and SEM of individual mice from one experiment (n = 5 mice 
per group). 
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3.3.7 Paclitaxel and ixabepilone reduce disease expression in a Balb/c EAE model  
In Balb/c mice, EAE manifests in a different form to that of C57BL/6 and is characterised 
by lower peak disease scores, reduced incidence and complete disease resolution. To test if 
MSD would also be effective in this model, Balb/c mice were administered with either 
PTX (20 mg/kg) or IXB (10 mg/kg) using a d6-12 p.i. QOD treatment regime. Mice 
treated with IXB exhibited no disease (Figure 3.15a and b). One mouse treated with PTX 
had disease symptoms that were delayed in onset and resolved faster than untreated sick 
mice (Figure 3.15a and b). However, despite the inhibition of disease, significant toxicity 
was observed with 55% of PTX treated mice and 25% of IXB treated mice dying (on d13-
15 p.i.). These results indicate that MSDs can prevent EAE in Balb/c mice, although this 
mouse strain appears to be more susceptible to the toxic effects of MSD treatment during 
EAE.  
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Figure 3.15 Paclitaxel or Ixabepilone inhibits the development of EAE in Balb/c mice  
Balb/c mice were immunised for EAE and treated with paclitaxel (20mg/kg) or with Ixabepilone (10mg/kg) 
on days 6-12 QOD. (a) Disease score of all mice (b) Disease incidence; calculated as percent of mice that 
develop clinical disease. Data represents two experiments (n = 7 PTX, 3 IXB and 10 untreated mice per 
group). Any mice that died were excluded from the analysis. 
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3.3.8 Paclitaxel inhibits disease expression in a relapsing-remitting EAE model 
An alternate model of EAE that more closely resembles the relapsing-remitting form of 
MS uses SJL/J mice, which are susceptible to EAE induction using the proteolipid protein 
peptide 139-151 (PLP). To test if PTX could effectively inhibit relapses after initiation of 
disease, mice were treated with 4 doses of PTX (20 mg/kg, QOD), when the mice began to 
remit (drop below a disease score of 2) from their initial episode of paralysis. Disease 
symptoms of all the mice treated with PTX completely resolved following treatment and 
relapse was delayed for a minimum of 14 days (Figure 3.16a, c, and d). Drug treatment 
did not cause weight loss and there was also no difference in weight gain during disease 
remission between treated and untreated mice (Figure 3.16b). This effectiveness of 
treating after disease onset, provides further evidence of the potential applicability of using 
MSDs to treat MS as it is likely that in a clinical setting, this would be the time these drug 
could be administered to patients. 
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Figure 3.16 Paclitaxel reduces disease expression in a relapsing-remitting EAE model  
SJL/J mice were immunised for EAE and treated with paclitaxel (4x 20mg/kg QOD) during remission of disease 
(indicated as a disease score ≤ 2) or left untreated. (a) Disease score of all mice, (b) % weight change: calculated 
as % change of individual mice from d0, (c) Disease score of individual PTX treated mice (arrow indicates time 
range for initiation of treatment ), (d) Disease score of individual untreated mice. Data represents two 
experiments (n = 7-8 mice per group). 
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3.4 Discussion 
Previous work conducted in our laboratory had found that PTX when administered at the 
MTD of 20 mg/kg on days 0-4 following immunisation delayed EAE onset and reduced 
disease incidence (Crume et al., 2009). The current study aimed to further optimise the use 
of this treatment regime and explore the potential of other MSDs for the treatment of EAE. 
When the original experiments using PTX were replicated in the present study a similar 
effect was observed with a delay in disease onset in drug treatment groups. In the DTX or 
PTX treated mice, total EAE disease burden was reduced; however, this reduction was due 
to a delay in onset rather than a sustained reduction in disease severity. When peripheral T 
cell responses were measured, no reduction in antigen-specific responses occurred in 
splenocytes or lymphocytes from drug treated animals. In fact, proliferative responses in 
splenocytes from drug treated animals were increased relative to untreated splenocytes 
when stimulated with Con A or MOG. PTX and DTX had a very similar effect on the 
disease response suggesting there is little difference in the activity of these drugs in the 
EAE model. The delayed disease response but unaltered disease severity, combined with 
no observed reduction in peripheral antigen-specific proliferation, suggest that drug 
treatment results in only a transient alteration in immune response or the effect of the 
MSDs occurs though other mechanisms not detected in the analysis of peripheral immune 
responses.     
 
Both the current study and previous research has found that PTX administered at the MTD 
of 20 mg/kg on d0-4 p.i. causes fatal toxicity in some mice between d7-12 p.i. (Crume, 
2007). A study in Lewis rats found that PTX when administered at a MTD on days 6, 8 
and 12 p.i. was effective at suppressing EAE but also caused mortality in 11 out of 15 rats 
(Cao et al., 2000). Interestingly this toxicity is only seen in EAE immunised animals, as 
the same dosing regime in non-immunised mice caused no obvious alteration in weight or 
appearance (Crume, 2007). The timing of the toxicity coincides with onset of disease (in 
non-drug treated mice). It is possible, therefore, that this toxicity could be associated with 
the inflammatory process that occurs during disease induction. 
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Development of EAE undergoes a documented progression of immune events beginning 
with the immunisation of a myelin based antigen. During early stages of the disease 
process, antigen presenting cells (APC) acquire the antigen from the immunisation site, 
while simultaneously being activated by ‘immune danger signals’ present in the immune 
adjuvant, CFA. Following migration to the draining lymph node, APCs present this antigen 
to antigen-specific T cells, which then undergo the process of clonal expansion. This 
proliferation occurs early in the disease process and peaks within the periphery by d8-9 p.i. 
(Hofstetter et al., 2010; Targoni et al., 2001). Usually, from about day 7 onwards, activated 
T cells can begin to migrate into the CNS, and disease symptoms start to appear (Juedes et 
al., 2000). During this period higher than normal concentration of inflammatory cytokines 
are expressed in immunised mice (Hofstetter et al., 2010). 
 
It was initially thought that PTX, acting on TLR-4 receptors, could be further enhancing 
the inflammatory milieu to a toxic level. If this were the cause of the toxicity, DTX, an 
analogue of PTX that does not activate TLR-4 receptors, would not cause any mortality. 
However, DTX given to EAE immunised mice on d0-4 p.i caused a similar level of 
mortality to that of PTX treated animals (Table 3.1). This indicates that TLR-4 activation 
is unlikely to be the cause of MSD toxicity in immunised animals. As with the toxicity, 
there also appears little obvious difference in the disease modifying effects between DTX 
and PTX, indicating that the TLR-4 activity of PTX confers no obvious advantage or 
disadvantage to either the effectiveness or the toxicity of MTD in EAE.  
 
Treating at d6-10 p.i. with either PTX or DTX also caused a similar rate of mortality 
between d7-12 p.i., further supporting the concept that the toxicity may be related to the 
inflammatory events occurring during the drug vulnerable period. The variability in the 
occurrences of toxicity may be related to the specific kinetics of the inflammatory process 
as they occurr in individual mice and that toxicity appears only when drug treatment 
coincides with particular disease related events. A number of additional factors support 
hypothesis. Mortality of drug treated mice was only observed in about half the experiments 
using either the d0-4 or d6-10 p.i dosing regimen, and when toxicity did occur it did so 
only in a subset of drug treated animals. Additionally, no mortality occurred in mice that 
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were administered PTX on d21-25 p.i. This treatment time point is likely to be after peak 
inflammatory activity in the periphery has occurred (Kuerten et al., 2010; Targoni et al., 
2001).  
 
A potential cause of the toxicity that could explain the unusual combination of high drug 
concentration and inflammation could be pneumonitis or a more generalised pulmonary 
oedema. These adverse events would be consistent with the symptoms of dyspnea and 
hunched appearance in mice before they died. There are many reports in the literature of 
cancer chemotherapy patients having severe pulmonary oedema and/or pneumonitis, days 
to weeks after PTX or DTX treatment (Dimopoulou et al., 2006; Fujimori et al., 1998; 
Ramanathan et al., 1996; Semb et al., 1998; Wang et al., 2001).  While severe pneumonitis 
is a rare side effect of taxane treatment, it is a life threatening condition that often requires 
respiratory ventilation (Nagata et al., 2010).  
 
When CFA is injected intravenously in animals it can induce an experimental form of 
pneumonitis on its own (Edwards et al., 1983; Soler et al., 1975). While the administration 
route would assist in this process (as it is likely the CFA emulsion will lodge in the 
capillaries of the lungs), it is interesting to note that CFA causes an inflammatory response 
that can result in pneumonitis. In rodents PTX and DTX have been shown to lower 
interstitial fluid pressure which results in fluid flux, protein extravasation and tissue 
oedema  (Borge et al., 2006; Bronstad et al., 2004). Additionally, it has been found that 
pulmonary oedema can occur transiently after i.v. injections of PTX in rats. This was 
correlated to increased levels of substance P and could be inhibited by antagonism of 
neurokinin receptors. (Itoh et al., 2004; Sendo et al., 2004). Substance P acting thought 
neurokinin receptors causes vasodilatation and increased vascular permeability and can 
also can act as a chemoattractant to lymphocytes monocytes and neutrophils (O'Connor et 
al., 2004).  
 
If increases in vascular permeability were occurring due to PTX administration, the effects 
are likely to be acute and would occur when drug concentrations are high. It is conceivable 
that prolonged high drug concentrations causing increased capillary permeability and 
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potential oedema could initiate a pulmonary inflammatory response. The inflammatory 
response that results in lethal pneumonitis may be delayed until drug concentrations are 
low enough to allow for immune cell extravasation or until a large enough response has 
occurred. This effect may only occur, therefore, in drug treated immunised mice since the 
inflammatory milieu may exacerbate this effect to an extent that results in the toxic effects 
observed. Alternately a similar mechanism of increased vascular permeability and oedema 
caused by MSD administration could be directly affecting the CNS. No investigation was 
conducted in the current study to determine if oedema was occurring within the brain or 
lungs following drug treatment. Further in-depth research would need to be carried out to 
explore this hypothesis. As it was found that spacing the doses out by treating every 
second day did not cause any mortality C57BL/6 mice, this treatment regime was focused 
on for future experiments and the cause of toxicity was not further investigated. 
 
Similar to the day 0-4 p.i. treatment, MTD doses of PTX and DTX administered on days 6-
10 p.i. delayed disease onset and reduced disease incidence. As the initial induction of 
peripheral inflammatory responses occurs within the first week following immunisation 
(Hofstetter et al., 2010; Targoni et al., 2001), the alteration of disease following d6-10 p.i. 
drug treatment indicates that MSDs can alter pre-established autoimmune activity.  It is 
interesting that treatment on either d0-4 p.i. or d6-10 p.i. resulted in a similar delay in 
disease onset. If the alterations in disease observed following the d6-10 p.i. treatment were 
solely due to inhibition of T cell proliferation, it would be unlikely that the delay in disease 
onset would be as prolonged as that seen in d0-4 p.i. treatment. By day 6 p.i., clonal 
expansion of MOG reactive T cells has begun to occur, and antigen-specific responses can 
be detected within the dLN and spleen (Crume et al., 2009). Thus a large population of 
autoreative T cells would already be present in the secondary lymphoid organs, and MSD 
treatment on d6-10 p.i. is unlikely to cause ablation of these pre-established populations.  
 
If disease responses can be modified after initial inflammatory events, it was thought 
multiple dose regimes might confer improved disease modification. However when a dual 
dosing regime was used, little benefit in reducing disease burden was gained compared to a 
single dosing regime. Within the d21-26 treatment groups, mice that had not already 
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displayed disease symptoms had an increased delay in disease onset. In mice that already 
exhibited disease symptoms, this treatment time point would be after the majority of 
myelin reactive immune cells had already migrated from the periphery to the CNS (Flugel 
et al., 2001; Furtado et al., 2008). Both PTX and DTX have low permeability for the 
blood-brain barrier (BBB) and drug concentration in the CNS are very low compared to 
plasma levels (Fellner et al., 2002; Kemper et al., 2004). As the BBB can become leaky 
during EAE, it is possible PTX or DTX may more readily enter the CNS after disease 
onset. However, given both of these drugs are substrates for drug efflux pumps (which are 
highly expressed on CNS endothelial cells) the concentrations of drug within the CNS after 
disease onset is still likely to be much lower than that occurring in peripheral tissues 
(Fisher et al., 1996; Loscher et al., 2005). The lack of disease modification following 
disease onset indicate that PTX and DTX are only effective on the peripheral immune 
response and not that which is occurring within the CNS.  
 
Interestingly, treating mice with IXB after disease onset resulted in a reduction in disease 
severity. This contrasts the above results where the dual dosing of PTX or DTX did not 
alter disease burden. Additionally, a previous study had found that PTX administered at the 
peak of disease (20 mg/kg/d for 5 consecutive days) had no effect on disease burden 
(Crume, 2007). One possible explanation could be that IXB was having an effect within 
the CNS, as unlike the taxanes, IXB passes more readily into the CNS (Brunden et al., 
2011). However, as this IXB treatment regimen was only used in one experiment and was 
not compared directly to PTX, it is possible that this is not a typical effect of the drug. 
While not explored further in the present study future investigation into the effect of IXB 
after disease onset (i.e. repeating the experiment in section 3.3.6) may be warranted.   
 
A similar delay in disease onset and reduction in disease burden was seen between IXB 
and PTX treatments administered on d6-12 p.i. QOD (Table 3.2). The initial pilot 
experiment using IXB showed particularly impressive inhibition of disease. The disease 
severity in untreated immunised mice within this initial experiment was mild (mean peak 
score 3.3) compared to subsequent experiments (mean peak score 4.1), and disease onset 
also occurred at a later time point (d16 p.i. vs. d12.4 p.i.). This may indicate that the 
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efficacy of IXB treatment is related to the severity and/or the kinetics of disease expression. 
When multiple experiments were compared, disease protection in drug treated mice (PTX 
and IXB, d6-12 p.i. QOD) was correlated to disease severity of unimmunised mice (r = -
0.724, p = 0.0137). Thus, if disease severity in unimmunised mice is high, protection 
induced by drug treatment is reduced (Figure 3.17b). A similar (but non-significant), trend 
was also seen in PTX and DTX (d0-4 p.i. and d6-10) treatment (Figure 3.17a). This 
suggests that MSD may be more effective in a less aggressive inflammatory environment. 
However, irrespective of the disease severity, when the disease burden (as measured by 
area under the curve; AUC) of MSDs treated mice was compared to disease burden of 
untreated mice, it can be seen that all the MSDs tested provided protection against disease 
in each experiment (Figure 3.17).  
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Figure 3.17 Paclitaxel, docetacel or ixabepilone treatment is more protective in less severe 
disease    
Disease protection in drug treated C57BL/6 mice compared to mean peak disease score of untreated 
mice within experiments. Disease protection (a) PTX 20mg/kg or DTX 10mg/kg (administered on 
d0-4 or 6-10 p.i.). (b) PTX 20mg/kg or IXB 10mg/kg (administered on d6-12 p.i. QOD). Disease 
protection calculated as AUC untreated mice – AUC drug treated mice / AUC untreated mice. Each 
data point represents a single experiment shown as mean and SEM of individual mice. Any mice that 
died were excluded from the analysis. 
Figure 3.18 Paclitaxel, docetacel or ixabepilone treatment has a protective effect in EAE     
Protection or exacerbation of EAE for drug treated vs. untreated C57BL/6 mice; calculated as disease 
burden (AUC: area under the curve) of individual drug treated mice compared to untreated mice. (a) 
PTX 20mg/kg or DTX 10mg/kg (administered on d0-4 or 6-10 p.i.). (b) PTX 20mg/kg or IXB 10mg/kg 
(administered on d6-12 p.i. QOD). Each data point represents a single experiment shown as mean and 
SEM of individual mice. Any mice that died were excluded from the analysis. 
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In the initial experiment only 1 of 5 mice treated with IXB exhibited disease symptoms, 
and no overt changes in cellularity or antigen-specific responses were seen in splenocytes 
or lymphocytes from the IXB treated mice. Thus, even when disease was not apparent, 
MOG specific T cells were present in drug treated mice, and these cells were as responsive 
to antigen stimulation as those of untreated mice. Therefore, it is likely that drug treatment 
is either not inhibiting the autoreactive T cell response or is only doing so transiently. The 
fact that robust antigen responses were seen in IXB treated mice that did not exhibit 
disease symptoms suggests that the alteration of disease in drug treatment is not related to 
the anti-mitotic effects of MSDs. However, as the MOG/CFA depot is still visible at the 
injection site months after immunisation it is likely that even if MSDs were inhibiting 
clonal expansion or antigen-specific responses during or shortly after drug treatment, long-
term responses could potentially develop well after the drugs had been administered. To 
test if in fact this is occurring, a passive induction model of EAE could be used, since in 
this model encephalogenic cells are adoptively transferred into recipient mice, removing 
the need for immunisation.   
 
When a number of experiments were compared, a similar delay in disease onset and 
reduction in disease burden was seen between IXB and PTX treatments; however, IXB 
treatment also resulted in a significant reduction in peak disease score that was not seen 
with PTX (untreated = 3.9 +/- 0.1 vs. IXB = 3.3 +/- 0.3) (Table 3.2). While an overall 
reduction in average peak disease severity of 0.6 does not appear substantial, this reduction 
translates into considerable gains in functionality for IXB-treated mice. In terms of clinical 
symptoms, this difference equates to hind limb weakness as opposed to full hind limb 
paralysis. Likewise a maximal disease score of 4 for IXB compared to 4.5 for PTX and 5 
for untreated mice is a substantial improvement. These factors combined with the potential 
disease modifying effects observed when the drug is given after disease onset indicate that 
IXB provides a small therapeutic advantage over PTX within the context of EAE.  
 
In contrast to the C57BL/6 mice, Balb/c mice treated with IXB or PTX on d6-12 p.i. QOD 
exhibited little or no disease. A factor to consider in assessing the difference between the 
disease inhibition seen in the two strains is in the drug treated mice is likely to be 
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associated with the difference in disease expression between the two strains. The Balb/c 
EAE model exhibits a monophasic disease followed by complete remission of symptoms, 
whereas the C57BL/6 mice have a more severe disease peak followed by a chronic but less 
severe plateau. If MSDs cause a transient alteration in inflammatory responses, this might 
explain why inhibition of disease is far more pronounced in the Balb/c model compared to 
the C57BL/6 model.     
 
Despite the inhibition of disease in Balb/c mice 55% of PTX and 25% of IXB treated mice 
died. It is possible that the substantial disease suppression in drug treated mice could be 
due to more potent effects of the drugs in Balb/c mice (as indicated by the increased 
toxicity). However, this is unlikely, since, no correlation was found between toxicity and 
drug efficacy (number of deaths vs. untreated groups peak disease scores; r 0.171, p = 
0.686; data from 5 separate experiments) within experiments using C57BL/6 mice. 
Another possible explanation for the increased toxicity in Balb/c mice could be due to 
strain differences in sensitivity to the drug or susceptibility to the side effects. The Balb/c 
mice weighed on average 50% more than the C57BL/6 mice, and the drug concentrations 
were increased accordingly to give the same mg/kg dose as was used for C57BL/6 mice. 
As no unimmunised Balb/c mice were injected with these doses, it cannot be ruled out that 
the dose was too high and would have caused significant toxicity to unimmunised mice.   
 
Previous studies conducted in our laboratory using PTX have found that high 
concentrations of PTX are required to modify disease (Crume, 2007). The study by Cao et 
al. in Lewis rats found that PTX could modify EAE in Lewis rats when administered at a 
MTD on day 6, 8 and 12 p.i., but this dose also caused significant mortality (Cao et al., 
2000). Interestingly, when this experiment was replicated in mice, no mortality but also 
little alteration in disease progression was observed (Crume, 2007). Administering a MTD 
at d 6,8,12 p.i. is very similar to the effective dosing of 20 mg/kg on d6-12 QOD used in 
the current study. Collectively, these factors indicate that MSDs have a narrow therapeutic 
window with administration of high concentrations over a prolonged period required to 
effectively alter disease. The deaths observed in C57BL/6 mice treated daily and the in 
QOD treatmented Balb/c mice emphasise the narrow range between efficacy and toxicity. 
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While the toxicity at least within the C57BL/6 model appears to be EAE specific, it is also 
dose related. Toxicity in this model only occurred in mice treated using a daily drug dosing. 
Treating with a QOD regime may allow for drug concentrations to be maintained within 
the therapeutic window without causing peaks in concentration that, combined with the 
inflammatory environment, induce unwanted toxicity.  
 
Treating SJL/J mice with PTX after signs of disease remission resulted in a delay in 
relapse onset and a reduction in incidence. As relapses did occur, however, the PTX 
treatment was clearly not fully ablating the encephalogenic immune response. Unlike the 
Balb/c mice that have a single episode of disease, SJL/J mice exhibit waves of disease 
expression that are correlated with fresh influx periods of myelin reactive T cells, 
migrating into the CNS (Targoni et al., 2001; Vanderlugt et al., 2000). It seems likely PTX 
is inhibiting this influx of T cells. This could be due to either inhibition in migration of 
these cells into the CNS or transiently depleting the encephalogenic T cells to a level that 
is ineffectual at causing a relapse.  
 
Within the context of MS, in humans, any therapy would generally be administered after 
development of symptoms, as a prophylactic treatment is obviously not feasible. The 
disease modifying effects of PTX within the SJL/J model provides further evidence for the 
applicability of using MSDs for the treatment of MS. However, it is likely, given the 
results discussed above, the therapeutic effect of MSD in MS would be to lessen disease 
relapse or severity rather than to completely inhibit the disease.  
 
Many of the experiments conducted within this chapter were exploratory in nature and 
were focused on further optimising the dosing schedule of MSDs for the treatment of EAE. 
As such, some of these experiments were only conducted once or twice. Additionally, 
although most experiments began with 5 mice per group, due to the toxicity of some of the 
treatment regimes the final mouse numbers were often less than this. These factors need to 
be considered when interpreting the findings from some of the experiments within this 
chapter. However, while these factors may increase the potential variability, when the 
experiments are viewed collectively (Table 3.1 and 3.2; Figure 3.17 and 3.18), or alongside 
Chapter 3: Using microtubule-stabilising drugs to treat EAE                                            74 
previous research (Crume, 2007; Crume et al., 2009) consistent trends emerge, which have 
been summarised below. 
3.5 Summary  
The findings from these experiments show that MSDs can effectively alter the disease 
expression of EAE. High drug concentrations and prolonged drug exposure appear to be 
necessary for these disease-modifying effects. Drug toxicity in MSD-treated immunised 
mice is unlikely to be due to TLR-4 activation by PTX, and this toxicity can be avoided by 
altering the MSD treatment regimen. The lack of evidence for significant chronic 
alterations in cellularity and cytokine expression with all three drugs suggest that if MSDs 
cause any modulation of the immune system, this alteration only occurs during or soon 
after drug exposure.   
  
 
 
 
Chapter 4: 
Identifying microtubule-stabilising 
drugs mechanisms of action  
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4.1 Introduction  
It was shown in the previous chapter that MSD effectively alter EAE disease expression. 
However, the mechanism responsible for these alterations and the potential involvement of 
the immune responses in this mechanism are not well defined. While a number of studies 
have documented the effects of MSDs on inflammatory diseases including arthritis, 
psoriasis, systemic lupus and EAE, little is known about the direct effect on immune cell 
activity (Brahn et al., 1994; Cao et al., 2000; Ehrlich et al., 2004; Oliver et al., 1994; Song 
et al., 1998).  
 
The most obvious possible mechanism by which MSD treatment reduces inflammatory 
diseases is inhibition of proliferation. Diseases such as EAE are mediated by the activation 
and proliferation of self-reactive lymphocytes, and inhibition of these events would be 
expected to alter disease expression. For example, PTX has been shown inhibit in vitro 
proliferation of stimulated lymphocytes (Brown et al., 1985; Crume et al., 2007). 
Additionally, a reduction in leukocytes or ‘leukopenia’ is a common side effect of cancer 
chemotherapy (Sako et al., 2004; Tsavaris et al., 2002). These factors suggest that MSDs 
are likely to inhibit leukocyte proliferation in vivo, and this inhibition could be responsible 
for the efficacy of these drugs in inflammatory disease models.  
 
However, non-anti-mitotic effects of MSDs on immune cells have also been noted. 
Administration of PTX can impair the ability of cytotoxic T cells to kill antigen-specific 
target cells in vitro and in vivo (Chuang et al., 1994; Robinson et al., 2008). While with 
murine macrophages, cultured under inflammatory conditions, MSDs can inhibit TNF-α 
and NO production (Crume et al., 2007). It has also been noted that patients undergoing 
PTX- or DTX-based cancer chemotherapy have increased inflammatory cytokines IL-2, 
IL-5 and IFN-γ levels, but decreased TNF-α (Tsavaris et al., 2002). These results indicate 
that the effects of MSDs on the immune system are unlikely to be solely due to anti-
proliferative activity. 
 
In addition to cell division, microtubules are important for a wide range of cellular 
processes including intracellular transport, cell migration and cell polarity (Hirokawa, 1998; 
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Jordan et al., 2004; Nogales, 2001). Microtubule function is required for antigen 
processing and presentation by dendritic cells and macrophages, and PTX can interfere 
with these processes (John et al., 2010; Peachman et al., 2004). In macrophages, formation 
of podosomes, which are necessary for directional movement, and transcelluar diapedesis 
are microtubule-dependent processes (Calle et al., 2006; Linder et al., 2000). It is therefore 
conceivable that alterations in these processes may contribute to the disease modifying 
effects of PTX in the EAE model.  
 
4.2 Aims and Objectives 
The previous chapter demonstrated that MSDs, administered early in the disease process, 
had little effect in modifying chronic inflammatory responses. In contrast, this chapter tests 
the hypothesis that drug treatment modifies disease-specific immune responses at earlier 
time points in the disease process. Additionally, to better understand the mechanism by 
which PTX and MSD reduce EAE disease expression, the effects of PTX treatment on 
immune cell proliferation and migration were determined. 
4.2.1 Specific Aims: 
1. To assess changes in immune responses immediately following drug treatment 
2. To determine if proliferation  is altered by PTX treatment 
3. To identify if PTX treatment alters in vivo immune cell migration  
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4.3 Results 
4.3.1 Spleen and LN cellularity is altered following paclitaxel treatment immediately 
after immunisation.  
As was demonstrated in the previous chapter, MSDs effectively delayed EAE disease onset 
but did not appear to cause significant chronic alterations in immune parameters measured. 
Thus, it was hypothesised that effects of MSDs on the immune response may be transient, 
occurring only during or soon after drug administration. To explore this possibility, mice 
were immunised for EAE and treated with PTX daily from day 0-4 p.i.. On day 5 p.i. the 
dLN and spleens were isolated from untreated and treated, unimmunised and immunised 
mice and changes in cellularity and antigen responses were assessed. Because both PTX 
and DTX treatment had a very similar effect on the disease response, only PTX was used 
in these experiments.  
 
Five days after immunisation, total cell numbers were increased in the spleens and dLN of 
immunised untreated mice (iUT) compared to immunised PTX-treated (iPTX) and 
unimmunised PTX (uiPTX) or untreated, unimmunised (uiUT) mice (Figure 4.1f). The 
increase in cell numbers was particularly pronounced in F4/80
+
 and Gr-1
+
 populations 
within both the spleen and dLN within iUT but not iPTX treated mice (Figure 4.1d and e). 
Additionally, within the spleens of iPTX mice, there were significantly less total CD4
+
 T 
cells compared with iUT (Figure 4.1a). Although there were significantly less CD4
+
 T 
cells in iPTX compared to iUT mice, no difference was observed between iUT and uiPTX 
or uiUT mice. Within the dLN, a significant increase in CD4
+
 T cells was observed within 
the iUT mice when compared to all other treatment groups (Figure 4.1a). No difference in 
total CD4
+
CD25
+
 T cells was observed, indicating the increase in CD4
+
 iUT mice was due 
to CD4
+
CD25
+
 T cells (Figure 4.1b). Finally, no significant differences in CD8
+
 T cells 
were observed between the groups (Figure 4.1c) suggesting that the changes in cellularity 
were cell type specific and not due to generalised depression in leukocyte populations by 
PTX. 
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Figure 4.1 Spleen and lymph node cellularity is altered immediately after paclitaxel treatment (d0-4p.i) 
C57BL/6 mice were immunised for EAE and treated with paclitaxel (20 mg/kg) or left untreated. Five days 
p.i. spleen and lymph node cells were isolated, counted, stained for cell surface markers and analysed by flow 
cytometry. Mean total cell numbers of  (a) CD4
+
CD25
-
 (b) CD4
+
 CD25
+
 (c) CD8
+
 (d) B220
+
 (e) F4/80
+
 and (f) 
Gr-1
+
 splenocytes and lymphocytes. Shown are means and SEM of values from individual mice from two 
separate experiments (spleens) or one experiment (dLN) (n = 5-9/group). *p < 0.05 or **p < 0.01 compared to 
immunised paclitaxel treated mice, by one-way ANOVA with Newman-Keuls multiple comparison test. 
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4.3.2 Antigen-specific responses are impaired in spleen and LN cells following 
paclitaxel treatment immediately after immunisation  
To identify whether the differences in cellularity between PTX-treated and untreated mice 
extended to altered cellular responses, ex vivo cell proliferation and cytokine production 
was measured in spleen and LN cultures. Despite the increase in total CD4
+
 T cell numbers 
in the iUT mice, no difference in Con A-induced polyclonal proliferative responses were 
observed between any of the treatment groups (Figure 4.2a). In contrast, MOG-specific 
proliferation was inhibited in the spleen and LN cell cultures from iPTX mice compared to 
iUT mice (Figure 4.2a and b). Little response was detected in cultures of cells from 
unimmunised mice confirming that the response in immunised animals was antigen-
specific. 
 
Nitric oxide (NO) production has been shown to inhibit T cell proliferation in vitro (Albina 
et al., 1991; Krenger et al., 1996). Thus, to investigate the possibility that NO was the 
cause of the reduced antigen-specific proliferation in the cells from PTX immunised mice, 
the Greiss reaction was used to assess NO levels in the culture supernatants. Because NO 
is an unstable molecule with a very short half life, the Griess assay utilises the stable NO 
breakdown product, nitrite, as an indicator of relative NO production. No significant 
difference in nitrite levels were detected between any of the treatment groups in either the 
splenocyte or lymphocyte cultures (Figure 4.3a and b) suggesting that high level NO 
production was not responsible for the reduced proliferation.      
 
To investigate if cytokine production from these cells was affected by PTX treatment, 
culture supernatants from spleen and LN cells that had been stimulated with Con A or 
MOG
 
for 48 or 72 hours, respectively, were analysed for IL-1β, IL-2, IL-4, IL-5, IL-6, 
GM-CSF, IL-10, IL-17, IFN-γ and TNF-α. Of the 10 cytokines measured, only those 
showing differences have been included in the analysis (Figure 4.4a-f). Strikingly, 
splenocytes from iUT mice produced IL-6 in response to MOG
 
and polyclonal stimulation 
while IL-6 production by splenocytes from iPTX treated animals was inhibited both to 
antigen-specific and polyclonal stimulation (Figure 4.4e). Moreover, this inhibitory effect 
on IL-6 production extended to the uiPTX treated mice which produced only low levels of 
IL-6 in response to polyclonal stimulation. In contrast to splenocytes, only low levels of 
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IL-6 were detected from LN cells, and there was no significant difference between 
treatment groups (Figure 4.4f).   
 
In addition to the dramatic effect on IL-6 production, PTX treatment caused a significant 
reduction in antigen-specific but not polyclonal-induced IFN-γ production (Figure 7.4a). 
A similar trend was observed in the LN cell cultures; however, this trend did not reach 
statistical significance (Figure 4.4b). In contrast to IFN-γ, IL-17 production in response to 
polyclonal stimulation was significantly inhibited in both splenocyte and LN cell cultures 
of PTX-treated animals (Figure 4.4c and d). Furthermore, no IL-17 was produced by 
MOG stimulated splenocytes from iPTX mice. Despite these impairments in IL-17 
production after PTX treatment, similar levels of MOG specific IL-17 were produced by 
LN cells from iPTX and iUT mice (Figure 4.4d). Theses results indicate that following 
PTX treatment, the ability of splenocytes to respond in an antigen-specific manner is 
inhibited, and although LN cell responses are attenuated, antigen-specific cytokine 
production still occurs. The finding that antigen-specific responses were observed in the 
dLNs indicates that drug treatment does not completely ablate autoimmune activity. 
Additionally, the difference in the response between splenocytes and lymphocytes may 
indicate that the effects of PTX treatment are more pronounced in the spleen than within 
the dLNs. 
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Figure 4.3 Ex vivo nitric oxide production is not altered in spleen and lymph node cells immediately 
after paclitaxel treatment (d0-4p.i) 
C57BL/6 mice were immunised for EAE and treated with paclitaxel (20 mg/kg) or left untreated. Five 
days p.i. spleen cells were cultured in the presence or absence of ConA (3 µg/ml) or MOG (27 µg/ml) for 
48 or 72 hour respectively. Supernatant nitrate levels were measured from (a) spleen and (b) LN cultures 
using the Griess assay. Shown are means and SEM of values from individual mice (n = 5-9 per group) 
from two separate experiments. There were no significant differences, by one-way ANOVA. 
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Figure 4.2 Ex vivo antigen-specific proliferation of spleen and lymph node cells is inhibited 
immediately after paclitaxel treatment (d0-4p.i) 
C57BL/6 mice were immunised for EAE and treated with paclitaxel (20 mg/kg) or left untreated. Five 
days p.i. (a) spleen and (b) lymph node cells were cultured in the presence or absence of ConA (3 µg/ml) 
or MOG (27 µg/ml) for 48 or 72 hour respectively. Proliferation was assessed by 
3
[H]thymidine (1µCi) 
incorporation and is expressed as a proliferation index; CPM of stimulated wells/CPM of media alone. 
Shown are means and SEM of values from individual mice from two separate experiments (n = 5-9 per 
group). **p < 0.01 compared to immunised paclitaxel treated mice, by one-way ANOVA with Newman-
Keuls multiple comparison test. 
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Figure 4.4 Ex vivo cytokine production is not altered in spleen and lymph node cells immediately after 
paclitaxel treatment (d0-4p.i) 
C57BL/6 mice were immunised for EAE and treated with paclitaxel (20 mg/kg) or left untreated. Five days 
p.i. spleen (left column) or dLN (right column) cells were cultured in the presence or absence of Con A (3 
µg/ml) or MOG (27 µg/ml) for 48 or 72 hour respectively. Cytokine production in the supernatants was 
assessed using a cytokine bead assay (a,b) IFN-γ, (c,d) IL-17a, and (e,f) IL-6. One value in figure (b) within 
MOG-stimulated immunised untreated group was not included in the figure as it was far higher than the 
equivalent Con A stimulated sample, or any other sample; it was also identified as an outlier by the Grubbs 
test. No significant difference occurred when data was analysed either with or without this value.  Shown 
are means and SEM of values from individual mice (n = 5-9 per group) from two separate experiments **p 
< 0.01 or **p < 0.001 compared to immunised paclitaxel mice, by one-way ANOVA with Newman-Keuls 
multiple comparison test. 
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4.3.3 Immune cell infiltration into the spinal cord is inhibited following d0-4 or d6-12 
p.i. paclitaxel treatment    
To explore if a similar alteration in immune response occurs in mice with a pre-established 
encephalgenic immune response, PTX was administered QOD on d6-12 p.i. and a similar 
series of immunological assessments were conducted on d13 p.i. At this time point, disease 
symptoms (i.e. ascending paralysis) were observed in immunised, untreated mice while 
PTX-treated mice remained disease free (Figure 4.5). Because cellular infiltration into the 
CNS is evident at this point in untreated, immunised mice, changes in cellularity within the 
spinal cord (SC) could be compared in immunised PTX and iUT mice. Using flow 
cytometry, a substantial population of CD4
+
 T cells was identified within the SC of iUT 
mice as assessed by percentage of total CD45
+
 cells or relative cell number (indicated by 
number of CD4
+
 events) (Figure 4.6a and b). In contrast to iUT mice, no increase in 
CD4
+
 populations were detected in the spinal cords of PTX d0-4 p.i. (iPTXd0-4) or PTX d6-
12p.i. QOD (iPTXd6-12) treated mice. To assess the effects of PTX treatment on myeloid 
populations (i.e. monocytes, macrophages, neutrophils), CD11b was used to collectively 
identify these populations. While the percentage of CD11b
+
 cells within the SC of iUT 
mice did not significantly increase relative to other groups, the total number of cells did 
increase significantly, and this increase was only observed in the iUT mice (Figure 4.6c 
and d). These results indicate that by d13p.i., expansion or recruitment of CD4
+
 and 
CD11b
+
 populations in the SC of iUT mice has occurred and treatment of mice with PTX 
completely prevents this expansion or recruitment.  
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Figure 4.5 Paclitaxel treated mice do not exhibit disease symptoms 13 days after immunisation 
C57BL/6 mice were immunised for EAE and treated with PTX (20mg/kg) on days 0-4 p.i. or day 6-
12 QOD, or left untreated. (n = 5/group) 
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Figure 4.6 Paclitaxel inhibits immune cell infiltration into the CNS  
C57BL/6 mice were immunised for EAE. Thirteen days p.i. spinal cord cells were isolated, stained for cell 
surface markers and analysed by flow cytometry. (a) Representative scatter plots of (from left to right) 
immunised untreated, immunised PTX d6-12 p.i. and unimmunised untreated CD4
+
 cells. (see appendix 1 
for gating scheme). (b) Percent CD4
+
 positive cells of total CD45
+
 cells or (c) total number of CD4
+
 
events. (d) Percent CD11b
+
 positive cells of total CD45
+
 cells or (e) total number of CD11b
+
 events. Data 
represents one of two experiments (n = 5/group, PTX 0-4 n = 3). *p < 0.05 or **p < 0.01 compared to 
immunised paclitaxel mice, by one-way ANOVA with Newman-Keuls multiple comparison test. 
a 
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4.3.4 Administration of paclitaxel on d0-4p.i. has a different effect on spleen and dLN 
cellularity to paclitaxel administered on d6-12 p.i. 
Thirteen days after immunisation, mice treated with PTX on d6-12 p.i. QOD had similar 
total number of both splenocytes and LN cells compared to immunised, untreated mice 
(Figure 4.7f). Interestingly, iPTXd0-4 mice had significantly higher number of splenocytes 
compared to iUT or iPTXd6-12 treated mice. To understand which cellular populations were 
affected by PTX treatment, the major cell populations were identified by flow cytometry. It 
was found that, within the spleens but not dLN of iPTXd0-4 mice, both CD4
+
 and CD8
+
 T 
cell numbers were lower compared to other immunised groups (Figure 4.7a-c). Although 
the reduction did not reach statistical significance, the difference in cell numbers was 
substantial (>2 fold reduction). It is likely the reason the difference did not reach 
significance is due to the low numbers of mice in the iPTXd0-4 treatment group and 
inherent mouse-to-mouse variability. In contrast to T cells, a significant increase in F4/80
+ 
and Gr-1
+ 
cell numbers was observed in the iPTXd0-4 mice indicating that PTX does not 
cause lasting inhibitory effect on these populations (Figure 4.7e and f). Mice from the 
iPTXd6-12 treatment group had similar numbers of CD4
+
 CD8
+
 and F4/80
+
 cells to that of 
iUT mice within their spleens and dLNs (Figure 4.7a-e), suggesting that proliferation and 
expansion of these cell populations occurred before PTX administration. The only 
significant difference between iUT and iPTXd6-12 mice was in Gr-1
+
 cell numbers, which 
were reduced in the spleens of iPTXd6-12 mice (Figure 4.7e). As Gr-1
+
 cells, which are 
primarily neutrophils, have a rapid turnover, the reduction in this population in iPTXd6-12 
treated mice may indicate that PTX is inhibiting the replenishment of the neutrophil 
population.  
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Figure 4.7 Paclitaxel alters spleen cellularity when administered on d0-4 p.i. or on d6-12 p.i.  
C57BL/6 mice were immunised for EAE. Thirteen days p.i. spleen and dLN cells were isolated, counted, stained 
for cell surface markers and analysed by flow cytometry. Mean total cell numbers of  (a) CD4
+
CD25
-
 (b) 
CD4
+
CD25
+
 (c) CD8
+ 
(d) F4/80
+ 
(e) Gr-1
+
  and (f) total splenocytes and lymphocytes cells. Shown are means 
and SEM of values from individual mice from one (immunised PTX d0-4, unimmunised untreated and 
unimmunised PTX d6-12, n = 3-5/group) or two separate experiments (immuniszed PTX d6-12 and immunised 
untreated, n= 10/group). *p < 0.05 or *** p < 0.001 by one-way ANOVA with Newman-Keuls multiple 
comparison test. 
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4.3.5 Antigen-specific responses in spleen and LN cells are unaffected following d6-12 
p.i. paclitaxel treatment 
To determine if d6-12 p.i. PTX treatment alters cellular immune responses in addition to 
cellularity of lymphoid organs during EAE, the functional responses (i.e. proliferation and 
cytokine production) of spleen and LN cell were assessed on d13p.i.. When polyclonal 
proliferation was measured, reduced proliferation was observed within all immunised 
groups compared to unimmunised groups; however, no significant difference in splenocyte 
polyclonal proliferative responses were observed between drug-treated or untreated mice 
(Figure 4.8a). A similar effect was also observed within LN cell cultures (Figure 4.8b). 
Interestingly, the antigen-specific response in splenocytes from all immunised groups was 
low. However, while little antigen-specific proliferation was detected in iUT or iPTXd0-4 
treated mice, antigen-specific proliferation was significantly higher in the iPTXd6-12 treated 
mice (Figure 4.8a). In contrast to splenocytes, no difference in antigen-specific 
proliferation was observed in cultures of LN cells from any of the immunised treatment 
group (Figure 4.8b). Previous studies have shown that enhanced production of NO can 
inhibit proliferation (Albina et al., 1991), yet there was no correlation between 
proliferation and NO production, suggesting that antigen-specific NO production was not 
preventing T cell proliferation in these cultures (Figure 4.9).   
 
Although antigen-specific proliferation by splenocytes from all immunised groups was low, 
substantial inflammatory cytokine production by these cells was found within the cultured 
supernatants. IFN-γ production by splenocytes from immunised mice was similar in MOG 
and Con A stimulated cultures, and no difference in IFN-γ production between immunised 
PTX treated or untreated mice was detected (Figure 4.10a). Similarly, no difference was 
observed in IL-17 or IL-6 production by splenocytes from any of the immunised groups 
following MOG stimulation, although Con A stimulated splenocytes from iPTXd6-12   mice 
produced significantly less IL-17 but not IL-6 relative to the other immunised groups 
(Figure 4.10c and e). These data indicate that there is no significant difference in the 
antigen-specific IFN-γ, IL-17, and IL-6 responses of splenocytes from any of the 
immunised groups. 
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In contrast to splenocyte responses, MOG stimulation of LN cells resulted in much lower 
levels of IFN-γ, although no difference in levels occurred between groups. After Con A 
stimulation, LN cells from immunised, iPTXd0-4 treated mice produced higher levels of 
IFN-γ relative to iUT or iPTXd6-12 treated mice (Figure 4.10b). Likewise, no significant 
difference was detected in LN cells IL-17 responses between immunised groups following 
MOG
 
stimulation while LN cells from iPTXd0-4 treated mice produced significantly higher 
levels of IL-17 following Con A stimulation compared to the other immunised groups 
(Figure 4.10d). Finally, only very low levels of IL-6 were detected in the LN cultures, and 
no significant differences were found between immunised groups. Together with the 
results from the splenocyte cytokine responses, these findings indicate that there is little 
difference in antigen-specific cytokine responses between the immunised groups 13 days 
p.i.. 
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Figure 4.9 Antigen-specific nitric oxide production is not altered in ex vivo spleen and lymph node cells 
from d6-12 p.i. QOD paclitaxel treated mice relative to untreated mice  
C57BL/6 mice were immunised for EAE. Thirteen days p.i. spleen cells were cultured in the presence or 
absence of Con A (3 µg/ml) or MOG (27 µg/ml) for 48 or 72 hour respectively. Supernatant nitrate levels 
were measured from (a) spleen and (b) LN cultures using the griess assay. Shown are means and SEM of 
values from individual mice from one (spleen; immunised PTX d0-4, unimmunised untreated and 
unimmunised PTX d6-12, n = 3-5/group) or two separate experiments (immunised PTX d6-12 and immunised 
untreated, n= 10/group). **p < 0.01 compared to immunised paclitaxel mice (d6-12 p.i.), by one-way ANOVA 
with Newman-Keuls multiple comparison test. 
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Figure 4.8 Paclitaxel does not inhibit ex vivo antigen-specific proliferation when administered on d6-12 p.i. 
C57BL/6 mice were immunised for EAE. Thirteen days p.i. (a) spleen and  (b) lymph node cells were cultured in 
the presence or absence of Con A (3 µg/ml) or  MOG (27 µg/ml) for 48 or 72 hour respectively. Proliferation 
was assessed by 
3
[H]thymidine (1µCi) incorporation and is expressed as a proliferation index; CPM of stimulated 
wells/CPM of media alone. Shown are means and SEM of values from individual mice from one (spleen; 
immunised PTX d0-4, unimmunised untreated and unimmunised PTX d6-12, n= 3-5/group) or two separate 
experiments (immunised PTX d6-12 and immunised untreated, n = 10/group). *p < 0.05, **p < 0.01 or *** p < 
0.001 compared to immunised paclitaxel mice (d6-12 p.i.), by one-way ANOVA with Newman-Keuls multiple 
comparison test. 
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Figure 4.10 Antigen-specific cytokine production is not altered in ex vivo spleen and lymph node cells 
from paclitaxel treated mice 
C57BL/6 mice were immunised for EAE. Thirteen days p.i. spleen (left column) or dLN (right column) cells 
were cultured in the presence or absence of ConA (3 µg/ml) or MOG (27 µg/ml) for 48 or 72 hour 
respectively. Cytokine production in the supernatants was assessed using a cytokine bead assay (a,b) IFN-γ, 
(c,d) IL-17a, and (e,f) IL-6. Shown are means and SEM of values from individual mice from one (LN, n= 3-5 
mice/group; spleen immunised PTX d0-4, unimmunised untreated and unimmunised PTX d6-12, n=3-5/group) 
or two separate experiments (spleen, immunised PTX d6-12 and immunised untreated, n = 10/group). *p < 
0.05, **p < 0.01 or ***p < 0.001 compared to immunised paclitaxel mice (d6-12 p.i.), by one-way ANOVA 
with Newman-Keuls multiple comparison test. 
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4.3.6 Paclitaxel inhibits in vitro antigen-specific proliferation  
A previous study conducted in our laboratory had found in vivo proliferation of MOG 
specific T cells within the dLN was not inhibited by 5 daily doses of PTX in EAE 
immunised animals (Crume, 2007; Crume et al., 2009). It was postulated that: 1) the drug 
concentrations in the dLNs were not high enough to induce mitotic arrest or 2) high PgP 
expression on the T cells allowed the cells to pump out PTX and resist mitotic arrest 
(Crume, 2007). Either of these explanations are conceivably correct, particularly given that 
antigen-specific responses were completely inhibited in the spleen but not the dLN of 
immunised mice treated with PTX on d0-4 p.i. However, the alterations in cellularity 
observed in the current study and, in particular, the inhibition of CD4
+
 and Gr-1
+
 cell 
expansion, would suggest that PTX treatment did affect cellular processes occurring in the 
dLN. To better understand the specific effects of PTX on T cells in the lymph node or 
spleen, further experiments were conducted to confirm the anti-proliferative actions of 
PTX and its analogue DTX. 
 
It has previously been shown using an MTT assay, that PTX inhibits splenocyte 
proliferation at low nanomolar concentrations following polyclonal stimulation in vitro 
(Crume, 2007). To exclude the possibility that antigen-specific proliferation was less prone 
to the anti-proliferative actions of PTX, in vitro proliferation assays were conducted using 
splenocytes from 2D2 mice, which have transgenic T cell receptors specific for the MOG 
peptide (Bettelli et al., 2003). To specifically assess the effects of PTX on proliferation 
over the duration of the culture period, splenocytes were labelled with carboxyfluorescein 
diacetate succinimidyl ester (CFSE) at the start of culture (Wilmes et al., 2010a). CFSE 
readily enters the cell where it is converted to a non-permeable and fluorescent form; thus 
the cells are permanently labeled. Subsequent proliferation of CFSE-labelled cells leads to 
a reduction of fluorescence in the daughter cells, and this reduction can be quantified via 
flow cytometry (Parish et al., 2009). This method has two distinct advantages over the 
MTT assay: 1) the MTT assay uses metabolic activity as an indicator of proliferation since 
increased cell numbers results increase reduction of the MTT dye (Berridge et al., 1993); 
while, the CFSE-based assay measures proliferation directly and 2) by using flow 
cytometry, proliferation of specific cell populations can be identified with the CFSE assay.  
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In accordance with previous findings that used polyclonal simulation (Brown et al., 1985; 
Crume, 2007), the current study found that both PTX and DTX inhibited antigen-specific 
proliferation of splenocytes at low nanomolar concentrations (Figure 4.11a and b). 
Additionally, inhibition of proliferation was found to occur in all splenocytes as well as 
CD4
+
 T cells (Figure 4.11a and b). A similar anti-proliferative effect was also observed 
when splenocytes from immunised mice were isolated and stimulated in vitro in the 
presence of PTX or DTX (Figure 4.12). Both PTX and DTX had strong inhibitory effects 
on proliferation in response to either polyclonal or antigen-specific stimulation (Figure 
4.12c and d). Collectively these experiments confirm that within the context of 
autoimmune proliferation, MSDs can effectively inhibit proliferation at nanomolar 
concentrations in vitro.  
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Figure 4.11. In vitro paclitaxel inhibits antigen-specific proliferation  
Splenocytes from 2D2 mice were pulsed with CFSE and cultured in the presence of MOG (27µg/ml) and 
indicated concentration of (a) paclitaxel or (b) docetaxel. After 72 hours, cells were stained for cell surface 
markers and proliferation assessed by flow cytometry. The results are expressed as percent proliferation of all 
splenocytes or CD4
+
 splenocytes relative to proliferating untreated cells. Results represent means and SEM of 
two separate experiments conducted in duplicate. 
 
Chapter 4: Identifying microtubule-stabilising drugs mchanisms of action                      94 
 
0 5 10 15 20 25
0
1
2
3
4
5
a
Days
D
is
e
a
s
e
 s
c
o
re
Con A MOG
0
5
10
15
b
P
ro
lif
e
ra
ti
o
n
 I
n
d
e
x
0 20 40 60 80 100
0
25
50
75
100
125
PTX
DTX
c
drug concentration (nM)
P
ro
lif
e
ra
ti
o
n
 (
%
 c
o
n
tr
o
l)
0 20 40 60 80 100
0
25
50
75
100
125
PTX
DTX
d
drug concentration (nM)
P
ro
lif
e
ra
ti
o
n
 (
%
 c
o
n
tr
o
l)
Figure 4.12. In vitro paclitaxel and docetaxel inhibit proliferation in splenocytes isolated from 
EAE immunised mice 
C57BL/6 mice were immunised for EAE. Splenocytes were isolated 24 days p.i., pulsed with CFSE 
and cultured in the presence or absence of indicated concentration of paclitaxel or docetaxel and 
Con A (3 µg/ml) or MOG35-55 for 48 or 72 hours respectively. (a) disease score, (b) proliferation 
of Con A (3 µg/ml) or MOG (27 µg/ml) stimulated non-drug treated cells represented as 
proliferation index; expressed as CPM of stimulated wells/CPM of media alone. (c) Con A induced 
proliferation; expressed as percent of non-drug treated cells (d) MOG induced  proliferation; 
expressed as percent of non-drug treated cells. Proliferation was assessed by flow cytometry. 
Shown are means and SEM of individual mice (n = 5). 
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4.3.7 Paclitaxel inhibits in vivo antigen-specific proliferation 
To determine if PTX altered in vivo antigen-specific proliferation within the dLN of EAE 
immunised mice, within our experimental system, a similar experiment to that described 
by Crume et al. was conducted (Crume et al., 2007; Crume et al., 2009). However in 
contrast to Crume et al., the proliferation of antigen-specific T cells in the spleen and blood 
was also analysed to identify if there was a divergent effect of PTX on proliferation 
between these organs. Additionally, the experimental design was altered to more 
accurately distinguish the transferred antigen-specific T cells from the resident T cells 
within the recipient mice. Specifically, in the original study CFSE labelled 2D2 
lymphocytes were adoptively transferred to WT C57BL/6 recipient mice and proliferation 
of these transferred cells was measured by a reduction in CFSE fluorescence; however, 
CFSE was also used to distinguish the transferred T cells from those of the recipient mice 
(Crume, 2007). As proliferation causes a reduction in CFSE florescence, it was possible 
that multiple cycles of proliferation would have resulted in the transferred T cells 
becoming indistinguishable from the recipient T cells when identified by fluorescence 
alone. To avoid this possibility in the current study, the 2D2 cells (which express the 
CD45.2 isoform) were adoptively transferred into congenic C57BL/6 (B6.SJL-ptprca) mice, 
which express CD45.1 on a C57BL/6 background. This approach allowed the adoptively 
transferred cells to be independently identified by CD45.2 expression, removing the 
reliance on CFSE florescence as a way to differentiate transferred cells from recipient cells. 
 
In contrast to the previous studies findings, PTX treatment resulted in a significant 
reduction in the percentage of CD4
+
 2D2 cells within the dLN that proliferated following 
EAE immunisation (Figure 4.13b). Interestingly while the percent of 2D2 CD4
+
 
proliferation was reduced in iPTX treated mice, 2D2 proliferation was still significantly 
higher than in unimmunised mice, indicating that PTX attenuated but did not completely 
inhibit proliferation within the dLN. However, when looking at the representative plots of 
iUT compared to iPTX treated, it appears that fewer CD4
+
 2D2 cells are present in iPTX 
treated mice (Figure 4.13a). To quantify this difference, the total number of 2D2 CD4
+ 
proliferative events was assessed. When comparing total CD4
+
 2D2 proliferative events 
between iPTX treated and iUT, mice it is clear that PTX has a dramatic effect on antigen-
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specific proliferation within the dLN. No significant difference was observed between 
proliferative events in iPTX treated and uiPTX mice; whereas, iUT mice exhibited 
significantly more CD4
+
 2D2 proliferation than both iPTX and unimmunised groups 
(Figure 4.13c). Additionally, when the numbers of 2D2 CD4
+
 proliferative and non-
proliferative events were separated by their cycles of proliferation (i.e. generations of cell 
division), it can be seen that a substantial proportion of the total iUT events had undergone 
5-7 generations of cell division (Figure 4.13d). In contrast, only very small populations of 
iPTX treated mice had undergone such divisions (Figure 4.13d). Moreover, no difference 
in the numbers of non-proliferating CD4
+
 2D2 events was detected between iUT and iPTX 
treated mice (data not shown). Collectively, these findings indicate that PTX was 
inhibiting or inducing death in the proliferating population; whereas, the non-proliferating 
population remained viable.    
 
Analysis of the transferred CD4
+
 2D2 cells in the spleen or blood revealed that there was a 
high level of antigen-specific proliferation 5 days post immunisation. The anti-proliferative 
actions of PTX were even more pronounced in these tissues compared to the dLNs, as PTX 
treatment completely inhibited antigen-specific proliferation (Figure 4.14a-d). This 
inhibition of proliferation is evident when comparing the percent of transferred cells that 
are proliferating as well as the total proliferative events. The differences in the magnitude 
of the effect between the spleen or blood and the dLN may indicate that PTX does not 
reach as high a concentration in the dLNs as in the other tissues sampled. Taken together, 
these experiments indicate that PTX in fact inhibits antigen-specific T cell proliferation in 
vivo.  
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Figure 4.13 Paclitaxel attenuates in vivo antigen T cell proliferation within the lymph node  
Spleen and LN cells from 2D2 mice were stained with CFSE and transferred to congenic C57BL/6 recipient mice 
(B6.SJL-ptprca). One day following transfer, mice were immunised for EAE or left unimmunised and either drug 
treated (PTX 20mg/kg, d0-4p.i.) or left untreated. Five days p.i., cells from the dLN were isolated, stained for cell 
surface markers and analysed by flow cytometry. All samples were harvested, prepared and stained in an identical 
manner. The same number of events were collected for each sample and identical gating and analysis of each 
sample was conducted. (a) representative plots of lymphocytes isolated from immunised untreated and immunised 
paclitaxel treated mice (each plot represent a concatenation of data from 3 individual mice). (b) CD4
+
 proliferation; 
percent of transferred 2D2 CD4
+
 cells isolated from the dLNs that had undergone proliferation in vivo (see 
appendix 2 for the gating scheme). (c) CD4
+
 proliferation; total collected events of  2D2 CD4
+
 cells isolated per 
sample collected from the dLNs that had undergone proliferation in vivo. (d) CD4
+
 proliferation as events per cell 
division; represented as total collected events of  2D2 CD4
+
 cells per generation of proliferation (i.e. generation 0 = 
cell that has not undergone any proliferation, generation 7 = cells that have undergone 7 cell divisions). Discrete 
generations were defined using FloJo 7.6.1 cell proliferation analysis software. Shown are means and SEM of 
values from individual mice from two separate experiments (n= 7/immunised groups, n = 4/unimmunised groups). 
**p < 0.01 or ***p < 0.001 by one-way ANOVA with Newman-Keuls multiple comparison test. 
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Figure 4.14 Paclitaxel inhibits in vivo antigen T cell proliferation within the blood and spleen 
Spleen and LN cells from 2D2 mice were stained with CFSE and transferred to congenic C57BL/6 recipient 
mice (B6.SJL-ptprca). One day following transfer, mice were immunised for EAE or left unimmunised and 
either drug treated (PTX 20mg/kg, d0-4p.i.) or left untreated. Five days p.i. cells from the spleen and blood 
were isolated stained for cell surface markers and analysed by flow cytometry. All samples were harvested, 
prepared and stained in an identical manner. The same number of events were collected for each sample and 
identical gating and analysis of each sample was conducted. (a,c) CD4
+
 proliferation; percent of transferred 
2D2 CD4
+
 cells isolated from the (a) spleen or (c) blood that had undergone proliferation in vivo. (b,d) CD4
+
 
proliferation; total collected events of  2D2 CD4
+
 cells from individual samples isolated from the (b) spleen 
or (d) blood that had undergone proliferation in vivo. Shown are means and SEM of values from individual 
mice from two separate experiments (n = 7/immunised groups, n= 4/unimmunised groups). ***p < 0.001 by 
one-way ANOVA with Newman-Keuls multiple comparison test. 
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4.3.8 Paclitaxel inhibits in vivo immune cell migration  
The inhibition of antigen-specific proliferation by PTX is likely to explain why expansion 
of T cell populations and induction of antigen-specific responses were inhibited following 
iPTXd0-4 treatment. However, PTX also inhibited the increase in size of F4/80
+
 populations, 
and as these cells do not readily proliferate, PTX must be causing an alteration in the size 
of this population via another mechanism. A potential explanation for this is that 
trafficking of F4/80
+
 cells may have been altered. Additionally, despite similar antigen-
specific responses in splenocytes from iPTXd6-12, increases in CD4
+
 and CDllb
+ 
populations within the SC were only observed in iUT mice. Collectively these results 
suggest that PTX could be inhibiting the migration of immune cells to secondary lymphoid 
organs as well as from the periphery into the CNS.   
 
To explore the potential of PTX to inhibit immune cell migration in vivo without the 
confounding issue of proliferation that occurs following immunisation, the effect of PTX 
on chemokine-induced cell migration was investigated. To achieve this, the chemokine 
CCL5 (RANTES) was injected once into the left hind flanks of mice; whereas, an equal 
volume of PBS was injected into the right hind flank, and the migration of CFSE-labelled 
2D2 cells to the right or left dLN was assessed. CFSE-labelled 2D2 lymphocytes were 
injected i.p., and one day later mice were either injected i.p., with PTX (20 mg/kg/d) or an 
equal volume of PBS for five consecutive days. Following the final drug administration 
CCL5 (left hind flank) or PBS (right hind flank) was injected s.c., and 18 hours later, the 
dLNs were isolated and analysed by flow cytometry. Since CCL5 can attract a number of 
immune cells including T cells and macrophages (Schall et al., 1990), it was anticipated 
that cell numbers within the LN that drained the CCL5 injection site would increase. To 
control for potential variations in injection technique, some mice were injected with PBS 
in both the left and right hind flanks; no differences in cell numbers between LNs were 
observed in these mice (data not shown).   
 
As expected, a significant increase in CD4
+
 cell numbers was observed in LNs draining the 
CCL5 injection site in untreated mice (Figure 4.15a). In contrast, no increase was detected 
in PTX-treated mice, indicating that PTX treatment inhibited CCL5-mediated CD4
+
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migration into the dLN. Migration of F4/80
+
 cells was also inhibited by PTX treatment, as 
shown by the significant increase in F4/80
+
 cells within the LN draining the CCL5 
injection site in untreated but not PTX-treated mice (Figure 4.15b). Furthermore, when 
total cell numbers were analysed, PTX treatment was found to have a general effect on 
inhibiting migration (Figure 4.15c).  Collectively, these findings indicate that PTX inhibits 
chemokine-induced immune cell migration.  However, when the numbers of 2D2 CD4
+
 T 
cells were assessed, the difference between the LNs that drain the CCL5 or PBS injection 
sites in either PTX treated or untreated mice did not reach significance (Figure 4.16). This 
finding may be due to the combined effects of individual mouse variation and the 
relatively small numbers of 2D2 cells detected in the dLN. Alternatively, it is possible that 
2D2 CD4
+
 T cells express less CCL5 receptors (e.g. CCR5) than the WT recipient CD4
+
 T 
cells and therefore did not migrate as readily in response to the CCL5.  
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Figure 4.15 In vivo migration of T cells and macrophages is inhibited by paclitaxel  
Spleen and LN cells from 2D2 mice were stained with CFSE and transferred to C57BL/6 recipient mice. One day 
following transfer, mice were drug treated (PTX 20mg/kg/d for 5 consecutive days) or left untreated. Six days after 
cell transfer mice were injected with 100µl PBS in right hind flank and 1µg CCL5 in 100µL PBS into the left hind 
flank. 18 hours following hind flank injections, cells from the dLNs were isolated and counted. (a) CD4
+
 T cells, 
(b) F4/80
+
 cells, (c) total cells within individual dLN. Shown are means and SEM of values from individual mice 
from two separate experiments (n = 12-13 group). **p < 0.01 by one-way ANOVA with Newman-Keuls multiple 
comparison test. “Untreated” mice received injections of the equivalent concentration of vehicle that would be 
present in drug treated  mice. 
 
PBS CCL5  PBS CCL5
0
2000
4000
6000
8000
10000
PTX
Untreated
C
F
S
E
+
 C
D
4
+
 C
e
lls
Figure 4.16 In vivo migration of adoptively transferred antigen-specific cells is not significantly altered, 
following paclitaxel treatment   
Spleen and LN cells from 2D2 mice were stained with CFSE and transferred to C57BL/6 recipient mice. One 
day following transfer, mice were drug treated (PTX 20mg/kg/d for 5 consecutive days) or left untreated. Six 
days after cell transfer mice were injected with 100µl PBS in right hind flank and 100µl PBS or 1µg CCL5 in 
100µL PBS into the left hind flank. 18 hours following hind flank injections cells from the dLNs were isolated 
and counted. Shown are means and SEM of values from individual mice from two separate experiments (n = 12-
13 group). No significant difference between groups by one-way ANOVA with Newman-Keuls multiple 
comparisons test. “Untreated” mice received injections of the equivalent concentration of vehicle that would be 
present in drug treated  mice. 
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4.4 Discussion 
The experiments conducted in this chapter were focused on assessing potential changes in 
immune response immediately following PTX treatment and determining what effect drug 
treatment had on cellular proliferation and migration.  In contrast to the previous chapter’s 
findings, that PTX and other MSDs had little effect on long-term immune responses, the 
current chapter demonstrates that immediately after PTX administration, inflammatory 
disease responses are significantly altered. These drug induced changes appear to be 
associated with inhibition of immune cell proliferation and migration.   
  
Trafficking of immune cells into and out of lymphoid organs, as well as migration from the 
periphery into the CNS, are crucial processes for the development of EAE. In the present 
study it was clearly demonstrated that PTX treatment inhibited both macrophage and T cell 
migration. The impact of inhibited migration within the context of EAE is substantial. 
Immune cell migration into the dLN is important in initial induction of an encephalogenic 
response. It is also vital for the immune cell infiltration into the CNS and subsequent 
development of disease symptoms (Ajami et al., 2011; Carlson et al., 2008). Inhibition of 
immune cell migration from the periphery into the CNS is consistent with the finding that 
following iPTX6-12 treatment, no increases in CD4
+
 and CD11b
+
 cell populations were 
observed in the SC despite peripheral antigen-specific responses being similar to that of 
iUT mice. 
 
There are many ways by which PTX could inhibit cell migration. Leukocyte migration 
involves a  number of complex processes and microtubules have multiple roles in these 
events (Friedl et al., 2008; Sanchez-Madrid et al., 1999; Watanabe et al., 2005). While it is 
possible that PTX was inhibiting expression of adhesion molecules necessary for the 
migration of T cells and macrophages, this explanation is unlikely given that it has 
previously been shown that even high concentrations of PTX (10 µM) have no effect on 
monocyte adhesion to endothelial cells (Mamdouh et al., 2008). However, in vitro PTX 
has been found to directly inhibit cellular chemotaxis (Roberts et al., 1982). PTX can also 
hinder myeloid cell shape remodelling which is required for tissue infiltration 
(Lautenschlager et al., 2009). Additionally, both transcellular and paracellular leukocyte 
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migration can be inhibited by PTX acting on endothelial cells (Mamdouh et al., 2008; 
Mamdouh et al., 2009). This research indicates that PTX can have a direct effect on the 
mechanics of leukocyte migration as well as processes involved in cellular extravasation. It 
is likely that the effects of in vivo PTX treatment on migration, observed in the current 
study, are caused by similar mechanisms.  
 
In addition to altering migration, it was demonstrated that PTX could completely inhibit 
antigen-specific proliferation within the blood and the spleen of immunised mice. 
Additionally, PTX was found to limit antigen-specific T cell proliferation within the LNs 
that drain the EAE immunisation sites. It is therefore likely that the alterations CD4
+
 and 
GR-1
+
 cell populations following PTX treatment are due to inhibition of proliferation. It is 
interesting that some proliferation occurred within the LN but not spleen or blood of iPTX 
mice. An explanation for this could be that PTX might reach much higher concentrations 
within the blood and spleen compared to that of the dLNs. It is possible that the 
concentrations required to inhibit T cell proliferation within the dLNs were not reached 
until multiple injections of PTX had been given or that the once-daily-dosing leads to 
peaks and troughs of PTX concentrations within the LN. It has been shown that within 18 
hours of i.p. injection, PTX levels within the plasma drop to less than 10% of peak plasma 
levels (Tsai et al., 2007). While studies have not been conducted into the levels reached 
within the inguinal LNs, data from other organs, such as spleen and liver, indicate similar 
reduction in PTX concentrations over time (Soma et al., 2009). Peak drug concentrations 
within the dLN would be lower than those within the blood and spleen; therefore the 
concentration of PTX within the dLN between daily doses is likely to be lower. This could 
provide a window of opportunity during which T cells within the dLN could proliferate. 
Any proliferation that was occurring during a drug concentration trough would be 
unaffected by PTX; while, any proliferation occurring during or near a peak in drug 
concentration would be inhibited. At the concentration of CFSE used to stain the 2D2 cells, 
multiple cycles of proliferation can be detected before CFSE fluorescence is reduced to 
background levels (Parish et al., 2009; Quah et al., 2007). It can be seen from both the 
representative plots and the number events within each generation of proliferation (Figure 
4.13, a and d) that while far fewer proliferative events occurred in PTX treated mice, cells 
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that did proliferate did so multiple times, supporting the concept that there may have been 
multiple windows of opportunity for 2D2 cells to proliferate. To verify this, the in vivo 
proliferation assay could be repeated, with PTX administered every other day. If the 
proliferation was due to drug concentration troughs, it would be expected that more 
proliferation would occur in dLN cells due to the extended period between drug treatments.    
 
The complete inhibition of proliferation in antigen-specific T cells within the spleen but 
only partial reduction within the dLN is consistent with the results observed when spleen 
or dLN cells were isolated from iPTXd0-4 treated mice 5 days p.i.. In splenocytes from 
these mice antigen- specific proliferation and production of IFN-γ and IL-17 did not occur 
following in vitro stimulation. In contrast lymphocytes from the same mice exhibited 
antigen-specific proliferation and production of IFN-γ and IL-17, albeit at reduced levels, 
relative to iUT mice. This difference in responses between spleen and dLN is likely to be 
associated with the difference in anti-proliferative activity of PTX within the spleen and 
dLN. If so, it is conceivable that if PTX treatment had inhibited the encephalogenic 
responses in the dLNs to the level that occurred within the spleens, development of EAE 
could have been halted or further delayed.  
 
While iPTXd0-4 treatment resulted in inhibition of the expansion of CD4
+
 and Gr-1
+
 
populations, the F4/80
+
 macrophage population was also significantly smaller than that 
from iUT mice. As both Gr-1
+
 and CD4
+
 populations proliferate rapidly after EAE 
immunisation (Carlson et al., 2008; Targoni et al., 2001), it is likely that the inhibition in 
expansion of these populations is due to inhibition of proliferation. In contrast, 
macrophages do not generally proliferate (Jenkins et al., 2011). Thus, the inhibition of 
expansion of the F4/80
+
 population in iPTX treated mice must occur though some other 
mechanism. It is unlikely that PTX treatment reduced macrophage survival, as 
macrophages are viable in much higher in vitro concentrations than would be experienced 
in vivo (Crume et al., 2007). Therefore, the inhibition in expansion of macrophage 
populations is likely to be caused by an inhibition in the migration of these cells into the 
secondary lymphoid organs rather than alteration in proliferation of cell viability.  
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By d13 p.i. both Gr-1
+
 and F4/80
+
 populations in the spleen of iPTXd0-4 treated mice had 
recovered, indicating that the effect of PTX on cell proliferation and migration respectively, 
only occurs during or shortly after drug treatment. Additionally peripheral encephalogenic 
responses were rapidly re-established, since antigen-specific proliferation and cytokine 
production were similar in iPTXd0-4 and iUT by d13 p.i. However, despite these similar 
cellular and cytokine profiles at d13p.i., increases in CD11b
+
 myeloid cells or CD4
+
 T cell 
in the SC was only observed in iUT and not in iPTXd0-4 treated mice. This suggests that 
while peripheral encephalogenic immune responses develop rapidly following cessation of 
drug treatment, by d13 p.i. these are not yet sufficient to induce CNS infiltration 
 
The initial induction of peripheral inflammatory responses occurs within the first week 
following immunisation and by d6 p.i. clonal expansion of MOG reactive T cells is already 
well established (Crume et al., 2009; Hofstetter et al., 2010; Targoni et al., 2001). 
Therefore, in contrast to the iPTXd0-4 treatment regimen, alterations in disease expression 
following iPTXd6-12 treatment are unlikely to be due to the inhibition of T cell proliferation. 
This conclusion is supported by the data that indicate very little difference in antigen-
specific responses 13 days p.i. in spleen and dLN cells from iUT and iPTXd6-12 mice 
(Figure 4.7-10). Adding further support to this concept, no difference in CD4
+
 T cell 
number was detected between these groups.  
 
Of the cell populations analysed within the spleen, only Gr-1
+
 cells were significantly 
reduced in iPTXd6-12 treated mice when compared to iUT mice. Antibody depletion of 
neutrophil/polymorphonuclear leukocytes (PML) has been shown to delay EAE onset 
without altering peripheral antigen-specific responses (Carlson et al., 2008; McColl et al., 
1998). This is a possible factor that could contribute to the delay in disease onset in 
iPTXd6-12 mice; however it is unlikely to be the sole cause of disease modification since 
Gr-1
+
 populations were not fully depleted from these mice. Additionally disease expression 
following antibody depletion of PMLs occurs within a few days following cessation of 
antibody administration and follows a similar course to that of untreated immunised mice 
(Carlson et al., 2008; McColl et al., 1998). In the current study disease expression after 
Chapter 4: Identifying microtubule-stabilising drugs mchanisms of action                      106 
 
drug treatment was typically delayed for a number of days and often resulted in a milder 
disease score.  
 
Except for the reduction in Gr-1
+
 cell number in the spleens of iPTXd6-12 mice, similar 
cellular and cytokine responses were detected when thes mice were compared to iUT mice. 
Despite this, disease symptoms were only observed in iUT mice, and no infiltration of 
CD4
+
 or CD11b
+
 cells was evident in the SC of iPTXd6-12 mice. This finding indicates that 
within drug treated mice the encephalogenic cells present in the periphery are not 
trafficking into the CNS. As migration into the CNS requires similar processes and 
responses to chemotatic signals to those simulated in the in vivo migration assay, the 
findings that PTX inhibits both T cell and macrophage migration supports the concept that 
PTX could inhibit migration from the periphery into the CNS. 
 
Collectively, the findings from these experiments indicate that PTX alters immune 
responses to EAE immunisation when given either on d0-4 or d6-12 p.i. It is likely that 
PTX has a number of effects on the immune system and its therapeutic actions may differ 
depending on the timing of administration. While PTX administered on either d0-4 or d6-
12 p.i. results in similar delays in disease onset, the results from the current experiments 
suggest that a different combination of mechanisms may lead to the alterations in disease 
expression. Early drug treatment temporarily inhibits expansion of CD4
+
, F4/80
+
 and Gr-1
+
 
cell populations. Because CD4
+
 and Gr-1
+
 populations rapidly expand following EAE 
immunisation, the anti-proliferative effects of PTX would be the main contributing factor 
in inhibiting expansion of these populations, while an inhibition of macrophage migration 
is a conceivable explanation for inhibition in the expansion of F4/80
+
 populations. As was 
demonstrated, expansion of CD4
+
 and F4/80
+
 populations in the spleen and dLN occurs 
within the first week following immunisation. Therefore it is not surprising the iPTXd6-12  
treatment had little effect on the size of these populations. In contrast, neutrophils, which 
constitute the majority of the Gr-1
+
 cells and have a rapid population turnover, are likely to 
be affected by iPTXd6-12 treatment. The reduction in the size of the Gr-1
+
 population may 
be indicative of the antimitotic effect of PTXs on the proliferative processes needed to 
replenish this population. Therefore, while the antiproliferative actions of PTX are likely to 
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contribute to alterations in disease expression when administered either on d0-4 or days 6-
12 p.i. the relative contributions to the overall disease modifying effect may be more 
significant in early treatment; while PTX treatment at the later time point may be more 
dependent on inhibition of immune cell migration. 
 
4.5 Summary  
PTX administration alters encephalogenic immune responses during drug treatment. 
Administration of PTX immediately following EAE immunisation results in inhibition of 
antigen-specific responses within the spleen and attenuation within the dLN. PTX 
administered after induction of initial inflammatory events does not alter antigen-specific 
responses within either the spleen of dLN but inhibits immune cell infiltration into the 
CNS. Additionally five consecutive doses of PTX were demonstrated to inhibit in vivo 
antigen-specific proliferation and immune cell migration.     
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5.1 Introduction 
For MSDs to be effective in treating EAE and ultimately MS, high drug concentrations and 
prolonged drug exposure are necessary. Additionally, it appears that while adequate drug 
concentrations are reached within the spleen after i.p. administration, the concentrations 
within the dLN may be suboptimal. Because the maximal tolerated doses of MSDs were 
used for the previous experiments (see chapter 3), increasing the dose administered to 
animals is unlikely to improve efficacy without compromising the animal’s health. 
Therefore, in an attempt to further enhance the treatment efficacy of MSDs, two 
approaches based on combination treatments were explored: 1) the use of two MSDs 
simultaneously and 2) the use of an MSD in combination with an already approved MS 
treatment.  
 
These approaches are particularly beneficial if there are synergistic therapeutic effects, in 
which the efficacy of two compounds used in combination is greater than would be 
observed for either compound alone. The potential advantages of synergy include 
increased therapeutic efficacy, reduced off target side effects and lower concentrations of 
drug required for therapeutic effects. There is already a great deal of interest in exploring 
the synergistic potential of current MS therapies (Conway et al., 2008; Gold, 2008). 
However, it is also important to consider that the use of two therapeutic compounds could 
potentially result in undesirable additive or synergistic adverse effects.  
 
It has been demonstrated that combinations of different MSDs can act synergistically in 
inhibiting cell proliferation in vitro and within tumour bearing mice (Clark et al., 2006; 
Huang et al., 2006; Wilmes et al., 2007). Within in vitro tubulin polymerisation assays, 
synergy is often observed when two MSDs that bind to separate tubulin binding sites are 
combined (Hamel et al., 2006). PTX, DTX and IXB all cause microtubule stabilisation by 
binding to the taxoid binding site on β-tubulin. In contrast peloruside A (Pel A) and 
laulimalide (Laul) bind to a distinct site, which does not overlap with the taxoid site 
(Gaitanos et al., 2004; Pryor et al., 2002). By identifying combinations of MSDs that 
synergize strongly, it may be possible to improve the efficacy of MSDs in the treatment of 
EAE and reduce any adverse effects.  
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Because MS is a chronic disease that requires continuous treatment, it is important to 
consider how new MS therapies interact with the current MS drugs, such as glatiramer 
acetate and whether MSDs have the potential to enhance or complement the effects of 
these drugs. Glatiramer acetate (GA) is a well tolerated therapy already used for RRMS 
and helps to reduce relapse rate and slow the progression of disability. However it is only 
partially effective and the beneficial actions of GA can take up to 6 months to manifest 
(Boster et al., 2011a; Wolinsky, 2004). Pre-treating with an MSD before commencing GA 
treatment could potentially accelerate and/or enhance the efficacy of GA while extending 
the beneficial effects of MSD treatment.  
   
   
5.2 Aims and Objectives  
The current chapter investigates the potential of different MSDs to synergistically inhibit 
in vitro proliferation and to synergistically reduce EAE disease development in vivo. 
Additionally, the potential of PTX to enhance or complement the effects of GA in treating 
EAE was explored. 
 
5.2.1 Specific Aims:  
1. To identify if combinations of two MSDs act synergistically in vitro  
2. To determine if combinations of MSDs can act synergistically in the treatment of 
EAE  
3. To explore a combination treatment of PTX and GA for the treatment of EAE  
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5.3 Results 
5.3.1 Identifying the synergic potential of MSDs to inhibit in vitro proliferation   
To quantify the anti-proliferative capacity of IXB, DTX, Laul and Pel A, splenocytes were 
cultured in vitro for 48 hours with Con A at various drug concentrations. Inhibition of 
CD4
+
 T cell and total splenocyte proliferation was measured using a CFSE dilution assay. 
All MSDs tested gave similar dose response profiles for both CD4
+
 T cells and total 
splenocyte cultures (Figure 5.1). Using the dose response curves from individual 
experiments, the concentrations required to inhibit 50% of proliferation (IC50) was 
calculated (Table 5.1). It was found that of the four drugs tested Laul and DTX were the 
most potent with IC50s of around 10 nM; while Pel A was least potent with an IC50 of 
around 80 nM (Table 5.1). 
 
 
 
Compound       IC50 ± SEM (nM) 
    All Cells  CD4
+
 n 
Peloruside A 86 ± 7 75 ± 6 12 
Laulimalide 9 ± 1 11 ± 1 8 
Docetaxel 12 ± 2 10 ± 1 4 
Ixabepilone  24 ± 3 30 ± 2 8 
 
 
 
 
 
 
 
To investigate if combinations of these MSDs could act synergistically to inhibit 
proliferation, selected drug concentrations were combined and compared to the effects of 
the drugs when used individually. The inhibitory potential of combined drug 
concentrations was calculated using a combination index (CI). A CI value equal to one 
indicates additive effects of two drugs, a value greater than one indicates a antagonistic 
relationship and a value less than one indicates a synergistic relationship. (Berenbaum, 
1985; Chou et al., 1984).  
 
Table 5.1. IC50 values of individual MSD compounds 
Spleen cells from C57BL/6 mice were pulsed with CFSE and cultured in the presence of Con A 
(3µg/ml) and indicated concentrations of drug. After 48 hour incubation, cells were stained for cell 
surface markers and proliferation assessed by flow cytometry. The results are expressed as mean IC50 of 
CD4
+
 splenocytes or all splenocytes.   
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As expected, combinations of Pel A and Laul, which bind the same site on microtubules, 
did not result in a synergistic inhibition of CD4
+
 T cell proliferation, (Table 5.2) although 
within total splenocytes synergy was detected at two different drug concentration 
combinations of Pel A and Laul. Notably, the greatest synergy appears at the lowest 
concentrations of the 2 MSDs. Combinations of Laul and DTX did not result in substantial 
synergy, with only one concentration acting synergistically on CD4
+
 T cells but not total 
splenocyte populations, while no combinations of Pel A and DTX exhibited any significant 
synergistic activity. In contrast, Pel A and IXB showed substantial synergy at a range of 
concentrations in both CD4
+
 T cells and in total splenocyte populations (Table 5.2).  These 
studies indicate significant synergy between Pel A and IXB, but not between the other 
MSD combinations tested. 
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Figure 5.1. Determining the anti-proliferative activity of MSD in splenocytes  
Spleen cells from C57BL/6 mice were pulsed with CFSE and cultured in the presence of Con A 
(3µg/ml) and indicated concentrations of drug. Representative plots of (a,b) ixabepilone, (c,d) 
docetaxel, (e,f) laulimalide and (g,h) peloruside A. After 48 hour incubation, cells were stained for cell 
surface markers and proliferation assessed by flow cytometry. The results are expressed as percent 
proliferation of CD4
+ 
splenocytes or all splenocytes relative to total CD4
+
 or total splenocytes 
respectively. All experiments were conducted in duplicate and at least 4 replicates were conducted per 
drug.  
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  Table 5.2. CI values for peloruside A and laulimalide drug combinations
1
 
 
 
 
 
 
 
 
 
 
 
   Table 5.3. CI values for peloruside A and docetaxel drug combinations 
 
 
 
 
 
 
 
 
 
  Table 5.4. CI values for peloruside A and ixabepilone drug combinations 
 
 
 
 
 
 
 
 
 
 Table 5.5. CI values for laulimalide and ixabepilone drug combinations  
 
 
 
 
 
 
 
 
 
                                                 
1
 p-values determined by one sample student’s t-test 
Drug combination (nM) All cells CD4+ T cells 
Peloruside  Laulimalide CI ± SEM n p-value CI ± SEM n p-value 
50 6.25  0.97 ± 0.05 4 n.s. 1.08 ± 0.14 4 n.s. 
50  3.125  0.81 ± 0.06 4 0.041 0.96 ± 0.12 4 n.s. 
25  6.25  1.20 ± 0.08 4 n.s. 1.29 ± 0.21 4 n.s. 
25  3.125  0.93 ± 0.06 4 n.s. 0.98 ± 0.08 4 n.s. 
12.5  6.25  1.38 ± 0.20 4 n.s. 1.30 ± 0.27 4 n.s. 
12.5 3.125  0.77 ± 0.09 4 n.s. 0.79 ± 0.09 4 n.s. 
6.25  6.25  1.57 ± 0.27 4 n.s. 1.31 ± 0.27 4 n.s. 
6.25  3.125  0.74 ± 0.03 4 0.016    
Drug combination (nM) All cells CD4+ T cells 
Peloruside  Docetaxel CI ± SEM n p-value CI ± SEM n p-value 
50  12.5 0.94 ± 0.09 4 n.s. 0.88 ± 0.14 4 n.s. 
50  6.25  1.17  ± 0.20 4 n.s. 1.03  ± 0.07 4 n.s. 
25  12.5  0.97 ± 0.15 4 n.s. 1.01 ± 0.19 4 n.s. 
25  6.25  1.14 ± 0.14 4 n.s. 1.21 ± 0.11 4 n.s. 
12.5 12.5  1.16 ± 0.13 4 n.s. 1.19 ± 0.28 4 n.s. 
12.5 6.25  1.25 ± 0.18 4 n.s. 1.26 ± 0.07 4 n.s. 
6.25  12.5 1.30 ± 0.10 4 n.s. 1.25 ± 0.25 4 n.s. 
Drug combination (nM) All cells CD4+ T cells 
Peloruside  Ixabepilone CI ± SEM n p-value CI ± SEM n p-value 
50  12.5  0.84 ± 0.04 4 0.028 0.67 ± 0.08 4 0.029 
50 6.25  0.81 ± 0.09 3 n.s. 0.72 ± 0.05 3 0.036 
25 12.5  0.81 ± 0.05 4 0.038 0.76 ± 0.05 4 0.018 
25  6.25 0.67 ± 0.01 3 0.001 0.74 ± 0.06 3 0.045 
12.5  12.5  0.72 ± 0.07 4 0.030 0.74 ± 0.06 4 0.019 
6.25  12.5 0.78 ± 0.10 4 n.s. 0.98 ± 0.12 4 n.s. 
Drug combination (nM) All cells CD4+ T cells 
Laulimalide Ixabepilone CI ± SEM n p-value CI ± SEM n p-value 
12.5  12.5  1.21 ± 0.27 4 n.s. 1.14 ± 0.12 4 n.s. 
12.5  6.25  1.08 ± 0.11 3 n.s. 0.97 ± 0.12 4 n.s. 
6.25  12.5  0.94 ± 0.11 4 n.s. 0.97 ± 0.12 4 n.s. 
6.25  6.25  1.12 ± 0.15 4 n.s. 1.03 ± 0.15 4 n.s. 
3.125 25 0.81 ± 0.13 4 n.s. 0.82 ± 0.05 4 0.038 
3.125  12.5  0.81 ± 0.08 4 n.s. 0.82 ± 0.07 4 n.s. 
1.263  12.5  1.03 ± 0.15 4 n.s. 0.80 ± 0.05 4 0.036 
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5.3.2 Peloruside A and ixabepilone act synergistically to inhibit EAE  
As robust synergy was observed between Pel A and IXB in splenocyte cultures, the effect 
of combining these MSDs in the treatment of EAE was explored. Like with the in vitro 
experiments, it was first necessary to determine effective concentrations of these drugs in 
the EAE model. Administration of MSDs using a d6-12 p.i. QOD dosing schedule was 
chosen as this treatment regime was proven to be both well tolerated and effective. To 
determine effective therapeutic concentrations of each of these drugs, mice were 
immunised and treated on days 6-12 QOD with 10, 5, 2, or 1 mg/kg/dose of IXB (Figure 
5.2a) or Pel A (Figure 5.2b). These experiments revealed that all of the drugs lost ~50% of 
their protective effect at the 5 mg/kg dose and were ineffective at 2 mg/kg or 1mg/kg doses. 
 
The in vitro experiments demonstrated that synergistic effects were most pronounced at 
concentrations in which a higher or equal ratio of Pel A to IXB was present. Because 
worldwide stocks of Pel A are very limited, an equal ratio combination of the two drugs 
was chosen to minimise the amount of Pel A used for the in vivo experiments. As 
individual administration of Pel A and IXB were similarly effective at 10 mg/kg, it was 
expected that if the two drugs had an additive effect, the co-administration of 5 mg/kg of 
Pel A and 5 mg/kg of IXB would lead to a similar disease modification as observed when 
either drug was used separately at 10 mg/kg. If, however, Pel A and IXB acted 
synergistically, increased disease protection would be observed compared to mice treated 
with 10 mg/kg of either IXB or Pel A alone. However, when tested, the combination of 5 
mg/kg Pel A and IXB proved to be extremely toxic with all mice dying between d13-d15 
p.i. (Data not shown). 
 
When a lower concentration of 2 mg/kg of Pel A and IXB was used, less toxicity was 
observed with 40% of the mice dying between (d15-19) (Data not shown). However, in 
the mice that survived, only 30% developed any disease symptoms and these symptoms 
were considerably delayed in onset relative to all other groups (Figure 5.3). Despite the 
toxicity, no additional weight loss occurred in mice receiving the combined 2 mg/kg 
treatment, relative to that observed in untreated or individual drug treatment groups 
(Figure 5.4). Additionally, the overall disease burden of mice in the combined 2 mg/kg 
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treatment was significantly reduced when compared to 10 mg/kg individual Pel A or IXB 
treatment groups, indicating that Pel A and IXB act synergistically in vivo (Figure 5.5). 
Synergistic interactions were not observed at the lower dose combinations of 0.5 or 1 
mg/kg IXB and Pel A suggesting that there is a narrow window in which these drugs 
synergize without inducing adverse effects (Figure 5.3).  
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Figure 5.2. Determining the dose response effects of peloruside A and ixabepilone in vivo  
 C57BL/6 mice were immunised for EAE and left untreated or were treated with indicated 
treatments on days 6-12 p.i. QOD.  Data represents (a) one experiment (n = 5/group) or (b) two 
experiments (n = 5-10 mice/group).  
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Figure 5.3 Peloruside and ixabepilone act synergistically to inhibit EAE 
C57BL/6 mice were immunised for EAE and left untreated or were treated with indicated treatments 
on days 6-12 p.i. QOD. Figures (a,b) represent disease score of all mice from the same experiments.  
Data represents two experiments (n = 5-10 mice/group). Any mice that died were excluded from the 
analysis. “Untreated” mice received injections of the equivalent concentrations of vehicles that would 
be present at the highest combined drug concentrations.   
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Figure 5.4. Weight change following in vivo administration of peloruside and ixabepilone 
 C57BL/6 mice were immunised for EAE and left untreated or were treated with indicated treatments 
on days 6-12 p.i. QOD. Figure represents percent weight change; calculated as percent change of 
individual mice from weights at d0 p.i.  Data represents two experiments (n = 5-10 mice/group). Any 
mice that died were excluded from the analysis. “Untreated” mice received injections of the 
equivalent concentrations of vehicles that would be present at the highest combined drug 
concentrations.   
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Figure 5.5  Peloruside and ixabepilone act synergistically to reduce EAE disease burden 
C57BL/6 mice were immunised for EAE and left untreated or were treated with indicated treatments 
on days 6-12 p.i. QOD. Disease burden; represented as percent area under the curve (% AUC) 
relative to untreated mice. Data represents two experiments (n = 5-10 mice/group). **p < 0.01 or 
***p < 0.001compared to untreated mice, ## p <0.01 compaired to IXB (10 mg/kg) or Pel A (10 
mg/kg) by one-way ANOVA with Newman-Keuls multiple comparison test. Any mice that died were 
excluded from the analysis. “Untreated” mice received injections of the equivalent concentrations of 
vehicles that would be present at the highest combined drug concentrations.   
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5.3.3 Paclitaxel pre-treatment improves the efficacy of glatiramer acetate in the 
treatment of established EAE. 
The current study has demonstrated that MSDs are effective at delaying the onset of EAE, 
but these drugs only provide a modest long-term reduction in disease severity. This 
transient modification of immune response induced by MSD treatment may be beneficial if 
used prior to an immuno-modulatory therapy. To explore this possibility, a combination 
treatment of PTX followed by a short term GA treatment was used. High daily doses (2 
mg/d) of GA for 7 days before EAE immunisation can prevent disease development or, if 
given for 7 days following disease onset, can effectively reduce disease severity (Aharoni 
et al., 2010). In order to achieve a suboptimal GA treatment, a dose of 150 µg/d GA was 
used, as it had previously been shown to be ineffective in an EAE model similar to that 
used in the current study (Toker, 2009). In accordance with the previous study, 
administration of 150 µg/d for 7 days either before (d-6-0) EAE immunisation or following 
disease onset (d13-19) had no effect on disease expression (Figure 5.7a). Also, as 
expected, mice treated with PTX exhibited delayed disease onset and a reduction in disease 
burden (Figure 5.7 and 5.8). However, when PTX was administered (20 mg/kg d6-12 p.i. 
QOD) before GA treatment, a reduction in disease severity and overall disease burden was 
observed (Figure 5.7b and 5.8). This finding indicates that treating mice with PTX before 
GA treatment has the potential to enhance suboptimal GA responses and thus improve 
disease suppression. 
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Figure 5.6. Paclitaxel enhances the disease modifying effects of glatiramer acetate  
C57BL/6 mice were immunised for EAE and left untreated (U/T) or treated with (a) glatiramer 
acetate (GA: 150µg) on either d-6-d0 p.i. or d13-19 p.i. (b) or were treated with paclitaxel (PTX; 
20mg/kg) on days 6-12 QOD, or glatiramer acetate (GA; 150 µg) on days 13-19 or a combination of 
paclitaxel and glatiramer acetate. Data represents mean and SEM of disease scores from all mice of 
(a) one experiment (n = 5 mice/group) or (b) two experiments (n = 8-9 mice/group). 
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Figure 5.7 Paclitaxel and glatiramer acetate synergistically reduce disease burden  
C57BL/6 mice were immunised for EAE and left untreated or were treated with paclitaxel (PTX; 20mg/kg) 
on days 6-12 QOD, or glatiramer acetate (GA; 150 µg) on days 13-19 or a combination of paclitaxel and 
glatiramer acetate. Disease burden; represented as percent area under the curve (% AUC) relative to 
untreated mice. Data represents two experiments (n = 8-9 mice/group).*p < 0.05 or ***p < 0.001 compared 
to untreated mice, # p <0.05 compared to PTX by one-way ANOVA with Newman-Keuls multiple 
comparison test. 
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5.4 Discussion 
To further enhance the treatment efficacy of MSDs the potential for synergy between 
different compounds was investigated. These experiments demonstrated that combinations 
of Pel A and IXB exhibited substantial synergistic effects both in vitro and in vivo. 
Additionally, it was found that treating mice with PTX, prior to GA therapy, augmented 
disease suppression. Together these experiments demonstrate that although effective alone, 
MSD have greater potential when used as combination therapies. 
  
Studies using purified tubulin demonstrate synergy occurs between MSDs that have 
different binding sites on tubulin, but not in MSDs that share the same binding site (Gapud 
et al., 2004; Hamel et al., 2006). However, the actions of MSDs on purified tubulin do not 
necessarily translate into cellular effects. This has been noted in previous cell and animal 
based studies, where synergistic activity can occur between MSDs that share the same 
binding site or conversely no synergy occurs between two MSDs that have different 
binding sites (Huang et al., 2006; Martello et al., 2000; Wilmes et al., 2010a). This effect 
was also observed in the current study as Pel A and DTX, which have different binding 
sites, were not synergistic. Likewise previous research in ovarian carcinoma cells found 
that Pel A can interact synergistically with PTX and epotholine A but not DTX, despite all 
three compounds sharing the same tubulin binding site (the taxoid site) (Wilmes et al., 
2007; Wilmes et al., 2010a). Additionally, IXB, which also binds at the taxoid site, was 
found in the current study to be synergistic with Pel A in vitro. These results suggest that 
that synergy between MSDs is not solely due to tubulin binding interactions. A number of 
other factors may alter the effect of MSDs when administered in combination, such as 
alterations to microtubule-associated proteins, tubulin conformational effects or activity on 
secondary protein targets (Khrapunovich-Baine et al., 2011; Wilmes et al., 2010b). This 
work highlights the need for in vivo studies to identify clinically relevant synergetic 
interactions.  
 
As Pel A and IXB exhibited synergy at multiple concentrations in vitro, a combination of 
these two MSDs was used to explore potential synergy in the treatment of EAE. The 
combined administration of 2 mg/kg Pel A and IXB resulted in significant inhibition of 
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disease and a reduction in disease burden. This effect was far more pronounced than either 
of the individual 10 mg/kg Pel A or IXB treatments despite less than half of the total drug 
concentration being used in the combination treatment. These results demonstrate that the 
combination of Pel A and IXB leads to substantial synergy in vivo.  
 
At the higher concentration of 5 mg/kg IXB/PelA severe toxicity occurred. It is likely that 
this toxicity was due to the synergistic effects of the drugs at this concentration. Due to the 
limited availability of Pel A no unimmunised mice were treated with this drug combination. 
Therefore it is unknown if the toxicity was a result of interactions with the EAE disease 
process or simply due to exceeding the maximal tolerated dose. As some toxicity was also 
observed in mice administered the 2 mg/kg combination treatment, a further reduction in 
dosing may be desirable. However, when combination of Pel A and IXB were 
administered at 1 mg/kg or 0.5 mg/kg no disease modification occurred. This highlights the 
small therapeutic window between efficacy and toxicity of IXB and Pel A when used in 
combination. Whether or not a concentration lower than 2 mg/kg but higher than 1 mg/kg, 
would provide similar disease modifying effects without causing toxicity remains to be 
determined.  
 
The mechanisms with which the 2 mg/kg combination treatment enhanced the inhibition of 
EAE were not explored. However, it is conceivable that the combined treatment had 
increased anti-mitotic activity in the dLN and that MOG reactive T cell proliferation was 
completely inhibited. Likewise the combination treatment may have inhibited cell 
migration for a longer period of time. A combination of DTX and Laul has been 
demonstrated to inhibit in vitro endothelial cell migration synergistically and at 
concentrations much lower than needed to inhibit proliferation (Lu et al., 2006). If 
synergistic inhibition of immune cell migration was occurring, this could have contributed 
to the extended delay in disease onset that was observed in mice from the combined 
treatment group.  
 
This is the first study to document synergism between Pel A and IXB in vivo. These 
findings suggest that combinations of MSDs may provide improved efficacy in inhibiting 
Chapter 5: Identifying the synergistic potential of microtubule-stabilising drugs             124 
inflammatory disease. Further studies into the effective doses that can be used without 
inducing toxicity are however needed. The findings from these experiments may also be 
relevant to researchers interested in cancer chemotherapies. If the synergistic interactions 
of these two drugs cause enhanced inhibition of migration or proliferation, it likely a 
similar treatment would be beneficial in inhibiting tumour growth and metastases.    
  
The other combination treatment that was explored in this chapter was the use of PTX with 
GA. The combined effect of GA and PTX resulted in a reduction in disease severity greater 
than that observed in mice treated with either GA or PTX alone. Additionally, while GA 
was only administered for 7 days, the reduction in disease severity was sustained well after 
cessation of treatment. The results from these experiments indicate that PTX pre-treatment 
can enhance the immuno-modulatory actions of GA. 
 
The therapeutic effects of GA have been attributed to a number of different mechanisms. 
GA has been shown to promote Th2 immune response within EAE and increase production 
of IL-4, IL-10 and TGF-β (Arnon et al., 2004; Kala et al., 2011). However, protection 
from EAE development has been demonstrated in GA-treated mice that are deficient in IL-
4 and/or IL-10 responses, indicating Th2 responses are not the only protective mechanism 
(Jee et al., 2006). Interactions of GA with monocytes can induce a type II suppressive 
phenotype (Toker et al., 2011; Weber et al., 2007) and GA treatment can increase Treg 
number and function (Jee et al., 2007). Therefore, it is likely that the immunomodulatory 
activity of GA is not due to one single mechanism of action but rather a combination of 
effects exerted on different cell types and in different tissues. 
 
The delay in disease onset caused by PTX may provide a window of opportunity for GA to 
induce a regulatory response. In EAE immunised mice, increases in the Treg marker Foxp3 
can be detected 4-8 days after initiation of GA treatment (Hong et al., 2005). Likewise a 2-
3 fold increase in Treg numbers was noted within the CNS of EAE immunised mice 10 
days after GA treatment (Aharoni et al., 2010). This would coincide with the delay in 
effect of GA observed in the current study, as it took until around d19 before disease 
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symptoms in GA/PTX treated mice began to plateau and exhibit reduced disease severity 
compared to the PTX only treatment group.  
 
No alteration in EAE development was observed when GA was administered for 7 days 
before EAE immunisation. This finding suggests that some factor associated with either 
the disease environment or PTX treatment enhanced the effects of GA when administered. 
Interestingly, it has been shown within EAE, GA induced Treg development is dependent 
on IFN-γ (Hong et al., 2005). It is conceivable that GA-mediated Treg induction is 
therefore enhanced by the inflammatory environment that occurs during EAE. As PTX 
delays disease onset but does not inhibit the inflammatory milieu, administration of PTX 
prior to GA treatment may allow for the development of GA-induced regulatory responses 
before the disease becomes too severe for these regulatory process to be effective.  
   
A number of small studies on relapsing-remitting MS patents have shown that 
mitoxantrone followed by GA treatment is more effective that either treatment alone 
(Arnold et al., 2008; Ramtahal et al., 2006; Vollmer et al., 2008). In fact, this combined 
treatment has recently been patented by the makers of GA
2
, suggesting further research 
will be conducted. However, as mitoxantrone has a maximal lifetime dose and causes 
considerable and irreversible side effects, the use of this combination is likely to be of 
limited therapeutic value (Neuhaus et al., 2006). Given the combined effects of PTX and 
GA in altering EAE disease expression, further experiments into this combination may 
provide an effective alternative. 
 
5.5 Summary:  
Collectively these results indicate that the disease modifying effects of MSDs can be 
enhanced either though synergistic interactions between combinations of MSDs or when 
used in conjunction with an immuno-modulatory compound. The findings from these 
experiments highlight the potential of using these drugs in combination to treat 
inflammatory disease.  
                                                 
2
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6.1 Introduction 
Risperidone is an atypical antipsychotic used to treat schizophrenia and other psychiatric 
disorders. The pathophysiology of schizophrenia is complex and involves alterations in 
brain structure as well as a dysregulation of signalling by a number of neurotransmitters, 
such as dopamine and serotonin (Guillin et al., 2007; van Os et al., 2009). Alterations in 
dopamine and serotonin signalling, within particular brain regions (e.g. the mesolimbic 
pathway) may have a central role in this disease (Kapur et al., 2001; Meltzer et al., 2011; 
van Os et al., 2009). Atypical antipsychotics, such as risperidone can block dopamine and 
serotonin from binding to their cognate receptors and it is though this process that 
antipsycotics are thought to exert their main therapeutic effects. (Kapur et al., 2001; 
Meltzer et al., 2011). However, psychiatric disorders such schizophrenia are often 
associated with alterations or dysregulation of the immune system, and it has been 
hypothesised that some of the therapeutic benefits of antipsychotic medication may be 
associated with modulation of immune parameters (Akira et al., 2003; Meyer et al., 2011; 
Potvin et al., 2008; Strous et al., 2006). Supporting this concept a number of studies have 
found risperidone and other atypical antipsychotic drugs cause alterations in serum 
cytokine and cellular immune responses in schizophrenic patients and animal models 
(Drzyzga et al., 2006; Maes et al., 2002; Muller et al., 1993). Given the potential to 
modulate the immune system both peripherally and within the CNS, antipsychotic drugs 
may prove of therapeutic benefit in inflammatory diseases. This chapter explores if 
risperidone modulates macrophage inflammatory responses in vitro and if in vivo 
administration alters disease expression of EAE.  
 
While no studies have explored the use of atypical antipsychotics in the context of 
autoimmunity, it has been demonstrated that atypical antipsychotics such as  risperidone, 
clozapine and olanzapine have anti-inflammatory effects in induced inflammation models 
(Basta-kaim et al., 2006; Kato et al., 2007; Sugino et al., 2009). The mechanisms of action 
by which these drugs alter inflammatory responses are ambiguous; however, since many 
immune cells respond to neurotransmitter signalling, the antagonism of neurotransmitter 
receptors by antipsychotics is a likely cause of these effects. Leukocytes express receptors 
for many neurotransmitters including dopamine, serotonin, glutamate, acetylcholine and 
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catecholamines (Franco et al., 2007). Additionally it has been demonstrated that 
neurotransmitters including dopamine and serotonin can be synthesised and/or released by 
dendritic cells, macrophages and T cells (Brown et al., 2003; Cosentino et al., 2007; Flierl 
et al., 2007; Nakano et al., 2011; Pacheco et al., 2009; Rinner et al., 1998). 
 
Risperidone has a strong affinity for the dopamine D2 and serotonin 5-HT2a receptors but it 
also can bind to other dopamine and serotonin receptors at varying affinities (Horacek et 
al., 2006; Roth et al., 2003). Furthermore, risperidone has low nanomolar affinity for H1 
histamine and α1 adrenergic receptors (Horacek et al., 2006; Roth et al., 2003). All of 
these receptors are G protein coupled receptors (GPCR), with stimulation of the 5-HT2a, H1 
or α1 receptors causing phospholipase C activation while stimulation of the 5HT1 or D2 
receptor causes inhibition of adenylate cyclase (Jonnakuty et al., 2008; Missale et al., 1998; 
Piascik et al., 2001). 
 
The role of peripherally-expressed neurotransmitters in MS is unknown, although a 
number of studies have noted that peripheral catecholamine (dopamine, epinephrine, 
norepinephrine) levels within the serum or PBMCs are altered in MS patents, particularly 
during active disease (Cosentino et al., 2002; Heesen et al., 2002; Rajda et al., 2002). 
However, the effect of increases or decreases in catecholamine levels on the immune 
system is likely to be dependent on the concomitant expression of particular dopamine and 
adrenergic receptors. Thus, further research needs to be conducted in this regard. 
Interestingly, one study has noted that following IFN-β treatment sustained increases in 
PBMC produced catecholamines were detected, as well as increased mRNA expression for 
β2 adrenergic and  dopamine D5  receptors, while D2 mRNA expression was decreased 
(Zaffaroni et al., 2008). This raises the intriguing possibility that some of the therapeutic 
effects of IFN-β could potentially be related to altered catecholamine signal transduction. 
Additionally a number of studies have documented alteration in EAE disease response 
following antagonism of D1, α1, 5HT1 or H1 receptors, all of which risperidone can 
antagonise (Chemel et al., 2006; Dimitriadou et al., 2000; Freire-Garabal et al., 2003; 
Jadidi-Niaragh et al., 2010; Nakano et al., 2008; Roth et al., 2003).   
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Collectively this research raises the intriguing possibility that antipsychotics such as 
resperidone could be beneficial for the treatment of EAE. In further support of this concept, 
studies using microglial cell lines have shown that risperidone or similar antipsychotic 
compounds can reduce the production of inflammatory cytokines such as IFN-γ, IL-1β, IL-
6 and TNF-α (Bian et al., 2008; Kato et al., 2008; Kato et al., 2007; Zheng et al., 2008) In 
the context of MS microglia are involved both with pathology and repair, depending on 
their activation state; therefore reducing inflammatory activity of microglia may be 
beneficial in EAE and MS (Deng et al., 2005; Jack et al., 2005). 
 
Macrophages and microglia share a common lineage and macrophages have been shown to 
express dopamine, serotonin, histamine and adrenergic receptors (Dimitrijevic et al., 2009; 
Reyes-García et al., 2009). It is therefore likely that similar anti-inflammatory effects of 
antipsychotics as those seen on microglia will also occur in macrophages. This is of 
particular relevance to MS, as while MS and EAE are  primarily considered to be T cell 
mediated diseases, macrophages play a crucial role in disease induction and progression 
(Martiney et al., 1998; Tran et al., 1998). It has been shown that simply altering 
macrophage/monocyte activation within an inflammatory environment towards a less 
inflammatory phenotype, can inhibit EAE disease induction or reduce disease severity 
(Tierney et al., 2009; Toker et al., 2011; Weber et al., 2007). If antipsychotics induce a 
less inflammatory phenotype of both macrophages and microglia, the potential of these 
compounds in treating autoimmune disease would be enhanced. Therefore one of the aims 
of the current study is to determine if risperidone can alter macrophage activation. 
 
Macrophages can be polarised towards different activation phenotypes depending on the 
environmental signals they receive. These activation states dictate how macrophages 
respond within a particular situation. Following exposure to an inflammatory environment 
or microbial products such as lipopolysaccharide (LPS), macrophages usually become 
classically activated and support the induction of a Th1/Th17 immune response. This 
activation state is characterised by increased production of inflammatory cytokines such as 
TNF-α and IL-12, as well as increased co-stimulatory molecules, such as CD40 and CD80 
(Edwards et al., 2006; Qin et al., 2005). These factors are crucial for the induction of 
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autoreactive T cells in EAE (Alegre et al., 2001; Grewal et al., 1998; Segal et al., 1998). 
However, in the presence of immune complexes or certain compounds macrophages or 
monocytes from an inflammatory environment can be induced to exhibit a regulatory 
phenotype, known as Type II activation (Anderson et al., 2002b). Type II activation is 
characterised by increased IL-10 and decreased IL-12 production as well as reduced 
expression of co-stimulatory molecules (Anderson et al., 2002b; Tierney et al., 2009). This 
altered phenotype has been shown to be protective in EAE (Tierney et al., 2009). 
Additionally Type II activation of murine monocytes and microglia has been described 
following administration of the MS therapeutic GA, implicating Type II activation as a 
factor contributing to the effectiveness of GA treatment (Pul et al., 2011; Toker et al., 2011; 
Weber et al., 2007).  
 
6.2 Aims and Objectives 
The current study investigated whether risperidone could alter macrophage activation and 
if this activation was consistent with a type II phenotype. To this end, macrophages were 
cultured under inflammatory conditions and exposed to risperidone. The effects of 
risperidone were compared to compounds known to alter macrophage/monocyte activation. 
Immune complexes (IC; consisting of IgG opsonised sheep red blood cells) are the 
prototypical inducer of type II activation; whereas GA has also been shown to induce type 
II activation in monocytes. Additionally, the in vivo effects of risperidone on the 
development of disease and autoimmune responses in EAE were investigated. 
 
6.2.1 Specific Aims: 
1. To determine if risperidone alters the activation state of cultured macrophages 
2. To identify if risperidone is effective as a treatment for EAE 
3. To explore potential changes in chronic T cell responses in risperidone treated mice   
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6.3 Results 
6.3.1 Risperidone alters macrophage activation 
As EAE and MS are inflammatory conditions, it is likely that macrophages /monocytes 
will be biased towards classical activation. To simulate an inflammatory environment in 
vitro, bone marrow derived macrophages (BMMØ) were incubated with IFN-γ and then 
stimulated with LPS. Under inflammatory conditions both GA and IC have been shown to 
alter macrophage/monocyte activation towards a type II phenotype characterised by 
decreased IL-12 and increased IL-10 production (Kim et al., 2004; Tierney et al., 2009; 
Weber et al., 2007). To test if risperidone had a similar effect, macrophages were 
stimulated with LPS in the presence or absence of GA, IC or risperidone. As Type II 
activated macrophages exhibit significant differences in cytokine production by 8 hours 
post-stimulation and alterations in cell surface molecule expression by 24 hours, these two 
time points were analysed for cytokine production and co-stimulatory molecule expression, 
respectively (Tierney et al., 2009).  
 
To identify if any of these compounds altered macrophage viability, an MTT assay was 
performed following an 8 hour incubation of the compounds with BMMØ. The MTT assay 
works though cell dependent reduction of a yellow 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenoyltetrazolium bromide (MTT) dye to blue formazan crystals (Berridge et al., 2005). 
Therefore, a decrease in the formation of formazan indicates decreased metabolic activity 
or cellular death. Figure 6.1 illustrates that high concentrations of risperidone (100 or 200 
µg/ml) resulted in a substantial decrease in MTT metabolism compared to the untreated 
controls, indicating that at these concentrations risperidone is toxic to macrophages. In 
contrast, risperidone concentrations of 50 µg/ml or below did not alter the metabolic 
activity of LPS stimulated macrophages. 
 
Production of the inflammatory cytokine IL-12 was attenuated following treatment with 50 
µg/ml risperidone (Figure 6.2a). The reduction in IL-12p40 production was similar to that 
of IC-treated macrophages. While there appeared to be a trend towards decreased IL-12 
production with 20 µg/ml risperidone, this reduction did not reach statistical significance. 
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Interestingly, GA treatment did not cause any alteration in IL-12 levels. Production of the 
anti-inflammatory cytokine IL-10 was increased in both the 50 and 20 µg/ml risperidone 
treatment groups (Figure 6.2b); however, the increases in IL-10 were not as pronounced as 
the increase induced by IC treatment.  
 
Co-stimulatory and other cell surface molecules are important in shaping the immune 
response elicited by stimulated macrophages. CD40, CD80 and PD-L1 are all up-regulated 
following classical activation by LPS (Edwards et al., 2006; Loke et al., 2003; Qin et al., 
2005). In contrast, following type II activation these cell surface molecules are down-
regulated (Tierney et al., 2009). Similar to Type II activation, a reduction in CD40 
expression is seen on risperidone (20 µg/ml) + LPS treated macrophages compared to LPS 
alone (Figure 6.3a). While there appeared to be a general trend toward reduction in CD40 
by IC and GA treatment, neither of these reached significance. Likewise PD-L1 expression 
appeared to be reduced in risperidone, GA and IC treatments but did not reach statistical 
significance (Figure 6.3b). No changes in CD80 expression were observed (Figure 6.3c).  
Taken together these results indicate that risperidone deviates macrophage phenotypic 
expression away from a classical inflammatory activation state. This is evident by the 
reductions in the inflammatory cytokine IL-12 and co-stimulatory molecule CD40 as well 
as the concurrent increases in IL-10 production by risperidone treated macrophages.  
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Figure 6.1 Risperidone alters macrophage viability only at high concentrations 
Bone marrow derived macrophages were primed overnight with IFN-γ (20u/ml) then incubated 
with the described treatments. Following 8 hours incubation, MTT solution was added and 
incubated for a further 2 hours. Data are represented as percent absorbance of untreated 
macrophages. Shown are means and SEM of 2 experiments conducted in duplicate. * P<0.05 by 
one-way ANOVA with Dunnet’s post hoc test; unstimulated vs. unstimulated + treatment or LPS 
vs. LPS + treatment. LPS (200ng/ml); RIS V (risperidone vehicle). RIS100 (risperidone, 
100µg/ml); RIS 50 (risperidone, 50µg/ml); RIS 20 (risperidone, 20µg/ml); GA 20 (glatramer 
acitate, 20µg/ml); IC, (Immune complex, 5x106/ml).  
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Figure 6.2 Risperidone reduces IL-12 and increases IL-10 production in LPS stimulated 
macrophages 
Bone marrow derived macrophages were primed overnight with IFN-γ (20u/ml) then incubated 
with the described treatments. Supernatants were removed after 8 hours and IL-10 and IL-12p40 
production was assessed by ELISA. Data represented as percent change in expression relative to 
LPS stimulated untreated macrophages (a) IL-12p40 and (b) IL-10 production. Shown are means 
and SEM of 3 experiments conducted in duplicate. * P<0.05 by one-way ANOVA with Dunnet’s 
post hoc test; LPS vs. LPS + treatment. LPS (200ng/ml); RIS V (risperidone vehicle). RIS 50 
(risperidone, 50µg/ml); RIS 20 (risperidone, 20µg/ml); RIS 2 (risperidone, 2µg/ml); GA 20 
(glatiramer acetate, 20µg/ml); IC, (Immune complex, 5x106/ml).  
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6.3.2 Treatment of mice with risperidone reduces disease severity of EAE  
Previous studies have shown that Type II activation of macrophages or monocytes can 
contribute to reductions in EAE disease severity (Tierney et al., 2009; Toker et al., 2011; 
Weber et al., 2007). To investigate if risperidone similarly suppresses EAE disease 
expression, mice were treated daily with risperidone or left untreated. The doses of 
risperidone were chosen to be comparable to clinically relevant doses used in humans, 
estimated by comparable D2 receptor occupancy (Kapur et al., 2003; Karl et al., 2006; 
Naiker et al., 2006). To achieve a prolonged drug exposure, mice were administered 
risperidone via their drinking water, throughout the course of the experiments. No 
alteration in water consumption was observed between risperidone treated or untreated 
animals (data not shown). 
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Figure 6.3 Risperidone reduces CD40 expression of LPS stimulated macrophages  
Bone marrow derived macrophages were primed overnight with IFN-γ (20u/ml) then incubated with 
the described treatments for 24 hours. Surface marker expression was assessed via flow cytometry 
and is represented as percentage change in mean fluorescence intensity (%∆ MFI: MFI of specific 
antibody – isotype control/MFI medium alone) of (a) CD40, (b) CD80 and (c) PDL-1 expressed on 
F4/80
+
 macrophages. Shown are means and SEM of 2 experiments conducted in duplicate.* P<0.05 
by one-way ANOVA with Dunnett’s post hoc test; LPS vs. RIS 200. LPS (200ng/ml); RIS V 
(risperidone vehicle); RIS 20 (risperidone, 20µg/ml); GA 20 (glatramer acitate, 20µg/ml); IC, 
(Immune complex, 5x106/ml).  
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Risperidone treated mice exhibited reduced disease severity compared to untreated mice 
(Figure 6.4a). This was particularly pronounced in the 3 mg/kg/d treatment group that 
exhibited both a reduction in disease score and overall disease burden (Figure 6.4a and c). 
Incidence was similar between risperidone-treated and untreated, immunised animals; 
however, by day 40 p.i. both 1 mg/kg/d and 3 mg/kg/d risperidone treatment groups had a 
reduced incidence of 70% compared to 90% for untreated mice (Figure 6.4b). As it 
appeared that there was a relationship between increased doses of risperidone and a 
reduction in disease score, an additional experiment using risperidone doses of 5 and 10 
mg/kg/d was conducted. Interestingly, while a delay in reaching maximal disease score 
was observed in 5 mg/kg/d treatment group, no overall reduction in incidence or maximal 
disease score occurred (Figure 6.5 and data not shown). Additionally no alteration in 
disease severity was observed in the 10 mg/kg treated mice. Thus the high concentrations 
of 5 or 10 mg/kg/d risperidone appear to counteract the disease modifying effects observed 
at the lower concentration of 3 mg/kg/d.   
 
When spinal cords from immunised mice were analysed, no difference in total lesion area 
was detected between risperidone-treated (3 mg/kg/d) and untreated sick mice (Figure 6.6). 
From the two experiments analysed, there was however a decrease in the number of 
risperidone-treated mice with lesions, when compared to the untreated group (50% versus 
80%, respectively). As only one section from each spinal cord was analysed, it is possible 
that the reduction in lesions in risperidone treated animals was due to the limited sampling. 
However, in subsequent studies within our laboratory, similar reductions in lesion number 
has been identified in risperidone treated mice (Marie Kharhrang; personal 
communication), supporting the notion that risperidone treatment results in a reduction in 
the number of lesions.   
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Figure 6.4 Risperidone reduces EAE disease severity   
C57BL/6 mice were immunised for EAE and treated daily as indicated. (a) Disease score of sick 
mice. (b) Disease incidence of all mice (c) Disease burden as % area under curve (AUC) vs 
untreated sick mice. Shown are means and SEM of 3 experiments (n=9-10 mice/group).* P<0.05 
by one-way ANOVA; with Newman-Keuls Multiple Comparison test; untreated, RIS 1 vs RIS 3. 
“Untreated” mice received vehicle treated water at a concentration equivalent to that which would 
be present at the highest drug concentration. 
Chapter 6: Using risperidone to treat EAE                                                                         137 
Figure 6.6 Risperidone does not significantly reduce the size of spinal cord lesions 
C57BL/6 mice were immunised for EAE and treated daily (RIS 3; 3 mg/kg/d) or left 
untreated. Shown are lesion areas within one section of spinal cord from individual mice. 
Lesion area represented as percent of total spinal cord area surveyed (see appendix 3). Only 
sick mice were included in the analysis  (n = 5 untreated or 8 risperidone 3 mg/kg/d, 
mice/group). No significant diffrences by a Mann-Whitney test. “Untreated” mice received 
vehicle treated water at a concentration equivalent to that which would be present at the 
highest drug concentration. 
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Figure 6.5 High doses of risperidone do not reduce EAE disease severity 
C57BL/6 mice were immunised for EAE and treated daily as indicated. Shown are means 
and SEM of disease scores of 1 experiment (n = 4-5 mice/group). “Untreated” mice received 
vehicle treated water at a concentration equivalent to that which would be present at the 
highest drug concentration. 
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6.3.3 Risperidone treatment alters T cell populations in the spleen 
To determine if the attenuated chronic disease responses in 3 mg/kg/d risperidone-treated 
animals resulted in alterations in the cellular composition, splenocytes from risperidone-
treated and untreated mice were isolated 40 days post immunisation and analysed for 
surface markers (CD4, CD25, CD8, B220, F4/80 and Gr-1). The only notable difference in 
cellular composition was the percentage of CD4
+
 T cells, with a higher percentage of both 
CD4
+ 
CD25
+
 and CD4
+
 CD25
-
 occurring in risperidone-treated, immunised animals 
(Figure 6.7) This effect was not observed in unimmunised animals, suggesting that 
risperidone alone does not cause alterations in splenic cellular composition. Additionally, 
no difference in total number of spleen or dLN cells was observed between risperidone 
treated and untreated groups or between immunised or unimmunised mice (Figure 6.8). 
 
Interestingly, despite the increased percentage of T cells within the spleens of immunised, 
risperidone-treated mice, cellular proliferation in response to Con A stimulation was 
significantly less, compared to splenocytes from immunised-untreated mice (Figure 6.9a). 
In contrast, within the dLNs immunised, risperidone-treated mice exhibited increased Con 
A induced proliferation compared to immunised untreated mice. Moreover, proliferation of 
cells from the dLN of unimmunised untreated mice was significantly higher than cells 
from unimmunised, risperidone-treated mice. Despite these differences in ConA-
stimulated proliferation, no differences in the proliferative response to MOG
 
was observed 
by splenocytes or dLN cells from risperidone-treated or untreated, immunised mice 
(Figure 6.9b) suggesting that while polyclonal T cell responses may be altered by 
risperidone treatment, the antigen-specific T cell responses are not. 
 
Analysis of cytokines within culture supernatants showed a trend toward increase IL-10 
production in splenocytes from risperidone-treated mice; however, this effect was not 
significant (Figure 6.10a). No significant differences in production of IL-6, IL-17a, IL-4, 
IL-2 or TNF-α were observed between treated and untreated groups following either Con 
A or MOG
 
stimulation (Figure 6.10b and c and data not shown). Interestingly, 
production of IFN-γ was increased in splenocytes from immunised, risperidone-treated 
animals in response to MOG, but not Con A (Figure 6.10d) whereas the opposite effect 
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was observed in the LN where IFN-γ production by lymph node cells from risperidone-
treated, immunised mice was increased in response to Con A but not to MOG
 
(Figure 
6.11). Taken together, these results indicate that although risperidone reduces disease, it 
does not inhibit antigen-specific T cell proliferation or cytokine production during the 
chronic phase of the disease.  
Chapter 6: Using risperidone to treat EAE                                                                         140 
Immunised Unimmunised 
0
1
2
3
4
**
a
C
D
4
+
 C
D
2
5
+
 (
%
)
Immunised Unimmunised 
0
5
10
15
20
25
*
b
Untreated 
RIS (3mg/kg/d) 
C
D
4+
 (
%
)
Immunised Unimmunised 
0
5
10
15
c
C
D
8
+
 (
%
)
Immunised Unimmunised 
0
1
2
3
4
d
F
4
/8
0
+
 (
%
)
Immunised Unimmunised 
0
1
2
3
4
e
G
r-
1
+
 (
%
)
Immunised Unimmunised 
0
20
40
60
f
B
2
2
0
+
 (
%
)
Figure 6.7 Risperidone increases the proportion of CD4 T cells within the spleen   
 Splenocytes were isolated 40 days p.i. and analysed by flow cytometry for percentages of total (a) 
CD4
+
CD25
+
, (b) CD4
+
, (c) CD8
+
, (d) F4/80
+
, (e) Gr-1
+
 or (f) B220
+
 cells. Shown are means and SEM 
of individual mice from 3 experiments (immunised n=9-10/group) or 2 experiments (unimmunised n = 
4-6). * P<0.05, ** p< 0.01 by unpaired student’s t-test; immunised untreated vs immunised treated or 
# P<0.05 untreated vs. treated. “Untreated” mice received vehicle treated water at a concentration 
equivalent to that which would be present at the highest drug concentration. 
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Figure 6.9 Risperidone does not alter ex vivo antigen-specific proliferation in spleen or lymph node cells  
Spleen or lymph node cells were cultured in medium alone or in the presence of (a) Con A (3µg/ml) or (b) 
MOG (27 µg/ml) 40 days p.i.. Proliferation was assessed by 3[H]thymidine (1µCi) incorporation and is 
expressed as a Proliferation index; CPM of stimulated wells/CPM of media alone. Shown are the means and 
SEM from individual mice from 2 experiments (immunised, n=6-9) or 1 experiment (unimmunised n = 2-3). * 
P<0.05, **P<0.01 by unpaired student’s t-test; immunised untreated vs immunised treated or # untreated vs. 
treated. “Untreated” mice received vehicle treated water at a concentration equivalent to that which would be 
present at the highest drug concentration. 
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Figure 6.8 Risperidone does not alter total cell numbers in the spleen or lymph node  
Spleen and lymph node cells were isolated 40 days p.i. and counted. Shown are means and SEM of 
individual mice from 3 experiments (immunised n=9-10/group) or 2 experiments (unimmunised n = 4-6). 
There were no significant differences between immunised untreated vs immunised treated or untreated vs. 
treated when assessed by an unpaired student’s t-test. “Untreated” mice received vehicle treated water at a 
concentration equivalent to that which would be present at the highest drug concentration. 
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Figure 6.10 IFN-γ production is increased following antigen-specific stimulation of splenocytes from 
risperidone treated mice 
Forty days p.i. splenocytes were isolated and cultured in vitro and stimulated with Con A (3µg/ml) or MOG 
(27µg/ml) 48 and 72 hours respectively. IL-10 (a) IL-6 (b) IL-17(c) and IFN-γ (d) production was assessed 
by Cytometric Bead Array in culture supernatants. Shown are the means and SEM from individual mice 
from 2 experiments (immunised, n = 6-9) or 1 experiment (unimmunised n = 2-3). * P<0.05 by unpaired 
student’s t-test; immunised untreated vs immunised treated or untreated vs. treated. “Untreated” mice 
received vehicle treated water at a concentration equivalent to that which would be present at the highest 
drug concentration. 
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Figure 6.11 IFN-γ production is increased following polyclonal stimulation of lymph node cells from 
risperidone treated mice  
Forty days p.i. cells from the dLN were isolated and cultured in vitro and stimulated with Con A (3 µg/ml) or 
MOG (27 µg/ml) for 48 and 72 hours respectively. IFN-γ production was assessed by ELISA in culture 
supernatants. Shown are the means and SEM from individual mice from 2 experiments (immunised, n = 6-9) 
or 1 experiment (unimmunised n = 2-3). * P<0.05 by unpaired student’s t-test; immunised untreated vs 
immunised treated. “Untreated” mice received vehicle treated water at a concentration equivalent to that 
which would be present at the highest drug concentration. 
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6.4 Discussion  
EAE is considered primarily a T cell-mediated disease; however, macrophages play a 
crucial role in the disease induction and progression (Martiney et al., 1998; Tran et al., 
1998). Altering macrophage/monocyte activation within an inflammatory environment 
towards a more regulatory (type II) phenotype can inhibit disease induction or reduce 
disease severity (Tierney et al., 2009; Toker et al., 2011; Weber et al., 2007). As 
risperidone has previously been shown to induce IL-10 production and thus develop a 
phenotype similar to type II activation in microglia, the current study investigated whether 
risperidone would have similar effect on cultured macrophages.  
 
Classically activated macrophages produce high levels of IL-12 with little IL-10 being 
produced (Mantovani et al., 2004; Mosser, 2003); while type II activation induces 
macrophages to increase IL-10 and decrease IL-12 production (Anderson et al., 2002b; 
Tierney et al., 2009). The current study found that supernatant from IC–treated, LPS-
stimulated macrophages had high levels of IL-10 and reduced levels of IL-12p40 relative 
to LPS-stimulated macrophages, which is consistent with previous studies (Anderson et al., 
2002a; Gerber et al., 2001; Tierney et al., 2009). In contrast to previous studies; however, 
GA treatment had little effect on IL-10 or IL-12p40 production (Jasny et al., 2008; Pul et 
al., 2011). High but non-toxic concentrations of risperidone (50 µg/ml) resulted in a 
similar reduction of IL-12p40 production in LPS stimulated macrophages. Additionally IL-
10 production in risperidone (20 or 50 µg/ml) treated LPS stimulated macrophages was 
significantly increased, relative to untreated macrophages. This indicates that like IC 
treatment, risperidone induces a switch from classical macrophage activation towards a 
more anti-inflammatory phenotype. Despite a similar reduction in IL-12 production by IC 
or risperidone-treated macrophages, IL-10 production was not as pronounced following the 
latter treatment. This suggests that risperidone is not a strong inducer of IL-10 production. 
Alternatively, it is possible that risperidone-treated macrophages expressed higher levels of 
IL-10 receptor and therefore more IL-10 was taken up from the supernatant.  
 
The co-stimulatory molecule CD40 is expressed on macrophages and binds to CD40L 
(CD154) on T cells causing up-regulation of MHC-II and production of inflammatory 
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cytokines (Suttles et al., 2009). Signalling through CD40/CD40L interactions is also 
assocated with the activation of antigen-specific T cell responses (Grewal et al., 1998). A 
reduction of CD40 expression was observed on LPS-stimulated, risperidone-treated 
macrophages. This reduction provides further evidence that risperidone is altering the 
activation state of macrophages away from an inflammatory phenotype. Within the context 
of EAE, CD40/CD40L interactions have been implicated as having a crucial role during 
disease development (Girvin et al., 2002; Grewal et al., 1996; Perona-Wright et al., 2009). 
Additionally in CD40 -/- mice, IL-17 production is impaired while IFN-γ production is not, 
indicating CD40 may be involved with development a Th17 immune response (Perona-
Wright et al., 2009). Therefore, if risperidone treatment induced a down-regulation of 
CD40 expression on APCs in EAE immunised mice, this could result in the reduction of 
inflammatory cytokines, such as IL-6 and IL-12, as well as a deviation of T cells away 
from an encephalogenic Th17 response.  
 
The strength of signaling though CD40 appears to alter the macrophage response, with low 
level signaling increasing IL-10 production while stronger signaling increases IL-12 
production (Mathur et al., 2004). This suggests that the increased production of IL-10 in 
risperidone treated macrophages may be further enhanced following CD40/CD40L 
interactions. While no co-cultures of macrophages with T cells were conducted, it would 
be interesting to investigate if IL-10 production is further enhanced following CD40-
CD40L ligation. It has also been shown that IL-10 can inhibit up-regulation of CD40 on 
macrophages (Qin et al., 2006). Whether or not the reduction in CD40 expression on 
risperidone-treated macrophages was caused by increased IL-10 signaling in the current 
experiment is ambiguous.  
 
Another important co-stimulatory molecule expressed by macrophages is CD80. CD80 
provides either co-stimulatory T cell signaling that promotes T cell activation when it is 
bound to CD28 or an inhibitory signal when bound to CTLA-4 (Alegre et al., 2001). Up-
regulation of CD80 is associated with disease expression in EAE  and blockade of 
CD80/CD28 interactions can prevent disease symptoms (Karandikar et al., 1998; Miller et 
al., 1995). A previous study found CD80 expression was modestly down-regulated on IC-
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induced type II-activated macrophages (Tierney et al., 2009).  In contrast, no alterations in 
macrophage CD80 expression were observed following IC treatment. Additionally, neither 
risperidone nor GA altered CD80 expression. The low levels of CD80 expression in LPS 
stimulated untreated macrophages and variability in expression may have contributed to no 
change in CD80 being detected. 
 
PD-L1 expression is usually associated with regulation of T cells though PD-1/PD-L1 
interactions between T cells and APCs, respectively (Francisco et al., 2010).A lack of PD-
L1/PD-1 signaling has been found to exacerbate EAE (Latchman et al., 2004). 
Additionally, in vivo administration of GA up regulates PD-L1 on monocytes suggesting 
PD-L1 expression may be involved in regulation of disease processes (Weber et al., 2007). 
Despite the apparent regulatory role of PD-L1, expression on type II macrophages is 
usually down-regulated (Tierney et al., 2009). In the current experiment, no significant 
down-regulation was observed in IC, GA or risperidone treated macrophages; however, a 
trend towards reduction in PD-L1 by all three treatments is observed. What role a 
reduction in PD-L1 may have in type II activated macrophages is unknown, but it has been 
suggested that in combination with down-regulation of CD40, reduced PD-L1 could skew 
the T cells towards a Th2 type response (Tierney et al., 2009). Alternatively, it has been 
shown that in vitro blockade of PD-L1 results in increased IFN-γ production, macrophage 
NO production and subsequent inhibition of T cell proliferation (Yamazaki et al., 2005). 
This may also be a mechanism whereby decreased PD-L1 could play have a regulatory role 
on Th1 type T cell responses.   
 
Collectively these results demonstrate risperidone treatment of LPS-stimulated 
macrophages dampens down the inflammatory phenotype. This finding complements 
previous research that found similar effects of atypical antipsychotic’s in microglial 
cultures (Kato et al., 2007; Zheng et al., 2008). Whether the effect of risperidone on 
macrophages constitutes a true type II activation state as observed with immune complex 
treatment requires more thorough investigation. However, within the limited parameters of 
this study, the phenotypic changes induced by risperidone are similar to those induced by 
IC treatment suggesting that type II activation may be occurring.  
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The mechanisms by which these phenotypic changes are mediated are likely to be 
associated with risperidone’s neurotransmitter antagonism; although it is possible that 
these effects are mediated though a novel mechanism of action. At the concentrations of 
risperidone used in the current study, both D1 and D2 type receptors would be antagonised, 
and it is also likely 5-HT1,2,5,7, histamine H1 and α adrenergic receptors will also be 
antagonised (Roth et al., 2003; Schotte et al., 1996). In contrast, it is unlikely risperidone 
would antagonise β adrenergic and histamine H2,3,4 receptors, at the concentrations used.  
 
Interestingly, a study found mouse peritoneal macrophages exposed to dopamine (>1000 
nM) had reduced IL-12 and increased IL-10 production following LPS stimulation (Haskó 
et al., 2002). Additionally, there was no alteration in this effect when either a D1 (SCH-
23390) or D2 (raclopride) receptor antagonist was administered; however, antagonism of 
the β2 adrenergic receptors by propranolol inhibited the effect of dopamine (Haskó et al., 
2002). A similar effect of reduced IL-12 production has been observed in microglia when 
exposed to the β2 agonist salbutamol (Prinz et al., 2001). One caveat of these studies was 
the possibility that dopamine was being converted to noradrenalin via dopamine-beta-
hydroxylase. However another study in astroglial cultures using fusaric acid (a dopamine-
beta-hydroxylase inhibitor) found a similar β2 receptor mediated anti-inflammatory effect 
of dopamine, suggesting the effects observed were specifically dopamine mediated 
(Facchinetti et al., 2004). In the context of the current study it is conceivable that a similar 
mechanism could be occurring, whereby extensive receptor antagonism by risperidone 
results in preferential activation of β2 adrenergic receptor by any catecholamine present in 
the culture supernatant. As macrophages or microglia can produce both dopamine and 
noradrenalin either of these neurotransmitters could be responsible for this effect (Brown et 
al., 2003; Flierl et al., 2007). However, unlike dopamine, the effects of noradrenalin on 
macrophage activation are more contentious, with both anti- and pro-inflammatory effects 
being described (Dello Russo et al., 2004; Ley et al., 2010). 
 
Antagonism of the histamine H1 receptor is another potential mechanism by which 
risperidone could be eliciting its effects. On human monocytes histamine activation of the 
H2  (but not H1 or H3) receptor results in decreased TNF-α and IL-12 and increased IL-10 
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production following LPS stimulation (Elenkov et al., 1998; Morichika et al., 2003). 
Additionally, histamine signaling though either the H2 or H4 receptors causes a reduction 
of IL-12 production in poly IC (a TLR3 agonist) -stimulated human monocyte-derived 
dendritic cells (Gutzmer et al., 2005). There is little work published on the H3 receptor; 
however, it has been noted that within human monocytes its expression is down-regulated 
upon differentiation (Gutzmer et al., 2005). Likewise differentiation from a monocyte to 
macrophage also has been noted to result in preferential expression changing from H2 to H1 
receptors (Triggiani et al., 2007). While the majority of histamine is produce by mast cells, 
histamine is also produced by macrophages (Ghosh et al., 2002). Additionally, histidine 
decarboxylase the enzyme that converts histidine to histamine is up-regulated in LPS-
stimulated macrophages (Suzuki et al., 2009). As risperidone has strong affinity for the 
histamine H1 receptor but not H2, H3 or H4, histamine within the cultures will only be able 
to act via the latter receptors (Roth et al., 2003; Schotte et al., 1996). As H3 is likely to be 
down-regulated, histamine signaling though either H2 or H4 could contribute to a reduction 
in IL-12 expression and potentially increase IL-10 production. 
 
 Assuming risperidone’s activity on cultured macrophages is due to receptor antagonism 
and subsequent activation of neurotansmiter receptors that are not antagonised by 
risperidone, it is possible the alterations in phenotype are associated with increases in 
cAMP as both H2 and β2  receptors induce increases in cAMP, while the H4 rector, despite 
being considered a Gi coupled receptor, does not cause reductions in cAMP (Gutzmer et 
al., 2005). Thus in the current study signaling though histamine or catecholamines is likely 
to result in increased cAMP. cAMP has been shown in multiple studies to have a role in 
reducing IL-12 and increasing IL-10 production in macrophage/monocytes (Braun et al., 
2001; Delgado et al., 1999; Feng et al., 2002). Future studies investigating if cAMP 
concentrations are increased in risperidone-treated macrophages may help to elucidate the 
mechanisms by which risperidone modulates macrophage activation.  
 
The concentration of risperidone required to induce the observed changes in macrophage 
phenotype is higher than what is needed to induce responses following in vivo 
administration (Aravagiri et al., 1998). However, this difference does not preclude the 
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possibility that within an in vivo context, macrophages will respond in a similar manner to 
lower concentrations of risperidone. This situation is possible since other factors such as 
CD40/CD40L interactions, risperidone metabolites or production of neurotransmitters by 
other cell type may influence risperidones effects on macrophages in vivo. It would be 
interesting in future experiments to isolate monocytes/macrophages from mice treated with 
risperidone to investigate if similar phenotypic alterations have occurred after in vivo 
treatment.      
 
When EAE immunised mice were treated with 3 mg/kg/d risperidone a reduction in 
disease severity and overall disease burden was observed. This concentration of 
risperidone is comparable to doses used clinically to treat psychophrenia (Kapur et al., 
2003). Interestingly, higher doses of risperidone (5 mg/kg/d or 10 mg/kg/d) did not provide 
any protection. This finding suggests that risperidone has a dose dependent effect on the 
immune system. As risperidone can antagonise a number of neurotransmitter receptors, it 
is likely that as the concentration of risperidone increases neurotransmitter receptors which 
have a weaker affinity for risperidone begin to be antagonised (Aravagiri et al., 1998; Roth 
et al., 2003). It is therefore conceivable that high doses of risperidone may result in a 
different combination of receptor inhibition and thus a different alteration in immune 
response. An alternate explanation for the observed effects could be due to the fact that 
high doses of risperidone can cause extrapirimidal side effects such as ‘drug-induced 
Parkinsonism’ that is associated with postural instability and akinesia (Knable et al., 1997). 
As the disease severity rating scale used in the EAE model takes into account muscle 
tonicity, extra-pyramidal side effects may be falsely detected as EAE symptoms.   
 
Another potential explanation for the alterations in disease expression could be related to 
production of prolactin, as risperidone dose dependently increases prolactin production 
(Bowden et al., 1992; Fitzgerald et al., 2008; Rourke et al., 2006). Exogenous prolactin 
has been found to promote oligodendrocyte proliferation and white matter regeneration in a 
lysolecithin induced demyinating mouse model (Gregg et al., 2007).  Additionally, some 
psychotic patents have increased intracortical myelin volume following treatment with 
risperidone; however, it is unknown if this is due to hyperprolactinemia (Bartzokis et al., 
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2007; Bartzokis et al., 2009). These observations raise the possibility that the reduction in 
EAE disease severity in risperidone (3 mg/kg/d) treated mice is due to prolactin induced 
re-myelation. This however is very unlikely, as the concentrations of prolactin (20 µM/day) 
used to induce white matter regeneration in the demyelinating mouse model, were far 
higher than the nanomolar levels induced by risperidone (Gregg et al., 2007; Kapur et al., 
2002; Rourke et al., 2006). Likewise, if the reduction in EAE severity was associated with 
increased prolactin, it would be expected that the higher risperidone concentrations (5 or 
10 mg/kg/d) would provide increased disease protection, as increased prolactin levels 
occur at higher risperidone concentrations (Rourke et al., 2006). In fact the inverse could 
occur whereby the lack of disease modification in the 5 and 10 mg/kg treatment groups 
could even be associated with increased prolactin levels since previous studies have found 
prolactin levels positively correlate with EAE disease severity (Esquifino et al., 2006; 
Riskind et al., 1991). However as these studies used either bromocriptine, (D2 receptor 
agonist) or pituitary grafting to alter prolactin levels a clear causal link between prolactin 
and disease severity cannot be made (Esquifino et al., 2006; Riskind et al., 1991).  
 
When the cellular composition of spleens were analysed 40 days p.i. a significant increase 
in the percentage of CD4
+
 cells was observed within spleens of risperidone treated mice. 
There was no significant difference between the ratio of CD4
+
 CD25
+ 
to CD4
+
 CD25
-
 
indicting that this increase was not just due to expansion of CD4
+ 
effector cells. Following 
Con A stimulation splenocyte proliferation was significantly less in the risperidone 
treatment group; whereas, no significant difference was observed following MOG 
stimulation. This result indicates that the increased percentage of CD4
+ 
splenocytes 
detected within risperidone treated mice did not result in a proportional increase in T cell 
proliferative responses.  
 
Despite the reduction in proliferation in response to Con A, no difference in IL-17 or IFN-γ 
production between risperidone and untreated was observed. Additionally MOG-specific 
IFN-γ production was significantly increased in splenocytes from risperidone treated mice. 
This finding is in partial accord with a previous study, that found that 45 days after EAE 
immunisation splenocytes from mice treated with a D1 receptor antagonist (SCH23390) 
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produced more IFN-γ and less IL-17 (Nakano et al., 2008). Although IFN-γ producing Th1 
cells have typically been associated with EAE disease pathology, IFN-γ also has a 
protective role by limiting disease severity (Ferber et al., 1996a; Willenborg et al., 1996). 
Additionally Th1 cells have been shown to be less encephalitogenic than IL-17 producing 
Th17 cells (Murphy et al., 2010) (Berghmans et al., 2011). In the current study the 
increase in IFN-γ but not IL-17 suggests a slight biasing of Th1 over Th17 type response in 
risperidone treated mice, and this may have a beneficial effect in limiting disease severity. 
 
No significant differences in production of IL-6, or TNF-α were observed between 
risperidone treated and untreated mice. This contrasts with previous studies that have 
found reductions in plasma IL-6 and TNF-α levels following risperidone treatment within a 
necrotic pancreatitis mouse model and omega 3 deficient rats (McNamara et al., 2011; 
Yamaguchi et al., 2009). In the present study, cytokines were measured from supernatants 
of splenocyte cultures rather than plasma, and it is likely that the production of cytokines 
from stimulated splenocytes do not necessarly reflect the levels occurring in the plasma. 
This may also be true for IL-10 production, as although it appeared there was a trend 
towards increased IL-10 production in splenocytes from risperidone treated mice, 
particularly following Con A stimulation, this did not reach statistical significance. A 
previous study using an LPS based sepsis model showed that a single oral dose of 
risperidone significantly increased serum IL-10, indicating that risperidone can induce IL-
10 within an inflammatory environment (Sugino et al., 2009). In the current study, it is 
possible that IL-10 production would be more pronounced following in vitro stimulation, 
had risperidone been added to the cultures; or alternatively if serum cytokine production 
had been measured. 
 
Collectively the results from these experiments indicate that risperidone can alter EAE 
disease severity, although this effect is diminished at high concentrations. Risperidone 
treatment did not delay disease onset or inhibit antigen-specific T cell responses, indicating 
that the reduction in disease severity is not due to inhibited induction of a disease response. 
It is possible, therefore, that the main disease modifying effects occur in situ within the 
CNS rather than in the periphery. Assuming risperidone’s effects on in vitro microglial and 
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macrophage cultures occurs in vivo it is likely the altered phenotype of microglial cells and 
macrophages would lead to a reduction in chronic CNS inflammation. Additionally the 
observed increase in IFN-γ production in splenocyte may indicate stronger Th1 compared 
to Th17 T cell response, which could also assist in limiting disease severity. With future 
studies a more thorough investigation into potential immunological changes within the 
CNS may be helpful in determining potential mechanisms though which risperidone alters 
disease. As well as investigating if risperidone induces changes in macrophage and 
microglia, cytokine and surface marker expression needs to be investigated in vivo to 
identify if changes occur in a similar manner to those seen within in vitro cultures.  
 
6.5 Summary 
This is the first study to explore the effects of risperidone in EAE. The findings from this 
study raise the possibility that risperidone could provide therapeutic benefit in this 
inflammatory disease. As risperidone has been clinically used for treatment of 
schizophrenia for a number of years, dosing, safety and side effect profiles are well 
understood. It can be administered to patients orally or in slow release depots and has 
relatively mild side effects. All these factors suggest further investigation into the 
therapeutic potential for the treatment of MS is warranted. 
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7.1 Introduction  
MIS416 is a novel microparticle derived from Propionibacterium acnes that is comprised 
of a muramyl dipeptide cell wall skeleton and bacterial DNA (Girvan et al., 2010). While 
originally developed as a vaccine adjuvant, interest has grown around the potential use of 
MIS416 as immunomodulatory agent for treatment of inflammatory disorders. MIS416 
was approved for compassionate use
3
 and administered (i.v. once a week) to 8 patients 
suffering from progressive forms of MS. Anecdotal reports from these patients indicate 
that MIS416 is well tolerated and self-reported improvements in disease symptoms have 
been noted (personal communication; Gill Webster, Innate Immunotherapeutics). 
Additionally, given the positive results from the compassionate use, a phase 2A trial is 
currently underway to evaluate the safety, tolerability and dosing of MIS416 within 
progressive MS patients. However, while the immune targets of this microparticle are 
known (ie. TLR9 and NOD2), the mechanism by which activating these innate receptors 
leads to an improvement in MS patients is not clear. The current chapter explores the 
potential of MIS416 to prevent or reduce disease in the EAE model of MS and investigates 
what mechanisms could mediate disease modification. 
 
The muramyl dipeptide and bacterial DNA present in MIS416 principally activates the 
pattern recognition receptors (PRR) NOD2 and TLR9 respectively (Girvan et al., 2010). 
Signalling though these PRRs can result in activation of transcription factors including NF-
κB and MAP kinases resulting in the production of cytokines including type I (e.g. IFN-α 
and IFN-β) and II interferons (i.e. IFN-γ), IL-6 and TNF-α (Akira et al., 2006; Girvan et al., 
2010; Inohara et al., 2000; Magalhaes et al., 2011). Typically, acute activation of PRR 
causes a strong inflammatory response that is associated with the clearance of bacterial and 
viral pathogens (Meylan et al., 2006; Siamon, 2002). However, under certain 
circumstances such as robust or chronic activation PRR responses can act in an 
immunomodulatory manner (Marta et al., 2009; Vaknin et al., 2008). 
 
                                                 
3
 Compassionate use refers to the permitted use of an unapproved experimental medicine when prescribed by 
a medical practitioner under sections 25 and 29 of the NZ medicines Act 1989.  
(for more details: http://www.medsafe.govt.nz/profs/RIss/unapp.asp) 
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Activation of PRR has been both implicated in the development and pathogenesis, as well 
as, the regulation of EAE (Carty et al., 2011; Fernandez et al., 2010; Miranda-Hernandez 
et al., 2011; Shaw et al., 2011; Waldner, 2009). Signalling through PRRs such as the TLRs 
is necessary for the active induction of EAE, but what role TLR receptors have is 
modifying disease responses is less clear (Marta et al., 2008). Depending on the EAE 
induction protocols TLR9 deficiency can exacerbate or reduce disease severity, and a 
recent study has found NOD2 deficient mice are resistant to EAE (Marta et al., 2008; Prinz 
et al., 2006; Shaw et al., 2011). However, multiple studies have demonstrated that 
administration of TLR ligands (such as TLR7 or TLR3) have a protective effect in EAE 
(Hayashi et al., 2009; O'Brien et al., 2010; Touil et al., 2006). Collectively this research 
suggests that PRR signalling, when used in the right context, could provide a potential 
method for modifying disease response.  
 
MIS416 microparticles have a unique structure that incorprates TLR9 and NOD2 agonists 
while being devoid of other bacterial factors (Girvan et al., 2010). MIS416 was 
specifically designed to induce innate immune responses while limiting local and systemic 
toxicity (Girvan et al., 2010). Therefore, activation of PRR by MIS416 could provide a 
safe and effective way to modulate inflammatory immune responses. 
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7.2 Aims and Objectives  
The current chapter explores the potential of MIS416 as a treatment for EAE and identifies 
effective dosing regimes with which to administer this compound. Cytokine levels within 
the blood were measured to determine if MIS416 causes systemic alterations in 
inflammatory mediators. Preliminary studies were also conducted to identify if changes to 
the cytokine environment contributed to the MIS416 mechanism of action.    
7.2.1 Specific Aims:  
1. To identify if MIS416 is effective at modifying EAE 
2. To determine if MIS416 modifies cytokine production and how any 
modification contributes to its mechanism of action  
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7.3 Results 
7.3.1 Administration of MIS416 on the day of immunisation reduces EAE disease 
severity and alters cytokine production  
To determine if MIS416 has any effect on the development of EAE, 250 µg of MIS416 
was administered i.v. to mice either 3 days prior to or immediately before immunisation. 
This dose and administration route was chosen for the initial experiments as 250 µg i.v. 
had been found to be well tolerated in unimmunised mice (personal communication; Gill 
Webster, Innate Immunotherapeutics). Administration of MIS416 on the day of 
immunisation (d0 p.i.) resulted in a delay in disease onset and a reduction in disease 
severity (Figure 7.1a). Treatment on d0 p.i. with MIS416 also inhibited the weight loss 
observed in the untreated mice (Figure 7.1b). In contrast to d0 MIS416 treatment, mice 
injected with MIS416 3 days prior to immunisation (d-3 p.i.) exhibited no difference in 
disease expression or weight change compared to untreated mice (Figure 7.1 a and b). 
These results suggest that a single dose of MIS416 administered on the day of 
immunisation is effective at reducing EAE. 
   
To investigate if MIS416 treatment altered the levels of serum cytokines, blood samples 
were taken from the mice at multiple time points throughout the duration of the experiment 
and analysed for IL-1β, IL-2, IL-4, IL-5, IL-6, GM-CSF, TNFα, IL-10, IL-17, IFN-γ and 
TNF-α. Of the 10 cytokines measured, only those showing differences (IFN-γ and IL-6) 
have been included in the analysis (Figure 7.2). It can clearly be seen that MIS416 induces 
production of IFN-γ when administered either on d-3 or on d0 p.i. (Figure 7.2a). However 
the kinetics of expression is different between the treatment groups with mice that were 
administered MIS416 on d0 p.i. having delayed peak expression of IFN-γ compared to 
MIS416 d-3 p.i. treated mice.  A similar effect was observed for IL-6 production with peak 
concentrations occurring at day 0 for d-3 p.i. MIS416 treated mice compared to day 8 for 
d0 p.i. treated mice (Figure 7.2b).  Overall the cytokine analysis indicates that MIS416 
treatment induces a select but systemic cytokine response that peaks within 4-8 days post 
injection of MIS416. 
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Figure 7.1 MIS416 reduces EAE severity when administered on d0 p.i. 
C57BL/6 mice were immunised for EAE and injected i.v. with 250 µl saline vehicle (untreated) or 
with 250 µg of MIS416 either 3 days before immunisation (d-3), or on the day of immunisation 
(d0). (a) Disease score of all mice. (b) % weight change; calculated as % change of individual mice 
from d0. Data represents two experiments (n = 12-16 mice/group). Any mice that died were 
excluded from the analysis. 
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Figure 7.2 MIS416 increases serum IFN-γ and IL-6 levels  
C57BL/6 mice were immunised for EAE and left untreated or were treated with 250 µg MIS416 
either 3 days before immunisation (d-3), or on the day of immunisation (d0). Blood samples were 
taken on indicated days and cytokines within the serum of individual mice were analysed by 
CBA. (a) serum INF-γ and (b) serum IL-6 concentrations. Data represents two experiments (n = 
12-16 mice/group). *p < 0.05, **p < 0.01 or ***p < 0.001 compared to immunised untreated 
mice, by Kruskal-Wallis test with Dunn’s post hoc analysis.  
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7.3.2 Administration of MIS416 at disease onset reduces EAE disease severity  
To identify if MIS416 treatment would be effective if administered during or after disease 
onset a single 250 µg dose of MIS416 was injected on either d12 or d20 p.i., respectively. 
Two days after administration of MIS416 at d12 p.i. disease symptom within these mice 
began to plateau and continued to exhibit a milder disease expression throughout the 
experiment, when compared to the untreated mice (Figure 7.3).  However within 24 hours 
of the d12 p.i. MIS416 injection, 40% of the mice died (data not shown). A similar toxicity 
was observed in mice injected on d20 p.i., with 20% mortality occuring (data not shown). 
At either of the treatment time points the mice that survived exhibited no obvious toxicity, 
distress or weight loss (data not shown). No alteration in disease expression occurred in 
mice treated at d20 p.i., indicating that a single dose of MIS416 is effective during onset 
but not during the chronic phase of disease expression.  
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Figure 7.3 MIS416 reduces disease severity when administered on d12 p.i. but not d20 p.i.   
C57BL/6 mice were immunised for EAE and left untreated or were treated with 250 µg MIS416 
either 12 days after immunisation (d12) or 20 days after immunisation (d20). Data represents 
disease score of all live mice from one experiment (n = 3-5 mice/group). Any mice that died were 
excluded from the analysis. 
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7.3.3 Weekly administration of MIS416 reduces EAE disease severity and alters 
cytokine production 
As it appeared that 250 µg could be toxic if given during disease onset an alternate dosing 
strategy was employed. Mice were injected weekly with a lower dose of 100 µg beginning 
at d0 p.i.. This approach proved to be an effective dosing strategy that resulted in long term 
reduction in disease severity (Figure 7.4a). Although one mouse died on d15 this appeared 
to be an isolated incidence as toxicity was not observed in any other mice (data not shown). 
Additionally subsequent studies using this treatment regime, to chronically treat over 30 
mice, has not caused any mortality (personal communication; Anne La Flamme). 
Interestingly it appears that following MIS416 injection mice responded rapidly to the 
effects of MIS416 resulting in reduced disease scores. However this effect was transient as 
within 4-5 days post treatment, disease scores would often begin to increase. This trend 
can also be observed in the weight change of MIS416 treated mice (Figure 7.4b). These 
results suggest that MIS416, when administered at 100 µg, causes only a temporary 
alteration in diseases response and requires regular administration to effectively reduce 
disease burden.          
 
To determine if repeated administration of lower doses of MIS416 altered serum cytokines, 
blood was collected 1 day post MIS416 treatment at various points over the duration of the 
experiment. Analysis of serum cytokines indicated that IFN-γ production was significantly 
higher in MIS416 treated mice on d15 and d22 p.i.; however, by d65 p.i. no significant 
difference IFN-γ production was detected (Figure 7.5a). Within MIS416 treated mice, IL-
6 production appeared higher at all 4 time points measured, however only d15 reached 
statistical significance (Figure 7.5b). 
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Figure 7.4 MIS416 Reduces disease severity when administered weekly at a low dose  
C57BL/6 mice were immunised for EAE and left untreated or were treated with one dose of 
100 µg MIS416 every 7 days for the duration of the experiment (dashed lines). (a) Disease 
score of sick mice and (b) % weight change; calculated as % change of individual mice from 
d0. Data represents one of two identical experiments (n = 4 mice/group). Any mice that died 
were excluded from the analysis. 
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Figure 7.5 Weekly low dose MIS416 increases serum IFN-γ during disease onset   
C57BL/6 mice were immunised for EAE and left untreated or were treated with one dose of 100 µg 
MIS416 every 7 days for the duration of the experiment (dashed lines). Blood samples were taken on 
days 0, 8, 15, 22 and 65 p.i. and cytokines within the serum of individual mice were analysed by CBA. 
(a) serum IFN-γ and (b) serum IL-6 concentrations. Data represents one of two identical experiments (n 
= 4 mice/group).*p < 0.05 compared to immunised untreated mice, by a Mann Whitney test.  
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7.3.4 IFN-γ signalling is necessary for MIS416 induced disease modification 
As large increases in IFN-γ were detected within the serum of MIS416 treated mice during 
disease onset, it was speculated that this increase could be associated with the disease 
modifying effects of MIS416. To investigate if IFN-γ had a role in MIS416 disease 
protection, IFN-γ was depleted during the induction phase of EAE. To do this, groups of 
mice were treated with MIS416 on d0 p.i. or left untreated, then on day 3 and 7 p.i. mice 
were either injected with an anti-IFN-γ antibody (clone: AN18) or an equal concentration 
of non-specific rat-IgG.  
 
Disease symptoms and peak disease severity within untreated AN18-injected mice 
developed earlier than other treatment groups, indicating that AN18 treatment was altering 
disease expression (Figure 7.6). In comparison MIS416-treated, AN18-injected mice had a 
reduced disease course. Unfortunately within this experiment, administration of MIS416 
on d0 p.i. did not result in a reduction in disease expression in mice not receiving AN18 
making it difficult to ascertain if administration of AN18 had any effect on MIS416 
disease modifying activity. Interestingly when IFN-γ production in the serum was analysed 
very high levels of IFN-γ were detected in both AN18 treated groups (Figure 7.7). 
Whether these high levels of IFN-γ were the result of increased cytokine production (due 
to a lack of negative feedback) or the result of AN18 inhibiting IFN-γ receptor binding 
(thus inhibiting cellular uptake) is not known.    
 
To overcome the potential confounding factors that occurred with antibody depletion of 
IFN-γ, an alternative strategy using IFN-γ-deficient mice was used to explore the potential 
role of IFN-γ in MIS416-induced disease modification. Additionally, as the d0 p.i. 
treatment had been unsuccessful in the previous experiment, the more effective weekly 
dosing schedule of 100 µg MIS416 was used to ensure effective disease modification. This 
treatment resulted in a typical reduction in disease severity within WT mice compared to 
untreated mice (Figure 7.8). In contrast, IFN-γ-deficient mice treated with MIS416 
developed severe disease similar to that of untreated IFN-γ-deficient mice (Figure 7.8). 
This result indicates that IFN-γ is necessary for effective disease modification.    
Chapter 7: Using MIS416 to treat EAE                                                                             165 
0 5 10 15 20 25
0
1
2
3
4
5
Untreated + IgG
Untreated + AN18
MIS416 (d0) + IgG
MIS416 (d0) + AN18
Days
D
is
e
a
s
e
 s
c
o
re
Figure 7.6 Administration of anti-IFN-γ antibody does not alter the disease course in MIS416 
treated mice  
C57BL/6 mice were immunised for EAE and left untreated or were treated with 250 µg MIS416 on 
the day of immunisation (d0). Mice were injected with either 200µg anti-IFN-γ (AN18) or a non 
specific rat IgG (IgG) on days 4 and 7. (a) Disease score of sick mice. Data represents one 
experiment (n = 5 mice/group). 
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Figure 7.7 Administration of anti-IFN-γ antibodies causes increased detection of IFNγ  
C57BL/6 mice were immunised for EAE and left untreated or were treated with 250 µg MIS416 on 
the day of immunisation (d0). Mice were injected with either 200µg anti-IFN-γ (AN18) or a non-
specific rat IgG (IgG) on days 3 and 7. Blood samples were taken and on indicated days and IFN-γ 
concentrations within pooled serum of mice from each group was determined by CBA. Data 
represents one experiment (n = 5 mice/group). 
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Figure 7.8 MIS416 does not reduce disease severity in IFN-γ deficient mice 
C57BL/6 or C57BL/6-ifngtm1Ts (IFN-γ deficient) mice were immunised for EAE and left untreated or 
were treated with one dose of 100 µg MIS416 every 7 days for the duration of the experiment (dashed 
lines). Data represents one experiment (n = 4-5 mice/group). 
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7.4 Discussion 
This pilot study was conducted to determine if MIS416, a promising new MS therapeutic, 
was able to modify disease in the EAE model of MS and accordingly identify if the EAE 
model could be used to understand the mechanism by which MIS416 is protective. The 
results from the current study indicate that MIS416 effectively reduces disease severity 
when administered immediately before EAE immunisation or during disease onset. 
Furthermore, the disease modifying effects of MIS416 appear to be related to IFN-γ as 
MIS416 failed to protect IFN-γ deficient mice from normal disease development. Thus, 
EAE proved to be a valuable tool to further study MIS416 and to investigate potential 
mechanisms of action.  
 
Analysis of cytokines from d-3 and d0 p.i. treated mice revealed that MIS416 induced 
increased secretion of IL-6 and IFN-γ. Elevations in these cytokines indicate that MIS416 
was inducing a characteristic inflammatory response, as is observed after TLR9 or NOD2 
signalling (Girvan et al., 2010; Magalhaes et al., 2011). A difference in the kinetics of 
cytokine production occurred between the d-3 and d0 p.i. treatment groups, with peak 
levels of IL-6 and IFN-γ occurring at d0 and d8 respectively. Given disease protection was 
observed in the d0 but not d-3 p.i. treated mice, it was speculated that the peak in cytokine 
production at d8 and the sustained IFN-γ at d16 p.i. might be associated with disease 
protection in d0 MIS416 treated mice, as these time points coincided with the induction 
phase of the disease process. 
 
Most of the literature investigating the role of IL-6 in the context of EAE has implicated 
this cytokine in the disease process (Mendel et al., 1998; Okuda et al., 1999; Serada et al., 
2008). In contrast, IFN-γ has been demonstrated to have a paradoxical role in immune 
regulation, despite its classical pro-inflammatory actions (Zhang, 2007). Therefore, it was 
considered more likely that IFN-γ rather than IL-6 would be associated with the protective 
effects of MIS416. Indeed when IFN-γ deficient mice were injected once a week with 100 
µg of MIS416 no protection in disease expression was observed despite this treatment 
regime inducing a substantial reduction in disease severity in IFN-γ sufficient WT mice. 
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This result clearly indicates that IFN-γ is necessary factor in MIS416-induced disease 
protection.  
 
Although IFN-γ-producing Th1 cell have typically been associated with EAE disease 
process, a regulatory role for IFN-γ in EAE is also evident. It is well documented EAE is 
exacerbated in either IFN-γ-deficient and IFN-γ receptor-deficient mice (Billiau et al., 
1988; Ferber et al., 1996b; Sabatino et al., 2008). IFN-γ is also protective in EAE when 
exogenous IFN-γ is administered or if endogenous IFN-γ production is enhanced (Furlan et 
al., 2001; Gran et al., 2004; Voorthuis et al., 1990). Additionally, it has been demonstrated 
that certain myelin antigens, which are poorly encphalogenic, inhibit disease expression 
due to the induction of high levels of IFN-γ (Minguela et al., 2007; Sabatino et al., 2008). 
Collectively, these studies highlight the potential regulatory role IFN-γ can have on EAE 
disease expression. 
 
There are many potential ways IFN-γ could induce regulatory processes or protective 
effects in EAE. IFN-γ can induce macrophages and microglia to secrete T cell anti-
proliferative or pro-apoptotic factors, for example through up-regulation of iNOS or IDO 
production (Kwidzinski et al., 2005; Willenborg et al., 1999). Sustained levels of IFN-γ 
can also directly reduce T cell reactivity though alteration of receptor expression 
(Bronstein-Sitton et al., 2003) IFN-γ production may also counter regulate Th17 response 
resulting in a biasing of encephalogenic responses towards Th1 (Berghmans et al., 2011; 
Murphy et al., 2010). Attenuation of tissue destruction can also be induced though IFN-γ 
mediated down-regulation of MMP production (Ho et al., 2008; Hu et al., 2009). It is 
conceivable that one or multiple IFN-γ-induced regulatory mechanisms are associated with 
MIS416 disease modifying effects. 
 
In contrast to the conclusive results observed with IFN-γ-deficient mice, antibody 
depletion of IFN-γ failed to provide any definitive results. This failure is likely due to two 
confounding factors that are discussed below; 1) the lack of disease protection normally 
induced by MIS416 treatment and 2) the possibility that administration of AN18 (anti-IFN-
γ antibody) did not effectively deplete IFN-γ. 
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In the experiment using AN18, MIS416 was administered as a single 250 µg dose at d0 p.i. 
and uncharacteristically, no protection from disease was observed. Interestingly, however, 
the levels of IFN-γ in MS416 treated mice peaked early (at d4 p.i.) and returned to basal 
levels by d8 p.i. (Figure 7.7), which is in contrast to the previous experiments, that 
demonstrated MIS416 administered on d0 p.i. caused a sustained elevations in IFN-γ until 
d16 p.i. (Figure 7.2). It is possible that the lack of disease protection could be related to 
the alteration in IFN-γ concentration kinetics observed in this particular experiment.   
 
A slight delay in disease onset did however occur in MIS416 treated AN18 injected mice 
when compared to AN18 injected-untreated mice. A substantial increase in IFN-γ was 
detected in AN18 treatment groups particularly in MIS416 treated mice. It was not 
determined if these increases were due exclusively to AN18 bound IFN-γ or if unbound 
IFN-γ also contributed to the measured increase. Given the high levels of IFN-γ detected in 
AN18-injected mice, there is the potential that the binding capacity of AN18 to IFN-γ 
became saturated and thus unbound IFN-γ was present. Previous studies that have used 
anti-IFN-γ antibody in the context of EAE have used higher concentration of antibody (i.e. 
500 µg – 2mg per mouse) to achieve IFN-γ depletion (Duong et al., 1994b; Espejo et al., 
2001; Voorthuis et al., 1990). Therefore, it is possible that the 250 µg dose used in the 
current study was not large enough to fully deplete IFN-γ. If unbound IFN-γ was present, it 
is possible that the slight delay in disease expression of MIS416 treated AN18 injected 
mice could be due to the increased levels of IFN-γ. Collectively, these results indicate that 
antibody depletion of IFN-γ, using this protocol, cannot provide an accurate indication of 
the role IFN-γ has in MIS416 disease modifying effects. Despite this, given the results 
within IFN-γ deficient mice, it can be concluded that IFN-γ signalling is necessary for the 
disease suppression induced by MIS416. 
 
When 250 µg MIS416 was administered at d12 p.i. 40% of the mice died while the same 
dose, administered at d20 p.i. 20% of mice died. In contrast, mice administration of 250 µg 
MIS416 on d0 p.i. was well tolerated. This may suggest that the toxicity observed at d12p.i. 
and d20 p.i. was related to EAE disease kinetics and is supported by a previous study 
demonstrating that MIS416 is well tolerated in mice with no clinical abnormalities or 
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mortality being observed in doses as high as 900 µg (Girvan et al., 2010). It is likely that 
the toxicity observed following EAE immunisation was due to the combination of EAE 
induced inflammatory response and the induction of cytokine production by MIS416, 
which may have resulted in a ‘cytokine storm’ and systemic shock. Such an amplified 
response could be due to cytokine priming which results in enhanced TLR signal 
transduction increased TLR expression as well as inactivation of feedback inhibition 
pathways (Hu et al., 2009). The observed toxicity indicates that high doses (i.e. 250 µg) of 
MIS416 should not be administered during EAE onset. 
 
Administration of 100µg MIS416 every 7 days proved an effective and well tolerated 
treatment regime, which resulted in reduced disease scores sustained over the duration of 
the experiment. When looking at the disease score of MIS416-treated mice in relation to 
the timing of the weekly dosing an interesting trend appears that is particularly apparent in 
the chronic phase of disease (d40-d65 p.i.). Within a day or two after MIS416 
administration average disease scores of treated mice reduced or plateaued, while in the 
days proceeding the subsequent treatment disease scores began to increase. This pattern 
indicates a number of things: 1) MIS416 is having an active role in disease suppression 
even during the chronic phase of disease, 2) the disease modifying effects of MIS416 are 
rapidly induced, and 3) the disease modifying effects of a 100µg dose of MIS416 are 
transient and begin to diminish within 4-5 days of administration.  
 
It also appears that the effects of MIS416 are most pronounced during the earlier stages of 
disease. This time in the disease process is when increased IFN-γ levels were detected. As 
IFN-γ was demonstrated to have a role in MIS416 mechanism of action, it is conceivable 
that the dramatic suppression of disease following the administration of MIS416 on d14 p.i. 
is correlated to the large increase of IFN-γ detected within the serum of MIS416 treated 
mice on d15 p.i. If the large increase in IFN-γ induced by MIS416 is correlated to the 
disease suppression during the early stages of disease, it is interesting to note that no 
increase in IFN-γ was detected in the serum of MIS416 treated mice by d65 p.i. This may 
indicate that during the chronic phases of disease, the effects of MIS416 on disease are not 
dependent on IFN-γ but some other factor. Alternatively, it is possible that only low levels 
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of IFN-γ are induced during the chronic phase of disease, thus no systemic increase (i.e. 
within the blood) would be detectable.  
 
A potential disease modifying factor that was not explored in this pilot study is the 
production of type I interferons. Previous studies have shown TLRs and specifically  
MIS416 can induce type I interferon production (Girvan et al., 2010; O'Brien et al., 2010; 
Touil et al., 2006). Administration or production of IFN-β (a type I interferon) can reduce 
EAE severity (Floris et al., 2002; Galligan et al., 2010; Yu et al., 1996). Additionally there 
can be considerable cross talk between type I and type II interferon signalling pathways as 
IFN-γ can induce type I secretion and vice versa (Schroder et al., 2004). Interestingly a 
recent study found that the disease modifying effects of IFN-β were dependent on IFN-γ 
signalling (Axtell et al., 2010). Collectively these results suggest that some of the disease 
modifying effects induced by MIS416 could be mediated through IFN-β production, and 
any future studies into the effect of MIS416 in EAE should explore this possibility.     
 
7.5 Summary  
The current study has demonstrated that MIS416 is effective for the treatment of EAE and 
has provided evidence for the function of IFN-γ in MIS416 disease modification. How 
IFN-γ might mediate these effects and if other soluble factors are involved in this process 
remains to be determined. Additionally the effects of MIS416 on cellularity and CNS 
pathology needs to be explored in future experiments. Overall, the finding from the current 
study provides a useful foundation from which further in-depth studies can be conducted.    
 
 
  
 
 
 
Chapter 8:  
General Discussion 
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8.1 Overview 
Based on the work conducted in this thesis a set of hypothesised mechanisms with which 
MSDs, risperidone and MIS416 could alter EAE disease expression have been summarised 
below (Figure 8.1). A more in-depth discussion of the main findings from this thesis, the 
potential clinical implications, and possible future directions are addressed individually for 
each drug in the rest of this chapter. 
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Figure 8.1 How MSDs risperidone or MIS416 could potentially alter the EAE disease pathogenesis  
Following immunisation for EAE antigen presenting cells (APCs) within the draining LN present the myelin 
antigen (eg. MOG) along with co-stimulatory molecules to naïve T cells. Once activated these autoreactive T 
cells release inflammatory cytokines, proliferate, and migrate to the spleen or to the CNS. Following further 
encounters with APCs, autoreactive T cells within the spleen release inflammatory cytokines and proliferate, 
further amplifying the inflammatory process. Autoreactive T cells from the spleen and LN migrate across the 
blood brain barrier (BBB), and encounter myelin antigens presented within the CNS by resident microglia or 
infiltrating APCs. This process leads to the induction of a CNS based inflammatory response and subsequent 
damage to myelin. Shown are hypothesised mechanisms with which MSDs, risperidone or MIS416, could 
alter disease pathogenesis, based on the research within this thesis.       
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8.2 Microtubule-stabilising drugs 
8.2.1 Summary 
The current study demonstrated that MSDs are capable of delaying EAE onset and altering 
disease progression although high concentrations and prolonged exposure were necessary 
for MSDs to be effective. All three MSD compounds tested (PTX, DTX and IXB) 
exhibited disease modifying activity, suggesting that a common underlying mechanism of 
action may be responsible for these effects. Explorations into possible mechanisms of 
action found that PTX both inhibited immune cell proliferation as well as CNS infiltration. 
The relative contribution of these two factors in the overall disease modifying effect may 
be dependent on the timing of administration, with the anti-proliferative actions of PTX 
having a more significant role in early treatment; while the effects of PTX treatment at 
later time points may be more dependent on inhibition of immune cell migration. Finally, 
studies into potential synergy revealed that a combination of the MSDs, Pel A and IXB can 
act synergistically to inhibit EAE; as can PTX when combined with the commonly used 
MS drug, GA.  
 
8.2.2 Clinical implications  
In 2002, a Phase II clinical trial tested the efficacy of PTX for the treatment of secondary 
progressive MS. Patients in this trial were administered either a placebo or 50 mg/m
2
 PTX 
(1 dose/month for 6 months) (Angiotech-Pharmaceuticals, 2002). No significant reduction 
in disease parameters was observed between the treatment and placebo groups. Given the 
results from the current study, it is not surprising that PTX when administered 1 
dose/month had little effect on disease. In the current study efficacy of MSD for the 
treatment of EAE was only exhibited when MSDs were administered at high doses over a 
number of days. To translate these disease modifying effects into a clinical setting, 
administration of PTX, or any other MSD, would have to be prolonged either by using a 
multi-day infusion or administering multiple doses in close temporal proximity. A high 
dose prolonged exposure treatment is a feasible option, as 96 hour infusions of 140 mg/m
2
 
PTX are already used for treatment of metastatic cancers (Moulder et al., 2010; West et al., 
2005). Likewise a phase I clinical trial has demonstrated that a continuous 10 day infusion 
of  21 mg/m
2
/day  can be administered safely (Shade et al., 1998). As a 20 mg/kg dose in 
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mice roughly equates to a 60 mg/m
2
 within humans, the dose and treatment regimes used 
within the current study are applicable to a clinical setting (Denardo et al., 1997).  
 
In the current study, IXB was found to exhibit a small therapeutic advantage in modifying 
EAE expression over PTX or DTX. Therefore, if future clinical trials were to explore the 
use of MSDs to treat MS, IXB may prove most beneficial. Additionally, the finding that 
combined administration of Pel A and IXB results in a synergistic inhibition of EAE 
highlights the potential for enhancing therapeutic effects of MSDs though synergistic 
combinations. Although toxicity was observed in some mice treated with synergistic doses 
of Pel A and IXB, this toxicity is likely to be related to an interaction with EAE specific 
disease processes. Previous research has demonstrated that EAE immunised mice are 
acutely more sensitive to MSD induced toxicity than unimmunised mice (Crume et al., 
2009). Therefore, it is conceivable that the toxicity observed in some mice treated with 
synergistic combinations of Pel A and IXB may only occur in the context of EAE. 
However, the possibility that this toxicity could also occur if used clinically to treat MS 
cannot be discounted. Therefore, further experimentation into the exact cause of toxicity or 
identification of less toxic synergistic combinations of MSDs is necessary, before 
considering using such a treatment in a clinical setting. 
 
Assuming further research does indicate that the toxicity observed in the current study was 
is specific to the context of EAE, synergistic combinations of Pel A and IXB in a clinical 
setting may prove effective for either treating MS or for use as a cancer chemotherapeutic. 
Although the current study has demonstrated the synergistic effects of Pel A and IXB only 
within EAE, the benefits of this treatment regime are also relevant to cancer research. Most 
MSD based cancer chemotherapies have been developed based on their anti-proliferative 
actions. The current study has demonstrated that the disease modifying actions of MSDs in 
EAE are likely to be caused by inhibition of migration and proliferation. Inhibition of 
tumour growth and metastasis presumably also occurs though these same mechanisms. 
 
A limiting factor in the development of Pel A as a clinical chemotherapeutic is the supply 
of Pel A at the quantities needed (personal communication, John H Miller). The impact of 
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this limitation could be partially resolved if Pel A were used in a synergistic combination 
with IXB; as the total amount of Pel A required would be reduced. Additionally if Pel A 
has the potential to provide benefits in two diseases, there is a greater likelihood that the 
necessary funding could be obtained to synthesise clinically relevant quantities of Pel A.   
 
The most practical and effective way to use MSDs as a treatment for MS may be to 
administer a MSD as a brief pulse (eg a high dose over 3 days), then follow this treatment 
with a chronically administered immune modulating drug such as GA. The current study 
demonstrated that treating mice with PTX followed by a week of GA treatment proved to 
be effective at limiting long-term disease severity even though both PTX and GA were 
only administered for a short period of time. A number of preliminary clinical studies on 
relapsing-remitting MS patents have shown that mitoxantrone followed by GA treatment is 
more effective than either treatment alone (Arnold et al., 2008; Ramtahal et al., 2006; 
Vollmer et al., 2008). In fact this combined treatment has recently been patented by the 
makers of GA, indicating a perceived potential of this treatment
4
. However, as 
mitoxantrone has a maximal lifetime dose and causes considerable and irreversible side 
effects, the use of this combination is likely to be limited (Neuhaus et al., 2006). Given the 
combined effects of PTX and GA in altering EAE disease expression observed in the 
current study, further experiments into the efficacy of these compounds in combination 
may provide an effective treatment alternative. 
 
8.2.3 Future directions 
The current study identified that inhibition of immune cell migration and proliferation 
occurs following in vivo administration of PTX. To what extent each of these two 
mechanisms of actions contributes to alterations in the EAE disease response remains to be 
determined. Treatment with PTX immediately after immunisation inhibited immune cell 
proliferation and subsequently also inhibited encephalogenic T cell responses, indicating 
that the anti-mitotic actions of a MSD has a crucial role inhibiting the disease process 
when administered immediately after immunisation. The importance of these anti-mitotic 
                                                 
4
 http://www.freepatentsonline.com/7968511.html 
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actions, when drug is administered at a later time point, is not so clear. To identify 
specifically if MSDs are still inhibiting immune cell proliferation when administered at 
later time points in the disease process an experiment using BrdU incorporation could be 
conducted. BrdU incorporates into the DNA of dividing cells and can be detected by flow 
cytometry. Therefore, pulsing mice with BrdU at times points of interest (eg. d6-12 p.i.) 
would provide a snapshot of any cell proliferation occurring. MSD treated and untreated 
mice could then be compared to specifically identify differences in proliferation.      
  
Immune cell proliferation was found to be completely inhibited in the spleens and blood 
but only attenuated in the dLN of PTX-treated mice. This result is likely to indicate that 
higher concentrations of PTX are achieved in the spleen and blood compared to the dLN. 
To test this hypothesis, HPLC could be used to measure specific concentrations of PTX 
within the different tissues. Alternatively, fluorescently labelled PTX (eg. Flutax) could be 
administered to mice and the florescent intensity within the different tissue could be used 
as a relative indicator of of PTX distribution. 
 
Adoptive transfer experiments may prove valuable in teasing out the specific mechanisms 
by which MSDs inhibit disease expression. Induction of passive EAE could be compared 
between mice that received adoptively transferred T cells isolated from MSD-treated 
immunised mice and those that received T cells from immunised, untreated mice. If T cells 
from MSD-treated, immunised mice induced the same EAE disease response as T cells 
from immunised, untreated mice, it could be concluded that alterations in T cell 
encephalitogenic responses were not the cause of the disease modification by MSDs. 
Additionally this result would support the hypothesis that inhibition of migration is a more 
important factor in MSD disease modification than reduced proliferation of T cells. 
 
Although the current study demonstrated that in vivo administration of PTX inhibited 
immune cell migration, it still remains to be determined how this inhibition is occurring 
specifically. This question could be investigated directly in vivo using two photon 
microscopy (Kreisel et al., 2010; Matheu et al., 2011). Alternately, changes in migratory 
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ability could be indirectly analysed by isolation of macrophages or T cells following in 
vivo MSD administration and exploring migratory capacity using ex vivo migration assays.  
 
The current study is the first to demonstrate the potential for using MSDs in synergistic 
combinations to treatment an inflammatory disease. Further research should be conducted 
to investigate potential synergy between combinations of Pel A and IXB to identify if 
lower doses can be as effective without inducing toxicity. Additionally it would be 
interesting to explore the potential of these synergistic combinations as a treatment for 
other MSD-responsive diseases, such as cancer and vascular restinosis (Scheller et al., 
2006; Tepe et al., 2008). The current study also demonstrated the exciting potential of 
using MSDs to enhance the disease modifying effects of GA. The use of MSDs in 
combination with immune modulating drugs, such as GA, should be explored further. 
Optimisation of a combined MSD and GA treatment could be conducted, as well as 
exploring the potential of MSDs to enhance other currently used MS therapeutics.   
 
8.3 Risperidone  
8.3.1 Summary 
The current study demonstrated that risperidone could reduce EAE disease burden and 
severity when administered daily at a clinically relevant dose. The reduction in disease 
severity was accompanied by increased proportion of splenic CD4
+
 T cells and increased 
splenocyte antigen-specific IFN-γ production. Additionally, risperidone treatment of 
stimulated bone marrow-derived macrophages resulted in a reduction in IL-12, an increase 
in IL-10 cytokine production, as well as reduced expression of the co-stimulatory molecule 
CD40. These findings indicate that risperidone can induce an anti-inflammatory phenotype 
within in vitro cultured macrophages. Collectively the results from these experiments 
indicate that risperidone can alter inflammatory immune responses and highlight the 
potential value of developing risperidone as a treatment for MS.   
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8.3.2 Clinical implications 
The current study demonstrated that risperidone reduces EAE disease severity and raised 
the interesting possibility that this antipsychotic could be used to treat an inflammatory 
disease such as MS. Accounting for differences in pharmacokinetics between mice and 
humans the effective concentrations with which risperidone attenuated EAE in the current 
study is comparable to doses currently used clinically for the treatment of schizophrenia 
(Kapur et al., 2003; Karl et al., 2006; Naiker et al., 2006).  At these concentrations, 
risperidone is well tolerated and side effects relatively minor.  
 
Assuming the immunomodulating effects of risperidone in EAE translate into similar 
effects within MS, there is potential that risperidone could be beneficial if co-administered 
with the current MS treatment, natalizumab. One of the limitations of natalizumab therapy 
as an MS treatment is the increased risk of lethal progressive multifocal 
leukoencephalopathy (PML) (Chaudhuri, 2005; Tan et al., 2010). PML is caused by the JC 
virus, and there is evidence suggesting that this virus infects neural cells via the 5-HT2a 
receptor and inhibiting these receptors may reduce JCV infection (Elphick et al., 2004; 
Maginnis et al., 2010). There is, however, still some debate as to the specificity of this 
infection route, as non-5-HT2a expressing cells also can be infected with the virus in vitro 
(Chapagain et al., 2007). Despite this caveat, studies have shown that 5-HT2a receptor 
antagonists, including risperidone, can reduce or inhibit JCV infection although the effect 
may be strain dependent (Chapagain et al., 2008; Elphick et al., 2004; Nukuzuma et al., 
2009; O'Hara et al., 2008). There are also case reports of patients recovering from PML 
following risperidone treatment (Focosi et al., 2007; Kast et al., 2007). While case reports 
cannot provide a causal link between risperidone treatment and recovery from PML, 
combined with cell-based studies, these reports raise an interesting possibility that 
risperidone may confer some benefit in reducing JCV infection. If risperidone can reduce 
JVC infection, co-administration of natalizumab with risperidone may have an additive or 
synergistic effect at reducing MS disease symptoms with the additional benefit of reducing 
chances of contracting PML. 
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Risperidone can be administered orally or though slow release depot injections and has far 
less severe side effects than all currently available MS treatments. Indeed studies in healthy 
individuals, that do not suffer from any mental illness, have shown the most common side 
effects from acute administration of risperidone (drowsiness or headaches) are relatively 
minor (Artaloytia et al., 2006; Van Schaick et al., 2003). Collectively, it appears that 
risperidone is relatively well tolerated both within healthy individuals and when used as an 
antipsychotic (Artaloytia et al., 2006; Belotto et al., 2010; Corbeil et al., 2011; Leucht et 
al., 1999; Van Schaick et al., 2003). Given risperidone has been used clinically as an 
antipsychotic for a number of years, the dosing, safety, and side effects are well understood. 
These factors could allow a relatively quick approval process for the use of risperidone as a 
treatment of MS if clinical trials were successful. This combination of factors suggests 
further investigation into the therapeutic potential of risperidone as a treatment for MS is 
merited. 
8.3.3 Future directions   
To identify the specific mechanisms by which risperidone alters macrophage activation, 
the effect of neurotransmitter receptor antagonism by risperidone should be explore; as this 
is the most likely explanation for risperidone’s effects. These studies could be conducted 
though the use of receptor specific agonists (ie. to competitively alter risperidone’s 
antagonistic effects) or though receptor specific antagonists to identify specific receptor 
activity. Alternately identification of alterations in intracellular signalling, such as cAMP, 
which could be initiated or inhibited when particular receptors are antagonised may 
provide insight into risperidone’s mechanism of action.  
 
It was not determined if the alteration in macrophage phenotype induced by risperidone is 
stable in the absence of risperidone. This effect could be easy clarified by identifying if 
phenotypic changes persist after risperidone is washed out from the cultures. Additionally 
co-culture of macrophages with stimulated T cells could provide insight into whether 
risperidone-treated macrophages had a regulatory effect on T cells. To ascertain if in vitro 
risperidone-treated macrophages had regulatory effects in vivo, cultured risperidone-treated 
macrophages could be injected into EAE immunised mice to identify if they alter disease 
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expression. Any further research should also explore whether similar effects occur in 
human-derived macrophage cultures.  
 
Assuming risperidone’s effects on in vitro microglial and macrophages cultures occurs in 
vivo, it is likely the altered phenotype of microglia and macrophages would lead to a 
reduction in chronic CNS inflammation. Therefore, further studies should explore potential 
phenotypic changes of macrophages and microglia that occur following in vivo risperidone 
administration, and whether these changes result in altered cellular composition of CNS 
lesions or inhibition of myelin destruction. These studies could be conducted using 
histology and flow cytometry based techniques. 
 
Although oral administration via the drinking water allows for relatively stable 
concentrations of risperidone, the short half life in rodents means that there are still likely 
to be peaks and troughs of drug concentration as dictated by the amount of water 
consumed at a particular time of day. It is therefore conceivable that risperidone would be 
even more effective a reducing disease severity were consistent concentrations maintained. 
To investigate this risperidone could be administered via controlled release implants or 
osmotic minipumps (Aravagiri et al., 1998; Kapur et al., 2003). As risperidone is only one 
of a number of atypical antipsychotics that have similar receptor antagonistic activity, the 
immunomodulatory potential of other compounds within this class of drugs could also be 
explored.  
 
8.4 MIS416 
8.4.1 Summary  
The current study has demonstrated that EAE is an appropriate model for which to 
elucidate the immunomodulatory effects of MIS416. MIS416 was demonstrated to be 
effective in the treatment of EAE when administered immediately before immunisation, 
during disease onset or when a low dose was administered weekly. Additionally this study 
provided evidence for the involvement of IFN-γ in MIS416 disease modification.  
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8.4.2 Clinical implications 
Anecdotal reports from pre-clinical, compassionate use of MIS416 indicates that MIS416 
has minimal side effects and provides benefits to the progressive MS patients (personal 
communication; Gill Webster, Innate Immunotherapeutics). A phase 2A trial is currently 
underway to evaluate the safety and tolerability of MIS416. If this trial proves to be 
effective further in-depth trials will be conducted.  
 
For drugs to be approved for clinical use by regulatory agencies, such as the FDA, a large 
body of evidence needs to be provided indicating the safety and effectiveness of the new 
therapy (Lipsky et al., 2001). Animal studies have a fundamental role in the approval 
process. Additionally, having a comprehensive understanding of the drug’s mechanism of 
action facilitates the process of gaining regulatory approval. Identification of mechanisms 
of action usually occurs through intensive investigations in animal models, and the current 
study has demonstrated that EAE is an appropriate model for exploring how MIS416 alters 
an MS-relevant disease process. The findings from this study provide a foundation for 
future research and assist in the process of developing MIS416 as clinical therapeutic for 
MS. 
  
8.4.3 Future directions 
It was demonstrated that IFN-γ is a necessary factor for effective disease modification by 
MIS416. What specific role IFN-γ has, the cells that are producing it, and the location from 
which it is acting, remain to be determined. Additionally, whether or not IFN-γ is 
necessary only during disease induction or if it also has a regulatory role in the chronic 
phase of disease would be interesting to investigate. As MIS416 can induce the production 
of type I interferons in vitro, the potential of MIS416 to induce production of these 
cytokines and the effect they have on EAE should be explored (Girvan et al., 2010).  
 
Changes in cellularity induced by MIS416 were not investigated in the current study. 
Insight into the mechanisms by with which MIS416 suppresses disease may be gained 
through analysing changes in specific immune cell populations. Populations of particular 
interest would include regulatory subsets such a Tregs, MDSC or certain macrophages 
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populations. Additionally NK cells, which can be activated by NOD2 and TLR9 ligands, 
could also have a regulatory role (Fu et al., 2011; Xu et al., 2011). The increase in IFN-γ 
after MIS416 treatment may indicate, or result in, altered ratios of Th1/Th17 populations; 
therefore identifying changes in these populations may also contribute to understanding 
how MIS416 alters EAE expression.   
 
It is also unknown if the suppression of disease in MIS416-treated mice is due to 
alterations in peripheral immune responses or due to processes occurring within the CNS. 
Analysis of CNS lesions and oligodendrocyte pathology could indicate whether MIS416 
alters lesion development (eg. via alterations in immune events occurring in the CNS) or if 
MIS416 has a direct protective effect on oligodendrocytes (eg. by inhibiting cell death). 
Additionally, direct effects of MIS416 on the process of demyelination and remyelination 
could further be studied using other animal models, such the cuprizone-induced 
demyelination model (Matsushima et al., 2001).   
 
As it appeared that the effects of lower doses (i.e. 100 µg) of MIS416 began to diminish 
within 7 days of administration, it would be interesting to explore if more frequent dosing, 
for example once every 4 days further enhanced the efficacy of MIS416. Currently 
MIS416 is administered by intravenous injection; however, the ideal administration route 
would be oral as it is much less invasive for patients who would be regularly taking 
MIS416. It therefore would be interesting to explore whether oral administration could also 
induce similar regulatory effects in EAE. 
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Appendix 1 
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Spinal cord gating scheme Spinal cords were processed as described in the methods and analysed by flow 
cytometry. Shown are representative plots from one immunised-untreated and one immunised PTX-treated 
mouse. Microglia (red circles) can be distinguished by their intermediate expression of CD45 relative to high 
expression in other CD45
+
 cells (Olson, 2010) .  
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Appendix 2
CFSE
C
D
4
5
.2
C
D
4
a
b c
d e
C
D
4
5
.2
C
D
4
Identifying in vivo 2D2 cell proliferation. To identify donor CD4
+
 2D2 cells from recipient mice 
lymphocytes, cells were initially gated on CD4
+
 events (a), then on CD45.2 which is expressed on cells 
from 2D2 doner mice but not the congenic recipient mice. Total CD4
+
 CD45.2
+
 cells were gated 
(indicated on plots b,c,d,e as CD45.2
+
), a secondary gate (indicated on the plots by <CFSE) was placed 
within the CD45.2
+
 gate to identify cells that had undergone cell division, as determined by a reduction 
in CFSE florescence in cell progeny. To identify the percentage CD4= 2D2 cells that had undergone 
proliferation cells events within the <CFSE gate were divided by total events within the CD45.2
+
 gate. 
Representative plots of (b) untreated/unimmunised (c) PTX/unimmunised, (d) immunised/untreated (e) 
PTX/immunised from two experiments (n= 7/immunised group, n= 4/unimmunised group).  
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Appendix 3 
Analysis of lesion area in immunised, risperidone-treated or untreated mice 
H&E stained longitudinal section of spinal cord was analysed for lesions. Analysis was blinded 
as to if samples were from treated or untreated mice. Images of spinal cord lesions were acquired 
using an inverted olympus IX51 microscope with cell^A, software, version 3.4  (Olympus, PA, 
USA). Lesions area was determine by tracing around lesions and calculating total area using with 
cell^A,  software, version 3.4  (Olympus, PA, USA). 
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Appendix 4  
Buffers and solutions  
 
PBS  
NaCl      145 mM 
Na2HPO4     8.7 mM  
NaH2PO4     1.3 Mm 
 
In ddH2O, autoclaved sterilised. 
 
Pertussis toxin buffer  
Tris       15mM 
Sodium chloride     0.5M  
Triton X-100      0.017% (v/v) 
 
In ddH2O, filter sterilised using 0.22µm syringe filter. 
 
Zinc fixative  
Tris       0.1M 
Calcium acetate     3mM 
Zinc acetate      27mM 
Zinc chloride      37mM 
 
In ddH2O, adjusted to pH 7.4.   
 
Complete T cell media (CTCM) (v/v) 
Dulbecco’s Modified Eagle Medium  85.9% 
Fetal calf serum (FCS)   10% 
L-glutamate (200 mM)   1% 
Penicillin/Streptomycin    1% (100 U/ml/10 mg/ml) 
HEPES buffer (1 M)    1% 
β-Mecaptoethanol    0.1% 
Non-essential amino acids (10nM)  0.1% 
 
Wash buffer (v/v) 
Dulbecco’s Modified Eagle Medium  96% 
HEPES buffer (1 M)    3% 
Penicillin/Streptomycin    1% (100 U/ml/10 mg/ml) 
 
FACS buffer (v/v) 
FCS       2% 
Sodium azide      0.1% 
PBS      97.9% 
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Griess solution A (w/v) 
Sulphanilamide     1%  
 
In 2.5% Phosophoric acid  
 
Griess solution B (w/v) 
N-(1-napthyl) ethylenediamine   1%  
 
In 2.5% Phosohoric acid  
 
ELISA capture buffer  
 
Na2HPO4      0.1M 
 
In ddH2O, adjusted to pH 9.   
 
ELISA development stop solution  
H2SO4      0.18M 
In ddH2O 
 
Percoll diluent (v) 
10x PBS     45 mls 
3 ml 0.6MHCL    3 mls 
Sterile ddH2O     132 mls 
 
MTT solution  
MTT      5 mg/ml 
(3-(4,5-dimethylthiazol-2-yl)-2.5-diphenyrtetrazolium bromide)   
In dPBS 
 
Filter sterilised using a 0.22 μm syringe driven filter (Biofil, Guangzhou, China) 
 
MTT  solubiliser (w/v) 
SDS      10%  
Dimethylformamide    45%  
 
In ddH2O, adjusted to pH 4.5 with acetic acid
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Appendix 5 
 
Cell Surface Markers Fluorophore  Clone Isotype Manufacturer 
B220 FITC 
Biotin 
RA3-6B2 
RA3-6B2 
Rat IgG2a 
Rat IgG2a 
BD Bioscience 
BD Bioscience 
CD4 PE 
CyC 
V500 
PerCP-Cy5.5 
Biotin 
RM4-5 
RM4-5 
RM4-5 
RM4-5 
RM4-5 
Rat IgG2a 
Rat IgG2a 
Rat IgG2a 
Rat IgG2a 
Rat IgG2a 
BD Bioscience 
BD Bioscience 
BD Bioscience 
eBioscience 
BD Bioscience 
CD8 PE 
CyC 
PerCP-Cy5.5 
Biotin 
53-6.7 
53-6.7 
53-6.7 
53-6.7 
Rat IgG2a 
Rat IgG2a 
Rat IgG2a 
Rat IgG2a 
BD Bioscience 
BD Bioscience 
eBioscience 
BD Bioscience 
CD11b  FITC 
PE 
Biotin 
M1/70 
M1/70 
M1/70 
Rat IgG2b 
Rat IgG2b 
Rat IgG2b 
BD Bioscience 
eBioscience 
Serotec 
CD16/CD32 (FcγRII/III) Purified 2.4G2 Rat IgG2b BD Bioscience 
CD25 FITC 
APC 
3C7 
PC61 
Rat IgG2b 
Rat IgG1 
BD Bioscience 
BD Bioscience 
CD40 PE 3/23 Rat IgG2a BD Bioscience 
CD44 PE IM7 Rat IgG2b eBioscience 
CD45 CyC 
V450 
Biotin 
30-F11 
30-F11 
30-F11 
Rat IgG2b 
Rat IgG2b 
Rat IgG2b 
BD Bioscience 
BD Bioscience 
eBioscience 
CD62L FITC 
APC 
MEL-14 
MEL-14 
Rat IgG2a 
Rat IgG2a 
eBioscience 
BD Bioscience 
CD45.1  PE A20 Rat IgG2a BD Bioscience 
CD45.2 APC 104 Rat IgG2a BD Bioscience 
CD80 FITC 
APC 
16-10A1 
16-10A1 
Hamster IgG2 
Hamster IgG2 
BD Bioscience 
BD Bioscience 
F4/80 FITC 
PerCP-Cy5.5 
Biotin 
CI:A3:1 
BM8 
CI:A3:1 
Rat IgG 
Rat IgG2a 
Rat IgG 
Serotec 
eBioscience 
Serotec 
Gr-1 FITC 
PE 
APC-Cy7 
RB6-8C5 
RB6-8C5 
RB6-8C5 
Rat IgG2b 
Rat IgG2b 
Rat IgG2b 
eBioscience 
BD Bioscience 
BD Bioscience 
I-Ab PE AF6-120.1 Rat IgG2a BD Bioscience 
PDL-1 PE MIH5 Rat IgG2a eBioscience 
Isotype control FITC R35-95 Rat IgG2a BD Bioscience 
PE R35-95 Rat IgG2a BD Bioscience 
PE R3-34 Rat IgG1 BD Bioscience 
CyC R35-95 Rat IgG2a BD Bioscience 
APC R35-95 Rat IgG2a BD Bioscience 
APC-Cy7 A95-1 Rat IgG2b BD Bioscience 
V450 A95-1 Rat IgG2b BD Bioscience 
V500 R35-95 Rat IgG2a BD Bioscience 
Biotin R35-95 Rat IgG2a BD Bioscience 
 
